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ABSTRACT
Cyclic adenosine 5'-diphosphate ribose (cADPR) is a naturally occuring metabolite of 
nicotinamide adenine dinucleotide (NAD)+ and a potent Ca2+-mobilising agent in a 
variety of cells. Structural analogues of cADPR have been synthesised, to probe the 
structure-activity profile for cADPR. The synthetic method employed in this work relies 
upon synthesis of chemically modified NAD+ analogues from their mononucleotide 
subunits, followed by enzymatic cyclisation into cADPR analogues. Analogues were 
tested in two biological systems - sea urchin egg homogenates and in permeabilised 
Jurkat T-cells.
2' And 3'-hydroxyl group deletion in the adenosine ribose moiety of cADPR were used 
to investigate the role of ribose hydroxyl group on the Ca2+ releasing potential of 
cADPR. In the sea urchin egg system, EC50 values of 32nM, 58nM and 5pM were 
obtained for cADPR, 2 'A-deoxy-cADPR and 3'A-deoxy-cADPR respectively. This 
suggests that the 3'-hydroxyl group but not the 2 '-hydroxyl is important for calcium 
releasing activity in this system. Interestingly, replacement of the 3'-OH with a methoxy 
group in 3'A-0-methyl-cADPR generated an antagonist with an approximate IC50 of 
5pM. 3'-O-Methyl-cADPR is the first cADPR antagonist that is not modified at the 8 - 
position of the purine ring in the sea urchin egg system. Replacement of the 2'-OH with 
a phosphate resulted in an inactive analogue. 3'-cADPRP and 2',3'-cADPRP were both 
inactive in this system.
The data obtained from Jurkat T-cells showed some differences in the structural 
requirement for cADPR induced mechanism. cADPR mobilised Ca2+ with an EC50 of 
2.5pM. 2'-Deoxy and 3'-deoxy-cADPR analogues were both inactive . 3'-0-Methyl- 
cADPR was a potent agonist suggesting that the hydrogen acceptor ability of the oxygen 
atom is important for Ca2+ releasing activity. 2'-cADPRP was a potent agonist, but both 
2'-cADPRP and 2',3'-cADPRP were inactive.
Substitution of the hydrogen atom at the 8 -position of the purine ring with amino or 
bromo group are known to produce antagonists in the sea urchin system, hence these 
analogues and other substitutions at the 8 -positions were synthesised to investigate 
whether substitution at this position resulted in antagonism of cADPR- induced response 
in Jurkat T-cells. All 8 -substituted analogues were antagonists in the Jurkat T-cells, 
potency of which depended on the molecular volume and hydrophobicity of the 
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CHAPTER 1: GENERAL BACKGROUND
1.1 Cell Signalling
Communication between cells in multicellular organisms is essential for maintenance of 
life processes such as regulation of development and organisation into tissues, control of 
growth and division and co-ordination of cell functions. Communication can occur via 
gap junctions that directly join the cytoplasm of the interacting cells, by direct contact via 
plasma-membrane bound signalling molecules that influence other cells, and by secreting 
chemicals that signal to cells some distance away.
Chemical signalling can be achieved in three ways. First, endocrine signalling involving 
hormones which travel through the blood stream to influence target cells. Second, 
paracrine signalling where local chemical mediators are released to act on cells in the 
immediate environment, and third, synaptic signalling which is confined to the neurons in 
which neurotransmitters are released at specialised junctions called chemical synapses. 
The neurotransmitter diffuses across the synaptic cleft, typically a distance of about 
50nm and acts only on the adjacent post-synaptic target cell. The signalling molecule 
known as the first messenger, binds to specific proteins called receptors on the target 
cells leading to a response. Small hydrophobic signalling molecules such as thyroid 
hormones and steroids, diffuse through the lipid bi-layer of the target cell, thereby 
eliciting a response. However, many messenger molecules (all neurotransmitters and 
majority of hormones and local mediators) are too hydrophilic to cross membranes in 
which case additional messengers are required to link surface receptor activation to 
















^  CELLULAR RESPONSE ^
Figure 1.1: Mechanisms involved in signal transduction at cell surface receptors.
Illustrating the three types o f cell surface receptors, a) Ion-channel linked receptor, b) 
Tyrosine kinase receptors and c) G-protein linked receptors.
A single activated receptor protein can, in principle collide with and activate many 
molecules o f G-protein thereby activating many molecules of enzyme. In some cases the 
extracellular ligand may not remain bound to its receptor long enough for this 
amplification to operate. However the Gs is thought to remain active for up to 10-15s. 
before hydrolysing its bound GTP hence can keep the enzyme, AC or GC active long 
after such extracellular ligand is dissociated. The intrinsic GTPase activity o f the a - 
subunit hydrolyses GTP to bound GDP, the a-GDP subunit recombines with the py
subunit and the G-protein returns to its basal state. Receptors working through G- 
proteins include those for messenger molecules e.g. the 0 -adrenergic receptor and the 
muscarinic receptor and rhodopsin for light.
1.2 Calcium in Cell Signalling.
Elucidation of the role of Ca2+ as an intracellular messenger began over 100 years ago by 
Ringer 1883 [1]' Ringer observed that contraction of cardiac muscle was abolished when 
tap water in the medium was replaced with distilled water. The missing component in 
the distilled water required for muscle contraction was found to be calcium. It is well 
established today that transient elevation in cytosolic free Ca2+ plays a key role in diverse 
cellular processes. Agonists can raise tCa2+]i in two ways, a) by stimulating influx of 
Ca2+ through voltage gated or receptor gated Ca2+ channels in the plasma membrane. 
The large gradient of [Ca2+]i between the extracellular fluid (ImM) and the cytoplasmic 
space (0.1 pM) allows an influx of Ca2+ ions into the cell, b) Ca2+ can be released from 
intracellular pools. Ca2+ release from internal stores is important to cell signalling for a 
variety of cellular events. The cellular response observed depends on the type of cell 
targeted as well as the nature of the agonist.
1.3 Second Messengers.
The concept of a chemical second messenger was established with the identification of 
cyclic AMP as a mediator of the effects of epinephrine on glycogen metabolism about 
forty years ago [2]. A criterion for a second messenger role to be fulfilled was put 
forward in which the first messenger should increase the concentration of the second 
messenger in the target cell and an increase in the concentration of the second messenger 
inside the cell should transduce and amplify the effect of the first messenger.
The second messengers identified today include cyclic-adenosine 3 5  '-monophosphate 
(cAMP), cyclic-guanosine monophosphate (cGMP), Diacylglycerol (DAG) and D-myo- 
inositol 1,4,5-trisphosphate [D-Ins (1,4,5)P3] in combination with Ca2+ ions. Other 
putative second messengers include cyclic ADP-ribose (cADPR), nicotinate adenine 
dinucleotide phosphate (NAADP). There appear to be few second messengers available 
compared to the large number of different hormones and neurotransmitters, indicating 
that internal signalling pathways are surprisingly similar in spite of the plenitude of 
biochemical and physiological processes to be regulated.
1.3.1 Cyclic-AMP
cAMP was discovered by Sutherland and R ail[2] during investigation of the mechanism 
by which adrenaline and glucagon increase the activity of glycogen phosphorylase in liver 
slices. Two forms of glycogen phosphorylase (a and b) had been previously isolated from 
skeletal muscle [31. Sutherland and Rail later showed that ATP and Mg2+ were required 
for the conversion of isolated liver glycogen phosphorylase b (inactive in the absence of 
AMP) to phosphorylase a l4]. They were then able to develop a cell-free system in which 
addition of adrenaline or glucagon to a liver homogenate in the presence of ATP and 
Mg2+ caused an increase in phosphorylase activity. A heat stable factor was isolated 
from liver slices treated with hormone which was shown to activate glycogen 
phosphorylase in liver homogenates incubated in the absence of hormones. ATP was 
required both for the production of this factor in particulate fraction and for its activation 








Amplifier (e.g. adenylate cyclase, guanylate cyclase, Ptlns-PLC)
i




Cellular response (growth, secretion, contraction etc.)
Figure 1.2: Sequence of events in Transmembrane signalling
studying the activation of glycogen phosphorylase, Lipkin was investigating the
chemistry of compounds formed when ATP was treated with (BaOKb) I5]. One of the
products of this reaction was found to be similar in biological properties to the heat-
stable activator or phosphorylase. The two groups collaborated in the elucidation of the
structure of this factor which was subsequently identified to be an unusual nucleotide
known as cyclic adenosine-3 ',5 '-monophosphate. The identification of cAMP
established the concept of the second messenger. cAMP Is a ribonucleotide that
possesses a diester involving phosphoric acid and the hydroxyl functions on the 3' and 5'
carbons on the ribose ring. It is cyclic as it forms the ester with itself. cAMP is
6
synthesised from ATP by adenylate cyclase and it is degraded into AMP by cAMP 
phosphodiesterase (Fig 1.3). The activity of adenylate cyclase is principally controlled by 
extracellular agonists including corticotrophin, adrenaline, noradrenaline, glucagon and 
vasopressin. These act through a plasma-membrane bound receptor and either Gs 
(stimulatory G-protein) or Gi (inhibitory G-protein). The stimulatory part of Gs binds to 
AC and induces a conformational change in the enzyme. This allows the active site of 
AC to bind ATP.
NH










Figure 1.3: Metabolism of cAMP
The inhibition of AC through the action of G; is mediated indirectly by the released py 
subunits which bind to free cts subunit, thereby preventing them from activating cyclase
7
molecules, and directly by interaction of a  subunit with AC. cAMP exerts its effect in 
the cell mainly by activating an enzyme known as cyclic AMP-dependent protein kinase 
(A-kinase). This enzyme catalyses the transfer of terminal phosphate group from ATP to 
specific serine and threonine residues of selected proteins in the target cell, initiating a 
signalling cascade that results in long lasting alterations of cellular functions. A-kinase in 
its inactive state is tetrameric consisting of two regulatory (49kDa) and two catalytic 
(38kDa) subunits (R2C2). cAMP binding alters the conformation of the catalytic subunits 
causing them to dissociate from the complex. The dissociated C units known as active 
A-kinase phosphorylates substrate protein molecules. cAMP also inhibits protein 
phosphatase that would otherwise oppose the phosphorylation reactions stimulated by 
cAMP by activating A-kinase to phosphorylate a phosphatase inhibitor protein which can 
then bind to the protein phosphatase to inhibit it.
The response to cAMP varies with the type of cell concerned as different cells contain 
different enzymes serving as substrates for A-kinase. In liver cells for example, cAMP 
promotes glucose synthesis and glycogenolysis, in adrenal cortex, it produces an increase 
in glucocorticoid synthesis. Dissociation of the ligand is rapidly followed by 
disappearance of its effect, owing to degradation of cAMP by cAMP phosphodiesterase 
and dephosphorylation of kinase substrates by phosphatases.
1.3.2 Cyclic-GMP
The search for other cyclic nucleotides led to the discovery of guanosine 3',5'- 
monophosphate (cGMP) in mammalian urine by Ashman et a / 61. The subsequent 
detection of cGMP in many cells, and all the enzymes analogous to those involved with 
cAMP metabolism and action i.e. guanylate cyclase, cGMP phosphodiesterase and
cGMP-dependent protein kinase, suggested that this cyclic nucleotide may have a role as 
an intracellular messenger.
Three forms o f GC (enzyme which catalyses the production of cGMP from GTP-Fig. 
1.4) have been identified so far. These are plasma-membrane GC, a cytoplasmic form 
which is activated by endothelium-derived relaxing factor (EDRF), and a Ca2+ activated 
form which is found associated with the cytoskeleton and plasma-membrane. The 
plasma-membrane form of GC composes of single polypeptide chain with molecular 
weight between 120 and 1801cDa. It consists of an extracellular domain which binds 
ANP or a sperm-activating peptide, a single membrane-spanning sequence and a GC 
catalytic domain on the cytoplasmic side o f the membrane. A region of the polypeptide 
chain in the cytoplasmic domain is phosphorylated at multiple sites. The binding of an 
agonist to the extracellular domain of the plasma-membrane GC induces a 
conformational change in the activity of GC. For sperm-cell GC, this change also induces 
dephosphorylation of the cytoplasmic domain and a subsequent decrease in GC activity 
even though the agonist remains bound to the extracellular domain of GC. The 
cytoplasmic form of GC which is activated by EDRF is composed of 2 subunits with Mw 
of 82 and 70kDa. One of these contains haem as a prosthetic group. Activation of the 
enzyme by EDRF involves combination of this molecule with the haem group resulting in 
a conformational change in GC. These actions of Ca2+ are probably exerted through an 
intermediary binding protein. The biological effects of cGMP appears to be more 
diverse. In addition to activation cGMP-dependent kinase, it also regulates cyclic 















Figure 1.4: Formation and breakdown of cGMP.
1.3.3 Inositol-1,4,5,-trisphosphate
IP3 (Fig 1.5) is employed as an intracellular messenger in a large number of cellular
responses induced by agonists [9l  In 1953 Hokin and Hokin observed that in pancreatic
cells, acetylcholine stimulated the incorporation of [32P]HP04= into the minor
phospholipid, phosphatidylinositol tl0]. During the period o f 1970 to 1975 it became
apparent that for many agonists which bind to receptors on the plasma membrane, cyclic
AMP is not responsible for conveying information from the plasma membrane to
intracellular sites. It was not until 1975 that Michell pointed out that messengers that
activate phosphoinositol response invariably also cause an increase in cytosolic Ca2+
concentration and proposed a link between the two events tll]. It was later discovered
that the primary event by a number of agonists was the hydrolysis o f a minor derivative
PtdIns(4,5,)P2. Berridge consequently discovered that in blow-fly salivary gland, 5-
10
hydroxytryptamine increases the intracellular concentration of inositol trisphosphates 
together with the concentration of bis and monophosphates[12].
Streb and co-workers showed that in permeabilised pancreatic acinar cells, IP3 facilitates 
the outflow of Ca2+ from an intracellular store I131. This observation has now been 
repeated in many other cell types and the site of Ca2+ release shown to be most likely a 
component of endoplasmic reticulum. IP3 is a small water-soluble molecule which does 
not move through cellular membranes. It is synthesised from the polyphosphoinositide 
PtdIns(4,5)P2. Various phosphoinositides have been identified in animal cells. These are 
Ptdlns, PtdIns(4)P, PtdIns(4 ,5 )P2 and very small amounts o f PtdIns(3)P, PtdIns(3,4,)P2 
and PtdIns(3,4,5)P3 (Fig 1.6). Ptdlns(3,4, P2)and PtdIns(3 ,4 ,5 )P3 are only detected in 
cells stimulated by growth factor, for example PDGF, Insulin or CSF-1. 
Phosphoinositides are principally located in plasma membranes although they have been 
detected in other membranes such as nuclear membrane and the membranes of secretory 
vesicles. Formation o f IP3 from Ptdlns(4,5 P2) is catalysed by Ptdlns(4,5 P2) specific 
phospholipase C. This reaction occurs in the cytoplasmic face of the plasma membrane 






Figure 1.5: Structures of Inositol-1,4,5,-triphosphate (IP3)
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IPs interacts with specific intracellular Ca2+ release channel protein known as the IP3 
receptor. The receptor is a glycoprotein with a molecular weight of 260kDa. Opening 
of the Ca2+ channel which is part of the receptor protein allows Ca2+ to flow into the 
cytoplasmic space. IP3 is rapidly de-phosphorylated by specific phosphatases, However 
not all IP3 is de-phosphorylated some is phosphorylated to form Ins 1,3,4,5- 
tetrakisphosphate (L1SP4) which may mediate slower and more prolonged responses in 
the cell. At least two of the metabolites of IP3, namely IP4 and cyclic IP3 have been 
suggested to have second messenger functions of their own [14,15]. Activation of the IP3 
receptor therefore results not only in the mobilisation of intracellular Ca2+ but also turns 
on a family of cellular processes. It thus appears that the IP3 pathway is perhaps acting 
as a master switch for general activation of cell rather than a specific means of Ca2+ 
mobilisation. This raises the question of whether messenger molecules more specific for 
Ca2+ mobilisation other than IP 3 could exist.
Lithium has been found to inhibit two phosphatases which degrade inositol 1,4- 
bisphosphate and inositol-1-phosphate to free inositol thereby preventing the recycling of 
inositol into phosphoinositides. Since many peptide neurotransmitters activate 
phosphoinositide turnover, it is possible, that this explains the therapeutic effect of 
Lithium. There is substantial evidence that this pathway is involved in the control of 
smooth muscle, contractility, secretion, neuronal excitability, the activation of 
inflammatory cells and cell proliferation.
1.3.4 Diacylglycerol
In 1977 a protein kinase that requires Ca2+ and phospholipids for activity was discovered
[16]. This was originally called Ca2+ and protein-dependent protein kinase, but is now
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known as protein kinase C. They also found that DAG and tumour promoter phorbol 
esters such as 12-O-tetradecanoyl phorbol-13-acetate (TPA), are potent activators of 
this protein kinase. Stimulation of protein kinase C by DAG, results in phosphorylation 
of a variety o f proteins and produces profound effects on cellular activities [17]. DAG is 
rapidly metabolised whereas, TPA is hardly metabolised which leads to distortion in 
cellular response. DAG is formed in the inner leaflet of the plasma membrane by the 
hydrolysis of phospholipids of which PIP2 and phosphatidylcholine are the most 
common. DAG is lipophilic (Fig 1.7) and in contrast to cyclic nucleotides and IP3, 
remains associated with the membrane. They function as intermediates in the synthesis 
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Rt = R2 = P032', R3 = H Ptdlns(3,4)P2
R-, = R2 = R3 = PO32” Rdlns(3,4,5)P3
Figure 1.6 Phophatidyl-inositols
In contrast to IP3, DAG and protein kinase C chiefly convey information for cell 
responses which are slow in onset and involve longer term changes in cell growth, 
proliferation, differentiation and in movement of the cytoskeleton.
DAG together with the phospholipid, phosphatidyl serine, in the cytoplasmic half of the 
plasma membrane, binds to C-kinase, increase affinity of the enzyme for Ca2+ so that C- 
kinase becomes active at low concentrations of Ca2+ in the cytosol. In many cells, it 
appears that protein kinase is activated by the co-operative effect of DAG and increase in 
cytosolic Ca2+ brought about by IP3. Once activated, C-kinase transfers the terminal 
phosphate on target proteins that vary depending on the cell. The activation of C-kinase 
is transient because DAG is phosphorylated to form phosphatidate or further cleaved to 
arachidonic acid within seconds. The highest concentration of C-kinase is found in the 
brain where it phosphorylates ion channels in nerve cells, thereby changing their 
properties and altering the excitability of the nerve cells.
Figure 1.7: Structure of Diacylglycerol
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1.4 Cyclic Adenosine Diphosphate Ribose
Advances in the technique for the measurement of the concentration and distribution of 
intracellular Ca2+ have revealed unsuspected complexity in the spatiotemporal dynamics 
of Ca2+ during cell signalling I9]. Ca2+ mobilising agonists do not generally produce 
simple elevations in intracellular free Ca2+ concentrations, but more often produce a 
series of recurring fluctuations or oscillations [20l  Furthermore, these Ca2+ oscillations 
are well organised spatially and often propagate as transcellular waves in either single 
cells or through networks of adjacent cells t21]. The fact that IP3 may not be the only 
messenger for this process is supported by the findings of Ca2+ mobilisation with no or 
minimal change in endogenous IP3 [22'25\
It was proposed that an initial release o f Ca2+ from the IP3 sensitive Ca2+ pool could act 
as a primer for further Ca2+ release from IlVinsensitive pools producing a spike that 
could spread like a wave throughout a cell[9,201. This mechanism known as Ca2+-induced 
Ca2+ release (CICR), was first established in muscle cells[26,27] and later found in a variety 
o f other cell types, has since been proposed to be involved in mechanisms of Ca2+ 
oscillations and Ca2+ wave propagation [28_31]. The ability of Ca2+ to activate its own 
release in Ca2+ signalling is the important feature of CICR. There is evidence that CICR 
may be under additional control from cell surface receptors. This release was previously 
thought to be from IlVinsensitive stores [32]. The iyanodine receptor, a second 
intracellular Ca2+ release channel, also found widely in cells, was believed to solely 
mediate the CICR release mechanism [33J, however recent findings have shown that two 
closely related Ca2+ channels with these properties are the IP3 and ryanodine receptorl34]. 
IP3RS are well documented, where they appear to function as ubiquitous pathway for
generating intracellular signals [35], RyR-mediated Ca2+ signalling is less well understood.
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However, an awareness of the importance of this second pathway for Ca2+ mobilisation 
in an equally diverse set of cellular systems has increased [36"38]. Ryanodine and caffeine 
are known agonists for the RyR receptor[39]. Ruthenium red and procaine are commonly 
used antagonists for this receptor l40]. The physiological ligand for this receptor is 
however unknown. Experiments with classic RyR blockers indicated that cADPR acted 
via a RyR-like Ca2+ release channel[41). These results led to the hypothesis that cADPR 
acts via a RyR-like mechanism, distinct from the IP3R . Furthermore, agents that can 
activate RyRs, including divalent cations, caffeine, and ryanodine, can potentiate Ca2+ 
release by cADPR in sea urchin egg homogenatesI42,43].
1.4.1 Discovery o f cADPR as a C(f+- Mobilising Agent
cADPR (Fig 1.9) a metabolite of NAD+ was discovered in 1987 during investigations of 
the mechanism of Ca2+ mobilisation in sea urchin eggs [44]. The sea urchin egg has long 
been a favourite model system used to investigate the molecular mechanisms of 
fertilisation and also for understanding the basic mechanisms of intracellular Ca2+ 
signalling. Clapper and co-workersf44] developed an in vitro system that allows free 
access to internal Ca2+ stores by preparing homogenates from Lytechinus pictus eggs 
with a regular homogeniser equipped with a glass pestle [45]. A gentler technique of N2 
deactivation was needed for Strongylocentrotus purpuratus eggs [46]. In the presence of 
ATP, the endogenous Ca2+ pump in the homogenates sequesters the contaminating Ca2+ 
and lowers the ambient concentration of Ca2+ to the submicromolar range, allowing the 
convenient use of fluorescence Ca2+ indicators for monitoring the movement of Ca2+. 
The preparation was found to be ideally suited for use as a bioassay for Ca2+ release 
activators as it is highly stable and very responsive to IP3, which elicits a large and
16
immediate Ca2+ release. A large quantity of egg homogenates can be prepared for 
routine use and stored frozen without loss of responsiveness for long periods of time.
NAD+ whose concentration is known to change dramatically during fertilisation was 
tested along with other possible candidates for Ca2+ release activators I47]. In contrast to 
the rapid release induced by IP3 , there was a significant latency of l-4min before calcium 
release was observed in response to NAD+. Furthermore, pre-incubation of NAD+ with 
egg extracts, produced an active metabolite that can release Ca2+ without a delay. This 
release was found to be stereospecific, requiring (3-NAD*, the a-form had no effect. 
These data suggested that an enzymatic conversion of P-NAD* to the active metabolite is 
likely to be involved, hence the product obtained by incubation with the egg extracts was 
purified by HPLC and called “enzyme-activated”-NAD* (E-NAD*). Structural 
determination of E-NAD+ led to the identification of a novel cyclised ADP-ribose 
cADPR is synthesized from NAD* by ADP-ribosyl cyclase and hydrolyzed to its inactive 
metabolite ADP-ribose by cADPR hydrolase. CD38, is a bi-functional enzyme that 
catalyses both the synthesis and degradation of cADPR
1.4.2 Structure o f cADPR
Pure E-NAD* obtained from HPLC purification was subjected to structural analysis by 
Lee and co-workers [48]. The initial structural characterisation employed use of 
radioactive NAD* with labels at various positions of the molecule as precursors. The 
labels were lost only if they were on the nicotinamide group of NAD* prior to enzymatic 
conversion. This indicated that the nicotinamide group is lost during catalysis and this 
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Figure 1.8: Formation and metabolism of cADPR (1).
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missing are those on the nicotinamide and the rest of the hydrogens in NAD+ remained 
intact. The exact mass of E-NAD+ was determined by high resolution mass 
spectrometry, which together with total phosphate content determinations, uniquely 
specified the chemical formula of the molecule as C15H20N5O13P2. The strongest 
evidence that it is a cyclised structure came from the analysis of its hydrolytic product 
which was shown to be ADP-ribose by NMR and mass spectrometry. The fact that 
ADP-ribose is exactly one molecule of water heavier than the molecular weight 541 of 
the active molecule is analogous to the hydrolysis of cAMP to AMP. Addition of a 
water molecule to the 3'-phosphate bond of cAMP breaks the cyclic linkage by exactly 
one water molecule larger than cAMP. From this analogy, E-NAD+ was named cyclic 
ADP-ribose.
It was important to establish the exact site of cyclisation of cADPR. Two possible sites 
of cyclisation were identified; the terminal ribose can be linked to the adenine nitrogen at 
either position 1 or 6  (N1 or N6 ) of the adenine ring (see Fig 1.9). The N6 -linkage was 
originally proposed I48], however analysis by pH titration and UV absorption 
spectroscopy favour the N1-linkage t49]. The ambiguity has now been unequivocally 
resolved by X-ray crystallography of crystals of cADPR from saturated aqueous solution 
of its free acid, stereoselective chemical synthesis of cADPR from (3-NAD+, and various 
NMR techniques [50"52]. Thus, cADPR is a cyclised ADP-ribose with an N-glycosyl bond 
between the anomeric carbon of the terminal ribose and the N1 of the adenine ring.
The shape of cADPR was demonstrated in a CPK view by Lee as more square than 
round with a little empty space in the centre t53]. The phosphate backbone of the 




Figure 1.9: Computer modelling of cADPR[50]
the cyclising ribose and that between N9 and C l' of the other ribose are both in the P 
configuration, being directed toward a position opposite from those of the ribosyl -OH 
groups. This configuration is similar to that of NAD+ in which both glycosyl linkages are 
in the P configuration. The configuration of the adenine is syn with respect to the bond 
between N9 and the ribose, whereas the new cyclisation bond between N1 and the 
termilial ribose is in the anti configuration. In NAD+ both the adenine ring and the 
nicotinamide group are in the anti configuration[541. N6  is coplanar with the adenine and 
the three bond angles around C6  are all close to 120°, indicating N6 -C6  being a sp2 
double bond. Only one hydrogen was found bonded to N 6  indicating the imino 
tautomer.
1.4.3 Enzymes Involved in the Metabolism o f cADPR
A) ADP-ribosvl cvclase
The identification of an activity in sea urchin egg homogenates that activates NAD+ to 
release Ca2+ led to the discovery of ADP-ribosyl cyclase. This activity was latter 
demonstrated in a variety of mammalian cell extracts [55]. In contrast to other NAD+ 
utilising enzymes, the enzymatic activity of ADP-ribosyl cyclase does not require 
exogenous cofactors and activity in sea urchin egg is found to be lowest, about a million 
fold lower than in Aplysia ovotestis and 200-fold lower than in mammalian brain extracts 
[561. ADP-ribosyl cyclase exist both in soluble and membrane bound forms. The soluble 
form exists in dog testis, sea urchin egg and testis, and most abundantly, in the ovotestis 
of Aplysia califomica. This soluble form was first purified and sequenced from the 
ovotestis of the marine mollusc, Aplysia califomica [57~59]. It is a 29kDa protein, 
originally thought to be NADase because it was thought to convert NAD+ to ADP-
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ribose1581. Use of HPLC and NMR techniques have demonstrated that the product from 
transformation of NAD+ with this enzyme is cADPR, hence the name ADP-ribosyl 
cyclase. Purification of ADP-ribosyl cyclase by high resolution cation-exchange 
chromatography showed that the homogenous enzyme exists in multiple active forms 
differing in charge. The membrane bound form of ADP-ribosyl cyclase has been 
identified in sea urchin eggs and most mammalian tissues. Several membrane bound 
cyclases such as CD38, a 40kDa protein from lymphocytes, various homologous proteins 
such as CD38H 1603 from rat islets of Langerhans, a 39-kDa protein from canine spleen 
[611 and a surface molecule on erythrocytes [62], have been characterised. These are 
bifimctional enzymes catalysing the synthesis and degradation of cADPR hence the 
overall reaction resembles that of NADase although the two reactions are different 
mechanistically in that the bifimctional reaction involves the formation of cADPR as 
intermediate, whereas the NADase reaction, does not involve cADPR. The Aplysia 
isoform has low cADPR hydrolase activity, and this makes it suitable for use 
commercially in the synthesis of cADPR from NAD+.
B) cADPR hydrolase
For a second messenger role for cADPR to be established, there should be a pathway
for switching off the message. The presence of an enzyme that degrades cADPR was
noted by Rusinko and Lee 1989, during measurement of ADP-ribosyl activity in various
tissue extractsI55]. Incubation of tissue extracts with NAD+ resulted in the production of
cADPR and progressive increase in Ca2+ release activity. These release was found to
decline after reaching a peak, indicating that cADPR was destroyed by a degradation
enzyme in the incubation mixture. The hydrolase from the dog brain extracts has been
partially characterised[631. The enzyme activity is associated with membranes and similar
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to the cyclase is found to be equally widespread and does not appear to require any 
exogenous cofactors. cADPR hydrolase activities are often found associated with ADP- 
ribosyl cyclases, and both activities have been found on the same polypeptide I61]. also 
when the cyclase activity is high, as in brain extracts, the hydrolase activity is also high. 
The exception of this case is in Aplysia ovotestis in which the cyclase activity is so high 
that the hydrolase activity is insignificant in comparison. The product of cADPR 
hydrolase activity was identified as ADP-ribose indicating that this enzyme uniquely 
cleaves the N-glycosidic linkage between the adenine group and the terminal ribosyl 
moiety of cADPR by hydrolysis, hence the name, cADPR hydrolase. The enzyme has a 
Km of 160pM for cADPR and a Vma* of 1 .2 |imol/mg/hr. It displays a broad pH 
maximum near neutral and may be inhibited by millimolar ATP levelsf64].
C) CD38 and homologous proteins.
CD38 is a multifunctional protein expressed primarily in on lymphoid cells. It appears to 
mediate several diverse activities, including signal transduction, cell adhesion and 
cADPR synthesis [65]. Human leukocyte antigen CD38 and its rodent homologues have 
been demonstrated to have both ADP-ribosyl and cADPR hydrolase activities[64,66]
Comparative studies revealed that the amino acid sequences of Aplysia cyclase which do
not show cADPR hydrolase activity shows a high degree of amino acid sequence identity
with that of CD38 and that 10 cysteine residues are conserved between Aplysia enzyme
and human CD38 [66l  From recent results of cDNA cloning of r a t [60,641 and mouse [68]
homologous to human CD38, another 3 cysteine residues (Cys-16, Cys-116, Cys-209 in
human CD38) are conserved among the mammalian CD38s, but that the amino acid
residue corresponding to Cys-16 of CD38 is not in Aplysia enzymes and those
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corresponding to Cys-119 and Cys-201 of CD38 are Lys-95 and Glu-176, respectively in 
Aplysia enzymes. Introduction of site-directed mutations into the CD38 cysteine 
residues 119 and 201 results in a CD38 protein that exhibited only ADP-ribosyl cyclase 
activity. Furthermore, Aplysia ADP-ribosyl cyclase into which mutations K95C and 
E176C (corresponding to residues 119 and 201 in CD38) to Aplysia ADP-ribosyl 
cyclase exhibited both cyclase and cADPR hydrolase activities. The fact that these 
enzymes are bi-functional in that they reside on the same protein has led to the 
suggestion that many common ecto-NAD+ glycohydrolases, which convert NAD+ to 
ADP-ribose, may do so via cADPR as an intermediate[61]. However, the development of 
the NGD+/cGDPR technique to measure ADP-ribosyl activity per se has shown that in 
many cases NAD+ glycohydrolases do not exhibit any ADP-ribosyl cyclase activity[69].
Three major differences were identified between the enzymatic reaction of CD38 antigen 
and Aplysia ADP-ribosyl cyclase [70]. First, an intact adenine moiety is required for the 
cleavage of the N-glycoside bond by ADP-ribosyl cyclase, but not by CD38 NADase. 
Second, the reaction by ADP-ribosyl cyclase was fully reversible, but CD38 did not 
catalyse the formation of P-NAD+ from ADP-ribose and nicotinamide. CD38 NADase 
could produce |3-NAD+ from cADPR and nicotinamide, though it reaction rate was less 
than 4% of the hydrolysis rate of |3-NAD+. Third the NADase activity of CD38 was 
inhibited by DTT, but Aplysia ADP-ribosyl cyclase activity was not inhibited by DTT 
even though 10  out of 1 2  cysteine residues were conserved between the two enzymes. 
This suggests that the function of disulphide bond(s) if present, differed from each other 
with respect to catalytic activity. For CD38 to play a role in producing cADPR, a 
marked change in its enzyme property, such as conversion from NADase to cyclase
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would be required. cGMP has been shown to stimulate the formation of cADPR1711 and 
ATP has been shown to inhibit the hydrolysis of cADPR catalysed by CD38 NADaseI64], 
combination of these observations suggest that the enzyme property of CD38 antigen 
may be altered by post-translational modification, such as phosphorylation and 
dephosphorylation, or by interaction with an intracellular messenger(s). Interestingly, 
both CD38 and Aplysia cyclase have many consensus sites for cGMP-dependent kinase 
catalysed phosphorylation [56]. The best characterised example of bifimctional enzyme is 
6-phosphofructokmase-2/fructose-2,6-bishosphatase from liver. These two activities are 
regulated by cAMP-dependent protein kinase; phosphorylation results in the activation of 
the bisphosphatase activity and inhibition of the kinase[72J.
1.4.4 Regulation o f cADPR Synthesis by cGMP
It is essential that intracellular levels of cADPR be under control of extracellular signals
for it to be unambiguously assigned as a second messenger. Micro-injection of various
Ca2+-releasing molecules including IP3 and cADPR into sea urchin eggs exhibited
markedly different Ca2+ release pattern compared to that seen during fertilisation [73].
The only exception is cGMP whose pattern of Ca2+ release resembled that seen at
fertilisation [741. The effect o f cGMP on Ca2+ release in sea urchin eggs have been
examined at the level of the intact cell and of cell homogenates. The pattern is
characterised by a latency of ca. 20sec before the Ca2+ transient is initiated and the time
course is more protracted than that induced by IP3 or cADPR and can last for as long as
lOmin. Ca2+ release induced by micro-injection of cGMP into intact eggs was not
blocked by IP 3R  antagonist heparin [74], but extracellular application of the membrane
permeant analogue dibutyryl-cGMP in intact eggs was blocked by prior micro-injection
of the ryanodine receptor antagonist ruthenium red, suggesting that the RyR receptor is
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an essential element involved in the response to cGMP [71]. The fact that cADPR, like 
cGMP, releases Ca2+ by a mechanism sensitive to ryanodine and ruthenium red, 
suggested that cGMP may be releasing Ca2+ by the cADPR-sensitive mechanism. The 
pharmacology of the cGMP-induced Ca2+ release has been analysed in sea urchin egg 
homogenates[71].
In the presence of low concentrations of P-NAD+, cGMP desensitised release by 
cADPR but not by IP3; in cADPR-desensitised homogenates, cGMP failed to release 
Ca2+, but IP3 was still effective. This suggested that release by cGMP was via a cADPR- 
sensitive mechanism. That the effect of cGMP was indirect was revealed by the use 
cGMP-dependent protein kinase inhibitors (Rp-cAMPS and staurosporine) which 
blocked cGMP, but not cADPR induced release. This suggested that cGMP could be 
stimulating ADP-ribosyl cyclase, the enzyme that converts P-NAD+ to cADPR Analysis 
o f [14C]NAD+ metabolism by TLC egg homogenates treated with cGMP suggested that 
cGMP stimulates the conversion of P-NAD+ into cADPR and ADP-ribose (the 
hydrolytic product of cADPR). cGMP did not affect the rate of hydrolysis of 3H-labeled 
cADPR to ADP-ribose, suggesting that it was not inhibiting cADPR hydrolases. These 
experiments support the idea that cGMP activates ADP-ribosyl cyclase, perhaps through 
cGMP-dependent protein phosphorylation, resulting in enhanced conversion of NAD+ to 
cADPR
By analogy to the phosphoinositide pathway, for cADPR to function as a second
messenger, its synthetic enzyme, ADP-ribosyl cyclase would be expected to be regulated
either directly or indirectly by cell-surface receptor activation like phophoinositidase C.
cGMP itself has been established as a messenger for a number of different signalling
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molecules 1751 It is synthesised by intracellular guanylyl cyclases (see section. 1.3.2) of 
which there are two isoforms. The first isoform is particulate and constitutes a family of 
cell-surface receptors possessing cytoplasmic domains that have intrinsic guanylate 
cyclase activity while the extracellular domains are capable o f binding a variety of 
peptide hormones, including atrial natriuretic factor and a chemoattractant peptide 
secreted from eggs. The binding of these peptides to the receptor domain results in 
enhancement of the guanylate cyclase activity [76]. The second form of the GC is soluble; 
its enzymatic activity is stimulated by the gaseous transmitter nitric oxide and carbon 
monoxide [7?1. NO, which elevates cGMP in sea urchin egg, probably by activating 
soluble GC, also leads to Ca2+ mobilisation in intact eggs and egg homogenates [78l  The 
pharmacology of this Ca2+ release suggests that NO activates a pathway which involves 
both cGMP and cADPR, but not IP3, in that 8 -amino-cADPR a selective competitive 
antagonist of cADPR, and nicotinamide, an inhibitor of ADP-ribosyl cyclase, inhibit the 
Ca2+ mobilising effects of NO, while heparin, a competitive antagonist of IP3R, did not 
affect NO induce Ca2+ release. Rp-8 -pCPT-cGMPS, a cGMP-dependent-protein kinase 
inhibitor blocked the Ca2+ mobilising effects of NO, also the effect was dependent on the 
GC substrate GTP. Since the activation o f a number of cell-surface receptors leads to 
activation of GC, either directly or via the production of intermediate messengers such as 
NO [79], this pathway may be a way in which cell-surface events are linked to cADPR 
production. It will be interesting to see if such a pathway exists in mammalian cells too. 
[ndeed, nitric oxide induced mobilisation of Ca2+ from ryanodine-sensitive stores has 
aeen observed in interstitial cells of the mammalian colon and has been proposed as a 
nechanism for the amplification of nitric oxide production in the mammalian g u t[80].
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1.4.5 cADPR induced Ca2+ release
A) Sea urchin egg as a model system
The sea urchin egg has been used as a model system for studying regulation of cellular 
functions by ionic mechanisms. Various preparations have been developed for 
biochemical analyses. Large quantities of homogeneous cells can be obtained readily and 
at the whole cell level, the eggs are large and sturdy enough for various 
micromanipulations, such as microinjection. Unfertilised eggs released into sea water are 
in a dormant state characterised by a depressed metabolism and a slightly acidic internal 
pH. The life span of the egg in this state is 1-2 days. Once fertilised, the eggs undergo 
dramatic transformations. This change is followed by resumption of protein and DNA 
synthesis, and the developmental program is set into motion. The fertilised eggs 
eventually develop into adults. All these changes that eventually immortalise a dying cell 
are triggered by two ionic changes: alkalinisation of internal pH as a result of activation 
of Na+/H+ exchanger in the plasma membrane, and transient elevation of internal Ca2+ 
due to mobilisation of intracellular stores.
The egg is a good model system for elucidating various mechanisms for Ca2+
mobilisation as multiple Ca2+-regulation systems have been identified. Studies show that
IP3 and cADPR receptors are involved in mediating the Ca2+ mobilisation associated with
fertilisation [63,71]. This process is analogous to other ligand-receptor mediated events as
the external stimulus, the sperm, interacts with a surface receptor. Five other Ca2+
transients occur afterward which are different and so likely to involve other second
messenger systems, in that the Ca2+ changes do not require an external stimuli and are
temporally correlated with various developmental events such as pronucleus migration,
nuclear membrane breakdown and metaphase [81]. The source of Ca2+ for these latter
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transients appear to be internal stores, since the early development of the embryo, similar 
to the fertilisation process, can proceed normally for at least the first seven cleavages in 
the absence of external Ca2+ [791. All the developmental events, in conjunction with the 
multiple Ca2+ transients associated with them , are likely to be controlled internally by 
mechanisms that are turned on at fertilisation as the fertilised egg is capable of surviving 
in total isolation.
The egg homogenate preparation was developed specifically for studying the mechanisms 
of Ca2+ mobilisation [44,45l  The prepation can be used without further fractionation. 
Detailed characterisation of this preparation led to the discovery of cADPR. In addition 
to the IP3- and cADPR-dependent Ca2+ release systems, a third independent system 
sensitive to NAADP has been characterised [44,83] (section 1.5). The homogenate 
preparation has the simplicity and accessibility of a cell-free system, yet it contains a 
wealth of possibilities to be explored. Information obtained from the homogenate 
preparation has been applicable not only on the whole-egg level but also to other cell 
systems. Thus, cADPR was discovered in the in vitro preparation and has been shown to 
be active in intact eggs as well as in various mammalian systems I55,84]. Conversely, the 
Ca2+ mobilising effect of cGMP was first demonstrated in intact eggs [74] and later 
verified in the homogenate system. This preparation also allows identification and 
purification of various components of a complex pathway such as Ca2+ mobilisation. The 
plasma membrane and the associated cortical granules can be easily removed as large 
complexes by low speed centrifugation, since the gentle homogenisation largely 
preserves their association. The Ca2+ stores can be separated from mitochondria and 
yolk granules by Percoll density centrifugationI44,45].
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B) Pharmacology o f cADPR -induced Ca2+ release
The Ca2+ mobilising activity of cADPR was first demonstrated in sea urchin egg 
microsomes and since, then several mammalian cell systems have also been shown to be 
responsive. The sea urchin egg system remains the best characterised and much of what 
is known about the characteristics of the Ca2+ mobilising activity of cADPR come from 
investigations of this system.
Cyclic ADP-ribose is at least as effective as IP3 in releasing Ca2+ in eggs homogenates 
[841. Several lines of evidence indicate that cADPR-sensitive Ca2+ release mechanism is 
independent of the DVreceptor. First, the cADPR-sensitive Ca2+ release is insensitive to 
heparin, a competitive inhibitor of the DVreceptor. Second, high concentrations of IP3 
can desensitise the egg chromosomes to IP3 but not to cADPR and vice versa . This 
cross-desensitisation has also been observed in several mammalian [86_89]. Third, 32P- 
cADPR binding to egg chromosomes is insensitive to IP3 or heparin, but can be 
competitively inhibited by nanomolar concentrations of unlabelled cADPR[58]. The close 
proximity observed between the mode of action of cADPR and that of the Ca2+ release 
mediated via RyRs has led to the hypothesis that cADPR is an endogenous regulator of 
RyRs, perhaps by an analogous mechanism by which EP3R activated Ca2+ release via 
IPsRs[331.
O  cADPR as a modulator of CICR
The concept of Ca2+-induced Ca2+-release (CICR) originated from studies on excitation-
contraction coupling in muscles. Investigators found that a small rapid increase in
extravesicular Ca2+ could cause much larger release of stored Ca2+ from skinned muscle
fibres or sarcoplasmic reticulum vesicles [40]. CICR has now been demonstrated in a
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variety of other cell types [28,29]. The RyR was thought to solely mediate the CICR 
mechanism[33], however recent findings suggest that IP3R, under appropriate conditions, 
can also be gated by Ca2+ and thus contribute to CICR 1901. Pertinent to this is the 
observation that the nysensitive Ca2+ release is strongly Ca2+ dependent and, in fact, IP3 
and Ca2+ are coagonists of the IP3 receptor [91'93], but it is not known whether RyRs, in 
addition to being regulated by Ca2+ or mechanical activation, might also be regulated by 
small intracellular mediators. One candidate that might fulfil this role for RyRs is 
cADPR
The pharmacology of the cADPR-sensitive Ca2+ release is very similar to the ryanodine
sensitive CICR. Antagonists of CICR, such as procaine and ruthenium red, selectively
inhibit the cADPR-sensitive Ca2+ release without affecting the HVdependent component
[41]. Selectivity of the CICR antagonists is also observed in other cell system [87,94].
Ruthenium red, but not procaine has been shown to inhibit cADPR-induced release in
Jurkat T cells I9S1. Furthermore, agonists of CICR, caffeine and divalent cations such as
Sr+, at low concentrations, can dramatically potentiate the Ca2+ releasing activity of
cADPR No such stimulation of the nyindependent Ca2+ is seen with similar
concentrations of caffeine [42]. The converse is also true; low concentrations of cADPR
that are sufficient to release Ca2+ by itself can similarly potentiate the Ca2+ releasing
activities of caffeine and Sr+. Indeed, nanomolar concentrations of cADPR increased the
sensitivity of the Ca2+-release mechanism to Sr2* 10-20 fold. High concentrations of
caffeine and ryanodine can release Ca2+ by themselves and selectively desensitise the
response of the microsomes to cADPR but not to IP3 [411. These results indicated that
cADPR may be a modulator of the ryanodine sensitive CICR. It appears that cADPR
can function, in many respects as endogenous caffeine. Indeed, the structure of cADPR
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has some similarities with caffeine. Both compounds have substituents at the N1 
position. The N1 is linked with a methyl group in caffeine while it is the site of 
cyclisation in cADPR. The carbon atoms at the 6-position of both molecules are double 
bonded. It is an =NH group in cADPR, while it is an oxygen in caffeine. These 
structural similarities suggest that the two molecules could act on the same Ca2+-release 
mechanism, while their differences explain why cADPR is five orders of magnitude more 
effective than caffeine.
D) IP? and rvanodine-sensitive Ca2+ stores
Cell fractionation studies measuring binding or functional parameters of exogenously 
applied pharmacological probes reveals that Ca2+-release mechanisms are predominantly 
microsomal. Investigation of subcellular localisation of various Ca2+-release channels 
have employed the use of single-cell Ca2+ imaging to examine spatial aspects of Ca2+ 
signals activated by pharmacological agonists of these channels 1321 and use of electron 
microscopy in conjunction with specific immunocytochemical probes of the channels [96]. 
The results indicate that the IP3 and ryanodine sensitive stores overlap to degrees, 
depending on the cell types. No overlapping principle governing their subcellular 
distribution seems to exist [97l  Certain cells such as Xenopus and hamster eggs and 
oocytes seem to contain only a single type of Ca2+-release channel, the nysensitive 
channels [98,99\  whereas cardiac and skeletal muscle mainly express the ryanodine 
receptors [401. Most cells, including sea urchin eggs [711, neurons 1961 and smooth muscle 
[1001 contain both type of channels. In cells expressing dual Ca2+-release channels, some 
appear to contain a single store with two release mechanisms whereas others appear to 
have different mechanisms distributed on separate Ca2+ pools [32]. In hippocampal
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neurons, RyR are found in axons and dendritic spines wheres IP3 receptors are found in 
cell bodies; both channels colocalise to dendritic shafts[96].
E") cADPR sensitive Ca2+ stores
The nature of the cADPR-sensitive Ca2+ pools has been investigated mainly in sea urchin 
eggs. Fractionation of egg homogenates by Percoll density centrifugation showed that 
cADPR-sensitive Ca2+ stores were well separated from mitochondria, but comigrated 
with a marker enzyme of the endoplasmic reticulum, glucose-6-phosphatase t44,S9l  The 
nonmitochondrial nature is consistent with the fact that cADPR-sensitive Ca2+ release is 
not affected by mitochondrial inhibitors [44,841. Several pieces of evidence suggest that 
IP3 and cADPR-sensitive pools substantially overlap [84]. First, HVand cADPR sensitive 
microsomes comigrate during fractionation using Percoll density centrifugation. Second, 
n*3-and cADPR-induced Ca2+ releases are non-additive. Third, an inverse relationship 
between cADPR- and HVinduced Ca2+ release was detected. Sequential addition of the 
two agents to egg homogenates showed that, if one agent had released more Ca2+, less 
was available for the other to release. The total releasable Ca2+ was similar in all cases. 
These results is consistent with two overlapping Ca2+ pools.
Interestingly, it has been observed in egg homogenates that high concentrations of
cADPR can desensitise the microsomes so that subsequent additions of cADPR would
not produce more Ca2+ release. This effect is not due to elevation of Ca2+ concentration
since the effect persists even after the released Ca2+ is resequestered. The desensitised
microsomes are fully responsive to other Ca2+ releasing agents such as IP3. Similar
results can be obtained with IP3[45]. Researchers have shown that the sensitivity of the
refractory microsomes to IP3 could be restored only if the vesicles were washed to
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remove IP3. A simple interpretation of these results would be that cADPR and IP3 are 
releasing Ca2+ from two separate Ca2+ pools. This interpretation would be in 
contradiction with other results showing that the two pools overlap. Hence the 
mechanism involved may not be as simple as expected. It may be that the Ca2+-release 
channels in sea urchin egg microsomes could potentially be desensitised by their own 
ligand in a Ca2+ independent manner. Irrespective of the exact mechanism, this property 
has proven very useful and has been used to demonstrate the presence of multiple Ca2+- 
release mechanisms in egg microsomes. The apparent desensitisation has since been used 
to show the specificity of the bioassay for cADPR to identify a ryanodine receptor-like 
channel as mediator of the cADPR-dependent Ca2+ release I411, and to demonstrate the 
production of a cADPR-like metabolite in pancreatic P-cells following glucose 
treatments[87].
The question of Ca2+ pools has also been addressed at the intact egg level. IP3 and 
cADPR injections into sea urchin eggs have been reported to induce similar Ca2+ waves 
[1011. However a different spatiotemporal pattern of Ca2+ release was observed for 
cADPR- and ryanodine-induced responses. The difference may reflect activation of 
different RyR receptors or differences in the mechanism of activation of the same 
channels by these two agents since, although cADPR and ryanodine appear to release 
Ca2+ by activating the same channels, the time course of release induced by these agents 
is very different[41]. These results indicate the definite existence of multiple Ca2+-release 
mechanisms in the eggs.
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1.4.6 Identification o f cADPR receptor 
A) Specific binding to sea urchin egg microsomes
In order to demonstrate specific binding, radioactive cADPR with high specific activity 
[31P]cADPR was synthesised and the Ca2+ storing microsomes were purified [46]. The 
binding was not affected by either NAD+ (the precursor) or ADP-ribose (the hydrolysis 
product), but was eliminated by 0.3jjM of authentic cADPR. The unlabelled cADPR 
was an effective competitor of the binding, indicating that it was saturable. The specific 
binding was detected by filtration assay. Scatchard analysis inidicated a binding affinity 
of about 17nM and a capacity of about 25finol/mg protein. The Kd for the receptor is 
identical to the EC50 of cADPR for activation Ca2+ release from egg homogenates. This 
suggests that the cADPR receptor in the Ca2+ storing microsomes may also be 
responsible for mediating Ca2+ release. An obvious possibility would be that the receptor 
itself is also the Ca2+ channel as has been shown for the IP3 receptor. The binding is not 
affected by either IP3 or the IP3 antagonist heparin supporting the fact that the receptor 
for cADPR is different from the IP3R The nature of the binding site remains unclear.
B") Ryanodine receptors as cADPR receptor
The RyR receptor-Ca2+ channel complex is a homotetramer, in which each monomer has 
a molecular weight of approximately 550kDa. The purified receptors can be visualised 
as quatrefoil or clover-leaf structures by electron microscopyI401. Following the cloning 
and sequencing of the cDNA of the mammalian skeletal muscle ryanodine receptor (RY1 
receptor), two other mammalian isoforms of the protein have been identified and their 
amino acid sequence deduced from their cloned cDNA. The ryanodine RY2 receptor 
which shows 66% identity with the RY1 receptor, is expressed in cardiac muscle and
brain, while the RY3 receptor, which shows 67% identity with the RY1 receptor, is
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expressed in the brain and at low levels in many other tissues. The fourth type reported 
is much smaller than the other three isoforms and is a brain specific transcript of the type 
1 gene. This transcript encodes a protein of approximately 75kDa. The best 
characterised RYR isoforms are those expressed in mammalian cardiac and skeletal 
muscle (RyRl & 2), where they constitute the pathway for the rapid release of Ca2+ from 
the sarcoplasmic reticulum which triggers muscle contraction. The cytoplasmic domain 
of the RyR is very large. For the RyRl, this domain is thought to interact with the 
dihydropyridine receptor in the sarcolemma, which is believed to confer voltage 
sensitivity onto Ca2+ release from the sarcoplasmic reticulum. This protein-protein 
interaction allows for rapid activation of the Ca2+ release, leading to a fast contractile 
response as demanded of skeletal muscle, without the apparent involvement of difiusable 
cytoplasmic messengers. Thus, the type 1 receptor may be atypical of ryanodine 
receptors because of this important specialisation in its regulation. The RyR2 o f cardiac 
muscle is also opened by depolarisation of the sarcolemma but, in this case, the 
interaction is indirect in that it depends upon a small pulse of trigger calcium. In effect, 
calcium is functioning as a calcium-mobilising messenger.
Ryanodine receptors have been shown to be regulated by a variety o f physiological 
ligands. For example, adenine nucleotides, Mg2+, F t, inorganic phosphate, sphingosine, 
acyl carnitines and calmodulin, as well as Ca2+, regulate the opining and or closing of 
RYR channels in vitro. RyR activity is similarly modulated by a variety o f non- 
physiological ligands including ryanodine, caffeine, ruthenium red, procaine halothane, 
perchlorate, and certain peptide toxins. cADPR induces the release of Ca2+ from 
ryanodine-sensitive, IP3-insensitive, intracellular stores in sea urchin eggs and other cell 
types, and therefore it is not unreasonable to suggest that cADPR-induced release of
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Ca2+ might be mediated by a ryanodine-sensitive channel. The hypothesis that cADPR 
may be an endogenous regulator of one or more isoforms of the RyR has been 
investigated by scientists. The first direct demonstration of the activation of RyR2 
receptor but lack of effect on Ryl receptor by Meszaros and co-workers led to a general 
acceptance of the proposal that cADPR-induced Ca2+ release is mediated by the RyR 
receptor I931‘ However there are significant discrepancies between the pharmacology 
profile of cADPR-induce Ca2+ release and that of the RyR2 receptor. Mezaros co­
workers reported that cADPR had no effect on skeletal muscle SR Ca2+ efflux, yet 
showed ca. 70% inhibition of [3H]ryanodine binding to skeletal muscle SR in the 
presence of 2pM cADPR. It was also concluded from this data that cADPR produced a 
conformational change in the skeletal muscle RyR that inhibits ryanodine binding without 
affecting SR Ca2+ release. In contrast, another group reported that Ca2+ efflux from 
skeletal muscle SR vesicles was activated by 1-17pM cADPR, however this efflux was 
insensitive to RyR channel inhibitors [102]. This group also demonstrated that cADPR 
had no effect on single skeletal muscle RyR channels in planar bilayers, hence concluded 
that skeletal muscle SR does exhibit a cADPR-activated Ca2+ release pathway, but that 
this pathway operates through non-RyR channels. Fruen and co-workers failed to 
reproduce the effects of cADPR on [3H]ryanodine binding to cardiac and skeletal muscle 
[i°3] were also unable to confirm the reported stimulation by cADPR of cardiac
RyR single-channel activity in lipid bilayers and in SR preparations. The possibility of 
cADPR being an endogenous regulator of the RyR therefore remains controversial.
C) Photoaffinitv labelling of cADPR binding sites
8-azido-cADPR, an antagonist of cADPR was used as a photoaffinity probe for 
identifying the cADPR receptor as the azido group is photoactive. [32P]8-Azido-cADPR
was used to specifically label two proteins having molecular masses of 140kDa and 
lOOkDa from sea urchin egg preparations, and a 45kDa protein in cardiac muscle and a 
75kDa protein from mammalian brain [104l  There molecular weights are much lower 
than known subunits of ryanodine receptors which are around four to five times as large 
t85]. Interestingly caffeine, an agonist of the ryanodine receptor, preferentially inhibits the 
photolabelling o f the lOOkDa protein relative to the 140kDa protein. This could account 
for the desensitising effect of caffeine on cADPR-dependent Ca2+ release. The 
relationship o f these proteins to RyRs has yet to be determined. Further characterisation 
o f these proteins is required to determine whether lOOKDa and 140kDa represent 
smaller variants of the ryanodine receptor. A 75kDa variant of the ryanodine receptor 
has been described in brain[88]. It is possible that cADPR binds to an accessory protein 
which then interacts with the ryanodine receptor. The success of specifically labelling 
cADPR binding sites with 32P-labeled 8-azido-cADPR represents a major step toward 
the eventual purification and identification of these proteins.
1.4.7 Regulation o f cADPR-induced release
A) Calmodulin
Sea urchin egg microsomes purified by Percoll gradients were shown to loose sensitivity 
to cADPR, but the response can be restored by adding back cytosolic extracts whose 
active constituent was identified as an accessory protein known as calmodulintl05]. This 
was substantiated by the finding that addition of W7, a calmodulin antagonist, inhibited 
the cADPR-induced Ca2+ release. It is suggested that calmodulin may interact directly 
with and sensitise the Ca2+ release mechanism in a similar way to the potentiation of 
CICR in egg homogenates by low concentrations of caffeine and divalent cations as
ImM caffeine induced cADPR release without calmodulin as those treated with it.
38
Furthermore, increasing concentrations of Sr2* (10-50pM) progressively sensitised the 
microsomes, resulting in cADPR releasing as much Ca2+ as microsomes treated with 
either calmodulin or caffeine. Therefore, Sr2* and caffeine can substitute for calmodulin 
sensitising microsomes to cADPR, suggesting that cADPR is a modulator which can 
activate the Ca2+-release mechanism when it is in a sensitised state. Indeed, calmodulin 
binding sites have been characterised on mammalian RyRs [106]. Lack of calmodulin or 
other accessory proteins may account for the reason why some workers have difficulties 
in seeing effects of cADPR on Ca2+ release from certain broken-cell mammalian systems.
B) Inorganic phosphate and magnesium ions
The effect of magnesium ions on cADPR-induced Ca2+ release has been investigated in 
sea urchin egg homogenates 11071 and in Jurkat T-cells and HPB.ALL T-lymphocytes. 
Mg2+ is a known inhibitor of the RyR 1371 and has also been shown to inhibit cADPR- 
dependent Ca2+ release. In sea urchin homogenates ImM was the optimal concentration 
for cADPR-induced Ca2+-release. Inhibition of cADPR response by Mg2+ was specific, 
as up to lOmM Mg2+ had no effect on the Ca2+ release induced by IP3. The half maximal 
inhibitory concentration measured in sea urchin homogenates, 2.5mM Mg2+ is identical 
to the IC50 value observed for RyR. This further demonstrates the similarity of the two 
systems. In T-cells free [Mg2+] at 0 and 8.58mM completely abolished cADPR- 
dependent mechanism, whereas maximal Ca2+-release by cADPR was observed at 
1.06mM. These data further substantiate the fact that RyR is one of the central players 
in cADPR-induced Ca2+-release.
The dependency of cADPR-induced Ca2+-release on [Pi] has only been investigated in 
permeabilised T-cell lines ll08]. At low [Pi], very low Ca2+ release was observed in
response to cADPR, whereas at 4-5mM [Pi], cADPR-induced Ca2+ release was much 
more pronounced. Furthermore, stimulation of T cell receptor/CD3 complex with the 
anti-CD3 monoclonal antibody OKT3 in intact Jurkat T cells resulted in an increase in 
the intracellular [Pi] but there was no corresponding increase in [Mg2+]. The TCR/CD3- 
mediated increase of [Pi] from 2.8mM to 4.5mM, where cADPR released considerably 
more Ca2+ in permeabilised cells. Therefore, increase in [Pi] may be a switch to turn on 
cADPR-induced release in the intact T cell. This explains the finding that high 
endogenous concentrations of cADPR remain unchanged during stimulation of the 
TCR/CD3 t9S1. The catabolism of cADPR was shown to be reduced by high [Pi], 
compared to low [Pi] in permeabilised T-cells. Low [Mg2+] appear to have little or no 
enhancing effect on the catabolism cADPR Higher concentrations of magnesium ions 
did not show a significant difference in the catabolism of cADPR.
C) Polvamines
Spermine and related polyamines in physiological concentrations have recently been
shown to inhibit the Ca2+ release induce by cADPR in sea urchin egg homogenate
bioassays [1091 with a half-maximal inhibitory concentration range from 0.25-ImM when
Ca2+ release was triggered by addition of 60 to 200nM cADPR respectively.. Spermine
did not affect Ca2+ release induced by IP3 or NAADP (see section. 1.5.). and was a more
potent inhibitor of cADPR -induced mechanism compared to spermidine and putrescine.
Addition of caffeine and divalent cations such as Ca2+ and Sr2* to spermine-pretreated
homogenates counteracted the inhibitory effect of spermine on cADPR-induced Ca2+
release. In contrast to 8-amino-cADPR (a known specific antagonist of cADPR),
spermine was also able to inhibit Ca2+ release induced by caffeine and ryanodine. This is
consistent with the view that cADPR acts on the RyR indirectly by first binding to a
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specific receptor, whereas the polyamines probably bind directly to the RyR I811. 
Addition of up to 2mM Spermine did not produce a significant release of Ca2+.
A) Polyamines have been proposed as second messengers t1101. Levels of spermine and 
spermidine in sea urchin eggs increase just after fertilisation and reach a maximum 
concentration of l-2mM after 30min [111l  These results indicate that polyamines may be 
endogenous regulators of the cADPR-induced Ca2+ release by inhibition the RyR during 
sea urchin egg fertilisation.
D) Palmitovl-CoA
Palmitoyl-CoA and certain long-chain acyl-CoA derivative metabolites (14-18 carbons in 
length) have been demonstrated to greatly potentiate the effect of cADPR on Ca2+ 
release in sea urchin egg homogenates I1121. The half-maximal concentration of cADPR 
was decreased more than fivefold by pre-treatment of the homogenate with 7(jM 
palmitoyl-CoA, although the maximum Ca2+ release response to cADPR was not 
enhanced. At higher concentrations of ~12|iM palmitoyl-CoA induced calcium release 
on its own. Palmitoyl-CoA induced Ca2+ release was suppressed by drugs that prevent 
activation of the ryanodine channel such as ruthenium red, spermine and calmodulin 
antagonist N-(6-aminohexyl)-l-napthalenesulfonamide, but was not affected by heparin. 
Addition of 6pM palmitoyl-CoA did not produce any significant release of Ca2+ by itself, 
but it sensitised the system to subthreshold concentrations of ryanodine, caffeine and 
Sr2+. In contrast, similar potentiation effects were not observed for IP3 or NAADP- 
controlled Ca2+-release systems indicating that palmitoyl-CoA probably acts selectively 
by activating the ryanodine channel. cADPR was able to desensitise the sea urchin egg 
homogenates to subsequent Ca2+ release by palmitoyl-CoA and vice versa. Furthermore,
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palmitoyl-CoA was found to counteract the inhibitory effect of Mg2+ and spermine, 
which in physiological concentrations suppress cADPR-induced mechanisms. A possible 
detergent effect of palmitoyl-CoA was ruled out because the concentrations used were 
below that required for micell formation or detergent action.
Palmitoyl-CoA is a pivotal component of intermediary metabolism. Interestingly, 
palmitoyl-CoA is present in concentrations between 6.61-15mM in unfertilised sea urchin 
eggs and the level decreased after fertilisation t1131, clearly in a concentration range in 
which it may have a direct effect on the Ca2+ release and modulate effect of other agents. 
These observations provide evidences that palmitoyl-CoA and related long-chain acyl- 
CoA derivatives such as myristoyl- and stearoyl-CoA, in sea urchin eggs and probably in 
numerous other somatic cells, may serve as important modulators of the sensitivity of 
cADPR-regulated Ca2+ release and in higher concentrations may serve as a signal for 
triggering Ca2+-release by itself. Whether cytoplasmic concentrations of palmitoyl-CoA 
serves as endogenous modulators of the cADPR system in vivo remains to be 
determined.
1.4.8 cADPR-induced Ca2+- release in Mammalian cells
The finding that enzymes involved in the metabolism of cADPR (ADP-ribosyl cyclase
and cADPR hydrolase (Sectionl.4.3) are common enzymes in mammalian systems and
the demonstration that cADPR was present in a wide range o f mammalian tissue extracts
suggests that cADPR may be a general Ca2+-mobilising agent in mammalian cells [114].
Furthermore, the demonstration that cADPR exerts its effect through a RyR-like calcium
release channel, indicated that the most likely cells in which cADPR would be effective
were those displaying ryanodine-sensitive Ca2+ release. The widespread occurrence of
42
RyR receptors offered a number of cellular systems for testing cADPR action. Several 
studies have demonstrated cADPR-induced Ca2+ release in mammalian systems. cADPR 
is membrane impermeable because of its highly charged nature, hence the majority of 
these studies have been performed on microsomes derived from these cells or in 
permeabilised cell suspensions.
A) Cardiac muscle
High densities of RyRs in muscle cells made cardiac muscle an obvious choice in which 
to investigate the effects of cADPR in mammalian tissues I40]. The first direct evidence 
that cADPR-induced mechanism was present in cardiac muscles but not in skeletal 
muscle sarcoplasmic reticulum was demonstrated by Mezaros and co-workers [94]. This 
effect was Ca2+-dependent and was abolished by ryanodine. At submicromolar 
extravesicular [Ca ], it increased the rate of Ca efflux, but at free Ca above 10' M, 
the stimulatory effect of cADPR was diminished. Compelling data that cADPR is an 
endogenous activator of the type 2 RyR came from reconstitution studies, where cADPR 
increased the open probability of single RyR2s after cardiac SR vesicles are fused into 
lipid bilayers, but has little effect on RyRl incorporated by the fusion of skeletal SR 
vesicles. Although cADPR appears to be capable of regulating calcium release from 
cardiac SR in intact cardiac myocytes [115], another study of RyR2 properties in lipid 
bilayers suggests that the effects of cADPR are nonspecific and unphysiological as they 
are not apparent in the presence of physiological levels of ATP [116l  A further study 
suggested that cADPR has no effect at all on muscle RyRs I103]. These apparent 
contradictory data might suggest that other factors such as calmodulin (section 1.4.6) are 
involved in conferring cADPR sensitivity upon SR release channels in intact cells.
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B) Pancreatic cells
cADPR but not IP3 has been reported to stimulate Ca2+ release in a cell-free system of 
islet microsomes and to stimulate insulin release in digitonin-permeabilised islets of 
Langerhans[8?1. This is supported by the fact that glucose is effective in inducing insulin 
secretion in the absence of any change in inositol lipid turnover and that responses to 
cADPR or IP3 vary according to tissue or cell types. cADPR showed a Ca2+ release in a 
dose dependent manner with a threshold of 90nM and a maximal release at 500nM. The 
release mechanism desensitised in response to repeated additions to cADPR, showed 
cross-desensitisation with ryanodine at IOOjiM and was not affected by heparin. cADPR 
and Ca2+ both induced insulin secretion in permeabilised islets. The combined addition 
did not induce significantly more insulin secretion than addition of cADPR or Ca2+ alone. 
The mechanism by which cADPR stimulates production of glucose is not known.
C) Pituitary cells
c A D P R  has been shown to release Ca2+ in a dose-dependent manner from permeabilised 
GH4C1 cells at nanomolar concentrations[861. The mechanism of c A D P R  release in these 
cells is independent of the IP 3 R  since it persistes after IP 3  sensitive stores are depleted 
and it is insensitive to heparin. In support of this, GH4C1 cells appear to contain A D P -  
ribosyl cyclase since incubation of P ~ N A D + with an extract from pituitary cells for 15min 
resulted in the formation of a Ca2+-mobilising activity that cross-desensitises with 
authentic c A D P R .
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D) Dorsal root ganglion cells
The presence of a robust caffeine sensitive Ca2+-release mechanism in dorsal root 
ganglion cells made this cell a perfect mammalian cell in which to test the generality of 
cADPR as a Ca2+-mobilising agent from caffeine- and ryanodine sensitive stores.
Caffeine treatment of rat dorsal ganglion cells under whole-cell voltage clamp yields a 
stereotypic response of activating a series of oscillations of cationic currents across the 
plasma membraneI117]. These currents are sensitive to increases in intracellular free Ca2+ 
concentrations and can be considered a physiological index of the intracellular free Ca2+ 
levels. These oscillatory currents are believed to reflect pulsatile Ca2+ release from 
intracellular stores as they are abolished by intracellular application of EGTA and persist 
in the absence of extracellular Ca2+. Intracellular applications of cADPR as low as lOnM 
generated the Ca2+-dependent oscillatory currents. Ca2+ release was from the same pool 
as with caffeine since the effects of cADPR were abolished in cells where caffeine- 
sensitive pools were emptied by prior treatment of cells with caffeine in Ca2+-free media. 
The Ca2+-dependent current induced by cADPR was restored on reintroduction o f Ca2+ 
into the extracellular solution. Effect of cADPR was enhanced by increasing the 
intracellular free calcium concentration, consistent with cADPR modulating a CICR 
mechanism on a caffeine-sensitive calcium pool. Interestingly, in these cells, the 
responses to caffeine and cADPR were not abolished by ruthenium red (a known 




Brain microsomes were a good candidate for investigating cADPR-induced mechanisms 
as nanomolar levels were found in rat brain tissue. Brain tissue appear to have the 
highest activities of ADP-ribosyl cyclase and cADPR hydrolase activities in the 
mammalian tissues examined to date [59J. Cerebellar microsomes have both IP3 and 
cADPR-sensitive Ca2+-release mechanisms. There are several reports documenting 
cADPR-induced Ca2+ release from brain microsomes [64,90,94]. Maximum Ca2+ release 
occured at ~400nm cADPR, whereas maximal release by IP3 was at lpM, although IP3 
released nearly twice as much Ca2+
F) T^ceUs
The discovery of caffeine-sensitive Ca2+ pools in Jurkat T-lymphocytes suggested that 
cADPR mechanism may be a physiological modulator o f the caffeine and ryanodine 
sensitive Ca2+ stores I118],. Indeed, cADPR has been shown to release Ca2+ from 
intracellular stores of permeabilised Jurkat and HPB.ALL T-cells in a dose-dependent 
manner. Half maximal release was obtained at 2.25jjM [9S1 This release was insensitive 
to heparin, but was inhibited by ruthenium red and other known selective inhibitor of 
cADPR-induced Ca2+-release such as 8 -NH2-cADPR and 8 -Br-cADPR. Ryanodine 
prevented cADPR-induced Ca2+ release in Jurkat T-cells. cADPR has been shown to 
increase the binding affinity o f [3H]ryanodine to its receptor at lease 5-fold (Kd ~4-nM) 
in Mouse T-lymphoma cells lll9]. Furthermore cADPR was detected endogenously in 
Jurkat and HPB.ALL T-cells and cGMP-induced Ca2+ release in these cells were 
inhibited by ruthenium red indicating that cGMP may be involved in the synthesis of 
cADPR[95]-
46
1.4.9 Physiological Roles for cADPR
A) Fertilisation
Much of the current knowledge about the mechanism of action of cADPR, metabolism 
and role is derived from studies in sea urchin eggs as discussed in section 1.4.5. 
Microinjection of cADPR into intact eggs can induce a large Ca2+ transient, trigger the 
cortical reaction, and parthenogenically activate the eggs to undergo multiple cycles of 
nuclear envelope breakdown and DNA synthesis [84]. This effect is independent of 
external calcium [73]. The first of the multiple Ca2+ transients that occur during 
fertilisation reactions in the sea urchin eggs is triggered by surface interactions between 
the fertilising sperm and the egg and then sweeps across the egg as a propagating wave. 
Two studies demonstrate a redundancy in the mechanism of Ca2+ mobilisation at 
fertilisation [34,421. It was shown that ryanodine receptors and IP3 receptors both needed 
to be blocked by the pharmacological inhibitors ruthenium red and heparin before the 
wave was abolished. The first direct demonstration that the cADPR pathway is involved 
in fertilisation comes from the use of a novel specific antagonist of the cADPR-binding 
site, 8 -amino-cADPR [120l  Co-injection of heparin and 8 -amino-cADPR was required to 
block the fertilisation response. Inhibition of either was not sufficient to block response. 
Collectively, these studies provide direct evidence that the cADPR signalling pathway is 
activated at fertilisation in the sea urchin egg. Whether cADPR plays a permissive role, 
where it acts as a coagonist for Ca2+ mobilisation, or a true second messenger role, 
where its levels rise on fertilisation, remains to be determined.
B) Insulin secretion
The finding that drugs that inhibit glucose-induced insulin secretion also impair the ability 
o f glucose to stimulate the production of a cADPR-like activity in islets suggests a key
role for cADPR signalling pathway in stimulus-secretion coupling in the pancreatic 13- 
cells 1871 (see section 1.4.7B). Pancreatic islet cells have recently been shown to express 
BST-1, a CD38-like surface molecule having both ADP-ribosyl cyclase and cADPR 
hydrolase activities. This suggests the involvement of multiple enzymes in the regulation 
o f cADPR concentrations in pancreatic islet cells I1211. How glucose stimulates cADPR 
synthesis remains to be resolved. One possibility is that cGMP might be a coupling 
factor. cGMP has been proposed as a mediator of insulin secretion from rat islets since 
glucose causes an increase in cGMP levels in islets and since agents that elevate cGMP in 
islets such as ascorbic acid and sodium nitroprusside, enhance insulin secretion. Further, 
LY83583, an inhibitor o f guanylyl cyclase, abolishes glucose-induced insulin secretion 
[122l  Nitric oxide an activator of soluble guanylyl cyclase, can also enhance insulin 
secretion from pancreatic 3 cells as well as increase islet cGMP levels [1231. Whether 
cGMP/nitric oxide-enhanced insulin secretion is mediated by increasing cADPR synthesis 
needs to be investigated.
C) Smooth muscle
Previous studies has shown that agonist-induced Ca2+ mobilisation in longitudinal muscle 
cells is mediated by Ca2+ influx, which triggers Ca2+ release from HVinsensitive, 
ryanodine-sensitive Ca2+ stores [124]. In contrast, Ca2+ mobilisation in adjacent intestinal 
circular muscle cells is mediated by IP3-dependent Ca2+ release.
The study by Kuwemerle and co-workers suggests a functional role of cADPR as a Ca2+-
mobilising messenger in intestinal longtidunal muscle cells. Authentic cADPR was
shown to bind with high-affinity to permeabilised longitudinal muscle cells (IC50 1.9nM),
release Ca2+ from nonmitochondrial Ca2+ stores (EC50 3.8nM), increase cytosolic
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Ca2+(EC5o 2 .0 nM), and induce contraction in a concentration-dependent fashion. The 
pharmacology of cADPR- and ryanodine-induced 45Ca2+ fluxes appear to be similar: they 
were blocked by ruthenium red and dantrolene and augmented by caffeine, but not 
affected by heparin. cADPR release was also blocked by the competitive inhibitor 8 - 
amino cADPR. In contrast, cADPR did not bind to permeabilised circular muscle cells 
or induce Ca2+ release and contraction. cADPR binding and cADPR-induced Ca2+ 
release were dependent on the concentration of Ca2+. cADPR was capable of stimulating 
Ca2+ release at subthreshold concentration of Ca2+ (25-1 OOnM). Furthermore, 
longitudinal muscle extracts incubated with P-NAD+ produced a time-dependent increase 
in Ca2+ mobilising activity. This activity was increased by pre-treating extracts with 
CCK-8  in a concentration-dependent manner. The Ca2+ mobilising agent was identified 
as cADPR by blockade of response with 8 -amino-cADPR and ruthenium red. The 
increase induced by CCK-8  was suppressed by the CCK-A antagonist, L364,718, 
nifedipine, and guanosine-5'-thiophosphate.
These studies provide evidence that cADPR could act as an agonist-stimulated Ca2+- 
mobilising messenger in intestinal longitudinal muscle cells on a par with IP3 in intestinal 
circular muscle cells I125]. The Ca2+ requirement suggests that cADPR acts to modulate 
Ca2+-induced Ca2+ release rather than initiate Ca2+ release.
1.5 Nicotinic add adenine dinucleotide phosphate (NAADP)
Alkaline treatment of NADP generated a derivative which mobilised Ca2+ from sea
urchin egg homogenates I441' The active derivative was recently purified and shown by
HPLC to be chromatographically distinct from NADP and NADPH. Structural analysis
by NMR and MS identified this metabolite as NAADP (see Fig 1.10). The release from
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NAADP showed half-maximal effective concentration of 30nM and was specific as 
NADP and nicotinic acid adenine dinucleotide were ineffective even at 10-40 fold higher 
concentrations. NAADP-induced Ca2+ release was desensitised to further addition of 
NAADP. The conversion of NADP to NAADP involves deamidation of the amide 
group. The possibility that this reaction can be catalysed by a cellular enzyme was 
investigated by Aarhus and co-workers[126]. ADP-ribosyl cyclase and CD38 were tested 
as candidates. It was discovered that both these enzymes catalyse the conversion of 
NADP to NAADP. The conversion required an acidic pH and the presence of 
nicotinamide indicating a base-exchange reaction. At neutral pH, the cyclase converts 
NADP to cyclic ADP-ribose 2'-phosphate which does not mobilise Ca2+ in sea urchin 
eggs, although has been shown to mobilise Ca2+ in other systems such as rat brain 
microsomes [127] and Jurkat T-cells. In contrast, CD38 converts NADP to ADP-ribose 
2'-phosphate. In view of the above ADP-ribosyl cyclase and CD38 appear to be crucial 
enzymes in Ca2+ signalling.
NAADP Ca2+ stores are distinct from those of IP3 and cADPR as identified by Percoll 
densitiy fractionation. There is no cross-desensitisation between NAADP- and 
nVcADPR-induced Ca2+ mechanisms. Furthermore, NAADP-induced mechanism is not 
affected by known agonsits of IP3 and cADPR. The microsomal Ca2+-re-uptake inhibitor, 
thapsigargin, while functionally removing IP3 and cADPR-sensitive pools, leaves the 
NAADP-sensitive Ca2+ pool intact. However, the non-additive release of NAADP- 
induced release and that by IP3 and cADPR suggests either direct or indirect 







Figure 1.10: Structure of NAADP 
1.6 Adenophostins.
Adenophostins A and B (Fig 1.11) are potent IP3 receptor agonists which bind to the IP3 
receptor and induce Ca2+ release from nysensitive Ca2+ stores. They were discovered 
during the search for activities inhibiting the binding of [3H]-InsP3 to rat cerebellar 
membranes. Adenophostins A and B were isolated from the cultured broth of 
Penicillum brevicompactum SANK1191 and SANK12177 [18,19]. The compounds have 
been fully characterised using various techniques such as UV and NMR spectroscopy, 
chemical and enzymatic degradation together with elemental analysis and high resolution 
mass spectroscopy. They are adenosine-2'-phosphates with glucose unit at C3' position 
of the adenosine. The glucose unit possesses phosphate groups at positions C3" and 
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Figure 1.11 Structure of Adenophostins 
1.7 Aims o f the Project
Structural analogues of biologically active compounds have in many instances proven to 
be useful reagents or probes of studying biological processes. Synthetic analogues of 
cADPR are needed to probe structure activity relationships (SAR). Hence, our first aim 
was to test whether a chemo-enzymatic route which was designed could be generally 
applicable for synthesis of structural analogues of cADPR This method involves the 
chemical synthesis of NAD+ analogues followed by enzymatic cylisation into the 
corresponding cADPR analogue by ADP-ribosyl cyclase provided that the enzyme is 
sufficiently non-discriminatory. The loose substrate specificity of the Aplysia cyclase has 
been demonstrated in this work.
The second aim was to design, prepare and characterise structurally modified analogues 
of cADPR The structure of cADPR provides a wealth of opportunity to design 
structurally modified compounds. Three types of modifications can be envisaged: (a)
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modification to one or both ribose moieties (b) modification to the purine ring and (c) 
modification to the pyrophosphate linkage. This work has focused on the synthesis, 
characterisation and use of AMP analogues as tools for introducing modification to the 
purine ring and the adenine ribose moiety of NAD+ (chapters 2&3) and as a result 
produce structural analogues of cADPR (chapter 4). The analogues synthesised will be 
used as tools in defining the key recognition elements of cADPR which contributes to its 
potent activity and ultimately used to design potent antagonists (chapter 5).
The role of the ribose hydroxyl groups on the Ca2+ releasing potential of cADPR were to 
be investigated by synthesis of hydroxyl deleted analogues of cADPR and also by 
substituting other functional groups in place of the ribose hydroxyl groups (chapters 4 & 
5). Substitution of the hydrogen atom at the 8 -position o f the purine ring with amino or 
bromo group converted the molecule from an agonist to an antagonist when tested in the 
sea urchin egg system, hence we have looked at the effects of these analogues on 
cADPR induced mechanism in Jurkat T-cells. Several other 8 -substituted analogues 
were prepared and characterised for use in studying the important feature that are 
responsible for transforming the activity of the 8 -substituted molecule from an agonist to 
an antagonist. The structural analogues synthesised were tested in the non-mammalian 
sea urchin egg system and in the mammalian Jurkat T-cells in order to identify any 
differences in the structural requirements for the cADPR-sensitive Ca2+ release 
mechanism in these systems.
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CHAPTER 2: SYNTHESIS OF ADENINE NUCLEOSIDES AND
NUCLEOTIDES
Adenosine and adenosine 5 '-monophosphate play a pivotal role in the synthesis of 
modified nucleosides and nucleotides of biological and biochemical importance [132‘134]. 
The term nucleoside applies to carbohydrate derivatives of N-heterocyclic compounds 
whether the attachment is through nitrogen, carbon. A vast number of nucleosides have 
been isolated from natural sources and they exhibit a wide range of biological activities. 
Adenosine (1) consists of a purine base and a ribose moiety (Fig.2.1). Nucleotides are 
phosphate esters of nucleosides. In the simplest form, as in adenosine 5'- 
monophosphate, the hydroxyl groups of the pentose is esterified by a single phosphate 
monoester. Nucleoside 5'-monophosphates are quite stable in alkali in which they exist 
as the dianion [134], but are hydrolysed in acidic and neutral solution. The nucleotide 
monophosphate loses one proton at pH 1 and a second proton at around pH 7. 
Adenosine undergoes many reactions of its constituent base and sugar [135_137], however 
there are some reactions which are of particular importance in nucleoside chemistry. 
Several analogues of AMP have been synthesised as precursors in the preparation of 
cADPR analogues of interesting biological properties.
Chemistry of Nucleosides
2.1.1 Acy lotion and Alky lotion
Nucleosides undergo esterification and etherification reactions. They can be fully 
acylated on the sugar hydroxyl groups, or on any amino group(s) of the heterocyclic ring 
by treatment with an acylating agent. These reactions are useful for introducing
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protecting groups on the ribose hydroxyl groups and amino group(s). The chosen 
protecting group should be stable during synthesis and easily removed afterwards. 
Added protecting groups not only guarding against side reactions during synthesis, but 
also increases the lipophilicity of fully and partially protected nucleotides. Trialkylsilyl 
ethers are very useful when base-stable hydroxyl blocking groups are required. Base 
labile acyl groups such as acetyl (Ac) and benzoyl (B2) groups are often used for 2 ' and 
3 '-hydroxyl group protection. Acyl groups can be removed by ammonolysis at the end 
of the synthesis.
Alkylation of nucleosides with diazomethane or with alkyl-halides in the presence of 
alkali or silver oxide results in the alkylation of the ribose hydroxyl groups and alkylation 
of the heterocyclic moiety. For example, phenyldiazomethane has been used in the 
preparation of 2 ' and 3'-O-benzyl derivatives of adenosine, inosine and guanosine in the 
presence of stannous chloride as catalysttl38].
2.1.2 Reactions o f the Heterocyclic Base Moiety o f Adenosine 
A number of reactions of the nitrogen heterocyclic ring portion of adenosine may be 
carried out. Electrophilic substitution at carbon and nitrogen, nucleophilic subtitution of 
the amine group by nitrous acid (converts adenosine to inosine) [139] and other 
nucleophilic substitution reactions which require fuctionalisation of the purine, if no 
readily displaceable groups are present followed by nucleophilic displacement by other 
nucleophiles containing the desired substituent.
Studies on electrophilic substitution at the carbon of purines have been measured by 
deuterium incorporation, which occurs readily at the position 8  of nucleosides and
nucleotides of guanine and adenine [l40]. Several experiments have suggested that 
electrophilic substitution involves initial protonation at N-7, followed by proton 
abstraction from C-8  by hydroxide (or deuteroxide).
2.2 8 -Bromoadenosine and its Nucleotide
Introduction of a bromo group into the 8 -position of the heterocyclic ring of various 
purine nucleosides and nucleotides has provided intermediates that are invaluable for the 
preparation of many 8 -substituted derivatives. This is due to the ease at which the 
bromo group can be displaced with a suitable nucleophile. Initial attempts at the 
synthesis of 8 -bromoadenosine (3) were made by treating 2',3',5'-tri-0-acetyl adenosine 
with bromine in sodium acetate-glacial acetic acid giving the product in 59% yield [141]. 
This method was not suitable for more labile deoxynucleosides, as acidic conditions were 
required. This prompted a study of the use of neutral apolar conditions. 2'3'5'-Tri-0- 
acetyl adenosine was treated with A-bromoacetamide in chloroform to produce the 8 - 
bromo-derivative [141]. The acetyl groups were removed upon treatment with methanolic 
ammonia to give the 8 -substituted purine nucleoside. Treatment of adenosine with N- 
bromosuccinimide in DMF as solvent also produced 8 -bromoadenosine in reasonable 
yield [U2\  Bromination of purine nucleosides in aqueous solution has been adopted as 
standard practice. Appropriate use of buffers can minimise the possibility of glycosidic 
cleavage[I43,144].
Bromination of adenosine and AMP (Fig 2.1) was achieved by use of bromine in aqueous
acetate buffer. The reaction proceeded well at room temperature and excess bromine
can be removed by extraction into chloroform or by addition of sodium bisulphite.
Introduction of bromine into position 8  of adenosine and AMP caused a slight shift in the
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absorption maximum in the UV spectrum from 259 to 264nm. The bulky bromine atom 
restricts rotation about the glycosidic bond. X-ray diffaction studies by Tavale and
n h 2
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Y = O P O 3H2  (4)
Figure 2.1 Bromination of adenosine and AMP
Sobell indicated the syrc-conformation for 8 -bromoadenosine compared to anti in 
adenosine in their crystal structures [145]. This also appears to be the preferred 
conformation of 8 -bromopurine nucleotides in solution and thus confers interesting 
biological properties on the purine nucleotide analogues. JH-NMR spectrum of 8 -bromo- 
AMP (Fig 2.2) showed all the protons of the nucleotide. The important feature of which 
the H2' resonates at higher frequency (8  5.1) compared to the H2' (8  ~ 4.6) proton in 
AMP.
2.2.1 8-Methyladenosine (5)
8 -Substituted adenosines have been used as probes of the influence of substitution on 
conformation around the glycosyl bonds, since 8 -substituents tend to force the usual anti 
form o f adenosine to adopt the .^-conformation as a result of steric effects[146]. Alkyl
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Figure 2.2: ^ -N M R  (400MHz, D20 )  spectrum of 8 -bromo-adenosine 5'- 
monophosphate as its triethylammonium salt.
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groups have the least electronic effect on the adenine nucleus. Hence, this has generated 
interest for their use in the investigation of enzymes utilising adenosine derivatives such 
as adenosine deaminase and adenosine kinase. The synthesis of 8 -methyl-adenosine (5 - 















Figure 2.3: Synthesis of S-Methyladenosine (5) from 8-Bromoadenosine (3)
8 -Bromoadenosine smoothly cross-coupled with trimethyl aluminium in the presence of 
palladium catalyst to yield 8 -methyladenosine. It was necessary to protect the ribose 
hydroxyl groups and the amino group on the purine ring to prevent side reactions. This 
was achieved by silylation using hexamethydisilazane in the presence of a catalytic 
amount of ammonium sulphate. The lipophilicity of the starting material was also 
improved by the protecting groups as shown by TLC in dichloromethane:methanol (9:1) 
in which protected 8 -bromoadenosine had an Rf of 0.57 compared to 0.36 for the 
unprotected derivative. Protection was carried out in situ as it was not necessary to 
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under anhydrous conditions as trimethylaluminium is very reactive to small traces of 
water. De-protection of 8 -methyladenosine was carried out under acidic condition by 
refluxing in methanol with a small amount of ammonium chloride. The crude product 
was purified by silica gel column chromatography to obtain pure 8 -methyladenosine. 
The ^-N M R  chemical shifts exhibited by the pure product was as reported 
previously11473. It showed the absence of trimethyl esters indicating that the product was 
fully deprotected. A new peak at 5 2.46 equivalent to 3 protons confirmed that a CH3 
group had been added. FAB-MS showed a +ve m/z peak at [282 (M + H)+ - Fig 2.4] 
and -ve ion peak at 434 (M + NBA)- . The accurate mass was calculated as 282.120743 
for (M + H)+ and confirmed by +ve ion FAB-MS. These spectrosopic data confirmed 
the authenticity of the 8 -methyladenosine synthesised.
2.2.2 8-Methylaminoadenosine 5 -monophosphate (6 )
Nucleophilic displacement of the bromine atom of 8 -bromoadenosine with 
methylamine11481 was carried out in an excess of methylamine solution in methanol under 
reflux to obtain 8 -NHMe-AMP (6  - Fig 2.5). A shift in the UV absorption maximum 
from 264nm to 278nm accompanied the displacement reaction. The crude sample was 
purified by ion-exchange chromatography to obtain the pure product in 65% yield. 8 - 
Methylamino-AMP (6 ) is known to exist in the anti conformation as with 8 -amino-AMP 
and AMP11*". The H2' chemical shift in AMP, 8 -NH2-AMP (9) and 8 -NHMe-AMP is 
similar. A value of 6 4.6 was measured here with Jh(i>h(2') 8.0 Hz and Jh(2>h(3') measured 
as 5.8 Hz. These values are similar to those reported previously11481. The H(2') proton is 
sensitive to deshielding effects originating from the adenine ring depending on the 
glycosyl torsion angle. In the syn conformation, as in 8 -Br-AMP, H(2 ') resonates at a
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higher frequency, 8  5.1 compared to 4.6 in 8 -NHMe-AMP, with a Jh(i>h(2') value of 6.1 
Hz. A new peak at 8  2.8 represents the three methyl protons on methylamine. This 
supported the fact that a displacement reaction had taken place. jlP-NMR showed a 
singlet at 8  3.2 indicating the presence of a monophosphate. Mass analysis by 
electrospray showed m/z of the -ve ion as 375.4 (M-H)- which agrees with the 
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Figure 2.5: Synthesis of 8 -methylaminoadenosine 5'-monophosphate (6 )
2.2.3 8-Dimethylaminoadenosine 5 '-monophosphate (7)
Nucleophilic displacement of the 8 -bromo substituent of (4) using an excess of 
dimethylamine in methanol under reflux generated 8 -NMe2-AMP (7 -Fig 2.7). A shift in 
UV absorption maxima from 264 to 274nm accompanied the displacement reaction. The 
^ -N M R  spectrum was comparable to that reported previously11481. The presence of a 
new peak at 8  2 .8 , equivalent to 6  protons, confirmed the substitution by the 
dimethylamino group. The H(2') chemical shift in 8 -dimethylamino-AMP is similar to 
that of S-Br-AMP. It has been established that 8 -NMe2 exists in the syn conformer as in
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8-Br-AMP11481. H2' resonated at 5 5.1, a higher frequency compared to that for H2' in 
AMP, with a J(hi'-h2') value of 6.7. This difference is due to the deshielding effect from 
the adenine ring in the syn conformer. 31P-NMR spectrum showed a singlet at 6 +2.2 
indicating a monophosphate. Mass analysis was carried out using FAB-MS. m/z values 
of 391 (M + H)+ and 389 (M -  H)" were consistent with the molecular mass of 390 for 
8-dimethylamino-AMP.





Figure 2.7: Synthesis of 8-dimethylaminoadenosine 5'-monophosphate (7)
2.2.4 8-Aminoadenosine 5 '-monophosphate (9)
It is known that displacement of the bromo substituent of 8-Br-AMP with an amino 
group cannot be achieved by nucleophilic displacement with methanolic ammoniaI149J. 
Hence 8-NH2-AMP (9) was synthesised using the method used by Cartwright et a l [1501. 
This was achieved by reduction of 8-azido-AMP (8 -Fig 28) with dithiothreitol in TEAB 
(pH 8.3) under reduced light. A shift in the UV absorption maximum from 282 to 
274nm accompanied the reaction as previously reported11501. The crude sample was 
purified by ion-exchange chromatography to afford pure 8-amino-AMP in 65.3% yield. 
The !H NMR spectrum was as previously reported11481. The H2' chemical shift (8 4.6) is
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similar to that of AMP. This similarity in chemical shift suggests an cmti conformation as 
with AMP. The mass spectrum was not recorded due to limitation of sample.
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Figure 2.8: Synthesis of 8-amino-adenosine S'-monophosphate (9)
2.2.5 8-Piperidyladenosine 5 -monophosphate (10)
Substitution of the bromo substituent of 8-Br-AMP with a piperidyl group was achieved 
by treating 8-Br-AMP with piperidine at 50°C (Fig 2.9). Nucleophilic substitution by 
piperidine resulted in a change in UV absorption maximum from 264 to 275nm. The 1H- 
NMR spectrum of its product showed the presence of protons corresponding to the 
piperidyl protons at 8 3.2 (4 protons) and 1.6 (6 protons).. A chemical shift value of 8
5.1 was measured for H(2'), with a J(H1'-H2') value of 6.4 Hz and these are similar to 
the values obtained for H2' in 8-Br-AMP. This suggests that the nucleotide is in the syn 
conformation as in 8-Br-AMP, which may be a result of the steric bulk of the piperidyl 
group.. 31P-NMR showed a singlet at 8 +1.97 which is consistent with a monophosphate. 
m/z vadues measured by FAB-MS (-ve ion) of 860 (2M)~ and 429(M -  H)" also showed 
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Figure 2.9: Synthesis of 8-piperidyladenosine 5'-monophosphate (10)
2.2.6 8-Methoxyadenosine 5 '-monophosphate (11)
Nucleophilic substitution of 8-Br-AMP with methoxide anion was achieved using a 
similar procedure used for the synthesis of 8-methoxyadenosine 8-Br-adenosine11491 to 
yield 8-methoxy-AMP (11). 8-Br-AMP was treated with approximately 5 equivalents of 
sodium methoxide in methanol under reflux overnight. The UV absorption maximum 
changed from 264 to 260nm upon displacement of the bromo group with the methoxide 
group. The presence of a new singlet at 5 4.0 equivalent to 3 protons supported the 
presence of the methoxy protons. The protons resonated at a high frequency compared 
to methyl protons attached to carbon due to the deshielding effect of the oxygen atom in 
the methoxy group. The chemical shift measured for H2' was 6 4.8 with J(Hr-H2') value of
5.5 suggest that 8-methoxy-AMP may be in the syn conformation. The jlP-NMR 
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Figure 2.10: Synthesis of 8-methoxyadenosine 5'-monophosphate (11)
2.2.7 8-Oxyadenosine 5 -monophosphate (13)
Treatment of 8-Br-AMP with sodium acetate in acetic acid anhydride under reflux 
generated the 8-acetyl ester of 8-hydroxy-AMP. The ester formed at position "8 of the 
purine ring was hydrolysed to 8-hydroxylAMP. A shift in UV absorption maximum from 
264 to 270nm was observed with the formation of 8-Hydroxy-AMP. NMR 
spectroscopy identified all the ribose and HA2 adenine protons. The proton chemical 
shift for H2' at 5 4.9 with J(hi'-h2') of 5.5 is consistent with the predominant syn 
conformation of 8-hydroxy-AMP. 8-“hydroxy”-AMP (12) is known to exist 
predominantly in the keto tautomer in the physiological range 5 < pH <9 (13 -Fig 2.10) 
[i49,i5i]^  jjence there is a proton on N-7. The phosphorus peak for the monophosphate 










Fig 2.11: Synthesis of 8-oxy-adenosine 5'-monophosphate (13)
2.3 Phosphorylation of Adenosine Analogues
Nucleotides are phosphate esters o f the nucleoside. They are commonly prepared by 
phosphorylation of the nucleoside. Phosphorylation of adenosine to its 5'- 
monophosphate ester involves use of a phosphorylating agent. It usually involves 
nucleophilic attack of oxygen on an activated phosphorus atom. Hence a phosphorus 
atom and three oxygens are transferred to the hydroxyl group of the nucleoside. As 
phosphoric acid is tribasic, measures have been taken to protect one or more of the 
phosphoryl hydroxyl groups to achieve selective phosphorylation. Khorana showed that
— o- i) NaOAc/AcOfl
ii) NaOH




a monoalkyl phosphate reacts with DCC in pyridine to give an activated intermediate, 
which reacts to give an activated cyclic triphosphate tl52]. The phosphate-DCC 
intermediate, or other pyrophosphate intermediates may then react with an alcohol to 
give a new dialkyl phosphate. The early procedures for phosphorylation of nucleosides 
involved a phosphate bearing benzyl esters, e.g use of dibenzyl phosphochloridate and p- 
nitrophenyl esters. Hydrogenolysis was required in the former case for removal of the 
blocking groups and strong alkali or enzymic method for the latter case. A problem 
encountered when DCC is used to prepare phosphodiesters is that A-acylureas are 
frequently formed as by-products. This problem can be overcomed if the 
phosphomonoester is activated with an arenesulfonyl chloride (ArS02Cl)[153]‘ 
Arenesulfonyl chlorides have been used extensively to condense phosphomono- and 
diesters with hydroxyl groups in nucleosides. p-Cyanoethyl phosphate was introduced 
by Tener as a phosphorylating agentI154]. This group can be conveniently removed by 
dilute alkali or ammonia by an a , P-elimination of acrylonitrile from the phosphate. This 
reagent has been found to be useful especially in preparation of nucleotides that may be 
sensitive to other deblocking methods [155].
The search for new phosphorylating agents grew simultaneously with the need for new 
phosphorylated nucleosides. Yoshikawa and co-workers found that phosphoryl chloride 
with a very small amount of water added was highly effective in the phosphorylation of 
isopropylidene nucleosides [156]. In their developmental studies, they found that trialkyl 
phosphate was a good solvent for phosphorylation requiring only a slight excess of 
PO C I3. More importantly, it was found that a wide range o f unprotected nucleosides 
was selectively phosphorylated at the 5'-position by POCI3 in trialkyl phosphate solvent,
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particularly trimethyl or triethyl-phosphate. This method is now widely accepted and is 
elegant in its simplicity. Only very small amounts of 2' or 3' nucleotides are formed. 
Trialkyl phosphate is not only an excellent solvent, but it has recently been shown that 
reaction of guanosine with triethyl phosphate at 50°C for 15 min produced a guanosine -  
triethyl-phosphate complex in which the triethyl-phosphate is co-ordinated to guanosine 
of the high-anti form tl57]. This complex showed excellent selectivity and high reactivity 
toward phosphorus oxychloride. The rate o f selective phosphorylation was markedly 
improved by preheating the mixture of guanosine and triethyl-phosphate, followed by 
addition of the phosphorus oxychloride to the mixture at 0°C. We have adopted this 
method in the phosphorylation of adenosine analogues.
2.3,1 8-Bromoadenosine 5 -monophosphate (4)
8-Bromoadenosine (3) was selectively phosphorylated at the 5' position in good yield 
using POCI3 in triethyl-phosphate to yield the corresponding monophosphates (4 Fig. 
2.11). The reaction was quenched with pyridine :water to neutralise the acid produced 
as the product is labile to acid attack. The problem encountered with this method was the 
presence of inorganic impurity which could not be removed by ion exchange 
chromatography as this carries the same amount of charge as the mononucleotide
It is important to remove the inorganic phosphate impurity as this will interfere with the 
next stage of synthesis (i.e. synthesis of NAD+ analogues) leading to formation of side 
products. The nucleotide was freed from inorganic phosphate impurities by adsorption 
onto a charcoal column11351 (Fig 2.12). The inorganic impurity elutes off straight off the
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column and the pure nucleotide can be washed off the charcoal with 
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Figure 2.12: Phosphorylation of 8-bromoadenosine
2.3.2 8-Methyladenosine 5 -monophosphate (14)
8-Methyladenosine 5'-monophosphate was synthesised by selective phosphorylation of 
previously synthesised 8-methyladenosine (5- Fig 2.12) at the 5'-hydroxyl group, using 
PO C I3 in triethyl-phosphate. The crude product was purified by ion-exchange 
chromatography and the inorganic phosphate impurity was removed by passing the 
nucleotide solution through a charcoal column (Fig 2.13). The pure product was 
obtained in 60% yield. The 31P-NMR spectrum showed the presence of the organic 
monophosphate at 5p +4.0, which confirmed that phosphorylation was achieved. The 1H- 
NMR spectrum exhibited all the protons of the nucleotide in question.
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Figure 2.13: 31P-NMR (162MHz, D20 ) spectrum of 8 -C H 3 -A M P  (14): illustrating 
the use of charcoal to remove inorganic phosphate impurity, a) !H-coupIed 
spectrum before charcoal treatment b) ^-decoupled spectrum after charcoal 
treatment.
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HO OH 
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i) PO(OEt)3/POCI3 | __O__




Figure 2.14: Synthesis of 8-methyladenosine 5'-monophosphate 
2.3.3 3 -O-Methyladenosine 5 -monophosphate (16)
3 '-O-Methyl-adenosine 5'-monophosphate was prepared to introduce a small change in 
the cADPR molecule, for the study of the role of the ribose 3'-OH group in cADPR 
release mechanism. The commercially available 3 '-O-Me-adenosine (15) was selectively 
phosphorylated at the 5'-position using PO CI3 as the phosphorylating agent in triethyl- 
phosphate (Fig. 2.15). The product was purified by ion-exchange chromatography 
followed by treatment on a charcoal column to remove inorganic phosphate impurities.
NH
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The 31P-NMR spectrum showed the presence of organic monophosphate at 8 +2.3 and 
the !H-NMR spectrum exhibited all the nucleotide protons with the ribose methyl 
protons resonating at 5 3.4 equivalent to 3 protons. Mass analysis was carried out using 
ES-MS. m/z value of 360 (M -  H)~ is consistent with the molecular mass o f 361 for 3'- 
O-methyl-adenosine 5 '-monophosphate.
2.4 Purification and Analysis of Nucleosides and Nucleotides
The acidic and water-soluble nature of nucleotides governs the techniques used for their 
purification and analysis. Paper and thin-layer chromatography are useful techniques for 
the analysis o f simple mixtures, but are not always satisfactory for the analysis of 
complex mixtures due to poor resolving power. Thin-layer chromatography has been 
employed for qualitative analysis of nucleosides in this work and purification was carried 
out using silica-gel column chromatography. HPLC has proven invaluable for analysis of 
nucleotides in view of the excellent resolution offered with this technique. We have 
employed the use of ion-exchange HPLC for qualitative analysis of nucleotide mixtures. 
In all cases, the purity of the final products were verified by HPLC analysis. A 
representative HPLC trace is shown in Fig. 2.17. Ion-exchange chromatography has 
been used for routine purification of nucleotides. Other available methods include 
reverse-phase HPLC and gas-liquid chromatography although the latter is not very 










Column: Partisil 10p SAX (10x0.46cm) 
Guard column: Partisil 10p SAX 
(10x0.46cm)
Eluent: 0.5M KH2P 0 4 pH 3.0 with 
H5P 0 4
Flow rate: 1 ml/min 
Gradient: isocratic
1 2 3 4 5
Time (mins)
Figure 2.17: HPLC analysis of 3'-<9-methyI-adenosine 5'-monophosphate
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Mass spectrometric analysis of phosphorus-containing compounds has been well 
reviewed [158,159]. The problem encountered with nucleotides is that of low volatility. 
FAB-MS has emerged as an important technique for the analysis of nucleotides as it 
offers many advantages over field desorption mass spectrometry particularly with respect 
to sample manipulation and the ease of obtaining reproducible data. Improvements in 
liquid chromatography-MS, for example use of electrospray techniques has found use for 
analysis of nucleosides and nucleotides. FAB-MS and Electrospray-MS techniques have 
been employed for routine analysis of nucleotides in this work. FAB-MS and ES in the 
-ve ion mode is the most structurally informative due to great stability of the phosphate 
monanion in the (M -  H)_ species.
Nuclear magnetic resonance is very well established and described in texts for the 
identification of nucleotides. *H and 31P-NMR spectroscopy have been employed 
routinely for structural analysis of nucleotides.
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CHAPTER 3: SYNTHESIS OF NAD+AND ITS ANALOGUES
The use of NAD+ as a common substrate for a large number of enzymes has generated 
widespread interest in the use of this coenzyme to investigate the mechanisms of enzyme 
catalysis. NAD+ analogues have been extremely useful as biochemical probes to increase the 
understanding of the mechanism of action of dehydrogenases. Chemical and enzymatic 
procedures have been used extensively to prepare analogues of NAD+ containing alterations 
in all major portions of the coenzyme molecule One hundred and eighty one analogues have 
been listed in a review11601 and various methods for the preparation of NAD+ and its analogues 
have been described in texts fl61]. NAD+ analogues were synthesised in this work for use as 
intermediates in the synthesis of cADPR analogues (see chapter 4).
3.1 Chemical Synthesis of NAD+ and its Analogues
NAD+ is a dinucleotide anhydride consisting of nicotinamide 5'-mononucleotide (NMN) and 
adenosine 5'-monophosphate (AMP) moieties. Hence, in general NAD+ and its analogues 
have been prepared through chemical condensation of nucleoside 5 '-monophosphate making 
use of a condensing agent, as these compounds themselves are not suitable for condensation 
reactions and must therefore be activated. A pyrophosphate bond is formed in the 
condensation process. Introduction of an additional substituent polarises the bond between the 
ligand and the central phosphorus atom of the nucleotide which allows for the cleavage of the 
polarised bond by a second phosphoric acid ester, forming a more stable nucleotide anhydride 
(Fig 3.1).
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Ri and R2 = nucleoside moiety 
X= activating group
+ HX
Figure 3.1: Formation of a pyrophosphate bond illustrating use of an activating 
group.
Amino-, imino-, isourea- and acid substituents are used for the activation of nucleoside 
monophosphates and in most cases the resulting activated phosphoric acid ester derivatives 
are unstable and are easily hydrolysed in aqueous solution. Phosphoramidates and isourea 
esters are relatively more stable due to the nitrogen electrons that decrease the polarisation. 
This stabilising effect is lost in acidic solution as protonation of the amide group results in an 
increase of polarisation which causes cleavage of the amide bond in the presence of a second 
phosphoric acid ester to form the desired diphosphate (Fig 3.2)[162].
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Figure 3,2: Use of phosphoramidates in pyrophosphate bond formation.
Imidazoles have been used frequently for the activation of phosphoric acid esters. 
Protonation is unecessaiy in this heterocyclic compound because of the aromatic character 
(Fig. 3.3), the imidazole is cleaved and the anhydride bond is formed in the presence of a
second nucleotide tl63] Acidic substituents are also suitable to form polarized bonds. The 
group transfer potential of phosphoric acid anhydrides is well known for example, in aqueous 
solution, adenosine tri-phosphate (ATP) forms a mixture of various oligonucleotides.
Figure 33: Imidazoles as activating groups in pyrophosphate formation.
This type of reaction is known as anion exchange (Fig. 3.4) [164]. Mixed anhydrides react 
similarly with trifluoroacetoxy residues being one of the most suitable groups [165l  
Carbodiimides and nucleoside 5 '-monophosphates react to form an isourea ester with the 
isourea ligand as the activating group. Isourea derivatives, as explained above, are often 
stable in aqueous solutions and are hydrolysed slowly except in acidic solution where 
hydrolysis occurs at a faster rate.
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Figure 3.4: Formation of a pyrophosphate bond by an anion exchange method.
Addition of another nucleophilic ligand leads to simultaneous formation of urea (Fig. 3.5). 
The first successful synthesis of NAD+ was described by Hughes and co-workers using a 
carbodiimide - N,N-dicyclohexylcarbodiimide (DCC) as the condensing agent [166l
H+,\
R— N = C = N — R
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Figure 3.5: Carbodiimides in pyrophosphate synthesis
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AMP and NMN were condensed with DCC in 75% aqueous pyridine as solvent. The two 
nucleotides were observed to react differently. AMP reacts with DCC to form the isourea 
derivative, however NMN isourea ester was only formed in small amounts possibly because 
of the betaine structure of NMN (inner salt). The unsymmetrical NAD+ was isolated as the 
main product with 70% yield, with the formation of only small amounts of the symmetrical 
dinucleotide. This type of reaction has since been used by several investigators to prepare 
NAD+ analogues. Variable yields have been reported, for example, 2'A-deoxy-NAD+ was 
synthesised in 16% yield[16?1, nicotinamide formycin dinucleotide (NFD ) was synthesised in 
11.6% yield11681
The experimental difficulty for the synthesis of NAD+ and its analogues is not due to the 
formation of the anhydride bond but due to problems caused by the solubility of nicotinamide 
mononucleotide. The positively charged pyridine ring of the nucleotide results in an excellent 
solubility in polar solvents such as water. It is easily dissolved in dimethylsulfoxide (DMSO), 
but the solvent slowly oxidises the ribose hydroxyl groups to ketones This side reaction is 
enhanced by carbodiimides. NMN is not readily soluble in common solvents such as N,N- 
dimethylformamide (DMF), pyridine or o-chlorophenol. Attempts to overcome this problem 
involve the use of water soluble carbodiimides. 1 -Ethyl-3 -(3 -dimethyl-amino-propyl)- 
carbodiimide (EDC) - a water soluble carbodiimide - has been used as a condensing agent 
with reasonable yields[1201
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Figure 3.6: Use of Dwi-butylphosphinothoic bromide as an activating group in
pyrophosphate syntheis.
A further attempt to resolve solubility problems involves reaction of di-w-butylphosphinothoic 
bromide with 5'-nucleotide (Fig. 3.6) to give mixed anhydrides which are sufficiently stable 
and are soluble in DMF. Addition of silver (Ag*) activates the thiohypophosphites thus 
formed, and an anhydride bond is formed by the nucleophilic attack of a phosphoric acid ester 
The silver salt of di-n-butylphosphinothoic acid is simultaneously released. NMN reacts with 
activated adenosine derivative to form NAD+ in yields exceeding 80% using this procedure 
[169] This kind of yield has been obtained by the ion-exchange method[170]. Michelson treated 
AMP with diphenyl phosphochloridate in anhydrous pyridine to obtain the ADP-p-diphenyl 
ester which is unstable and could be cleaved by NMN to give NAD+ (Fig. 3.7).
Moffatt and Khorana have activated nucleotides via amidation [171]. The morpholidate of 
AMP was prepared by the reaction of AMP with morpholine and DCC as the condensing 
agent to form A^N-dicyclohexyM-morpholinocarboxamidine (Fig 3.8). A variety of 
monophosphomoipholidates could be prepared by this general method. The morpholidates 
are quite reactive and react with an equimolar quantity of the second nucleotide to give NAD+ 
(or its analogue), with the cleavage of the morpholidate. Typical yields for diphosphates are 
about 50%. This was increased up to 70% when originally used solvents, o-chlorophenol and 





Figure 3.7: Diphenyl phosphochloridate method of pyrophosphate synthesis.
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This method has an advantage over the method used by Hughes, Kenner and Todd as no 
symmetrical side products are formed, because only one of the nucleotides is activated 
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Figure 3.8: Morpholidates in pyrophosphate synthesis
3.2 Enzymatic Preparation of NAD+
In biological systems NMN is formed from nicotinamide and 5 '-phosphoribosyl-1 - 
pyrophosphate by a nicotinamide phosphoribosyltransferase catalysed reaction,[172J NMN and 
other pyridine mononucleotide reacts with ATP or other purine riboside triphosphates in the 
presence of NAD+ pyrophosphoiylase to give NAD+ and inorganic pyrophosphate [173,174]. 
For preparative purposes, this reaction can be shifted completely to the side of NAD+ 
formation by the addition of inorganic pyrophosphate [174l  This enzymatic route is very
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limited by the specificity of the enzyme tl75J and as a consequence, this method has been 
applied predominantly for reactions of nicotinamide mononucleotide with nucleoside 
triphosphates containing nonpolar heterocyclic bases other than adenine. Adenine-substituted 
analogues of NAD+ have been prepared with this procedure [168,175,176l
The major enzymatic route used for the preparation of pyridine nucleotide coenzyme 
analogues involves the transglycosidase activity of mammalian NAD+ glycohydrolases. This 
enzyme-catalysed transglycosidation reaction is frequently referred to as the pyridine base- 
exchange reaction. It involves an exchange reaction between the nicotinamide moiety of 
NAD+ and added nicotinamide or analogue I177l  This method is however not applicable for 
this work as the nicotinamide ring is removed during the enzymatic cyclisation of NAD+ to 
cADPR, hence will not lead to the formation of cADPR analogues.
3.3 Nomenclature of NAD+ analogues
In the nomeclature used in this thesis for NAD+ and NAD+ analogues as shown in Figure 3.9, 
HnT, -2', -3', -4', -5' refer to protons on the nicotinamide ribose, Hn2, -4, -5, -6 refer to 
protons on the nicotinamide ring, HAT, -2', -3', -4', -5' refer to protons on the adenine ribose, 
Ha2 and HA8 are protons on the adenine ring.
3.4 Results and Discussion
NAD+ is the biological precursor for ADPR, hence several analogues were prepared for use 
as intermediates in the synthesis of cADPR analogues. The carbodiimide method described 
in Fig 3.6 has been employed for routine synthesis of NAD+ analogues in this work. This
method was found to be reasonable and convenient as it is a one-step synthesis. Moreover,
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the method is generally applicable for the synthesis of dinucleotides. DCC was used as the 
coupling agent. Attempts at using the water soluble carbodiimide, EDC, were not 
succcessful.
3.4.1 2 'a and 3 fA-Modijied NAD+ Analogues 
A) 2 \  and 3VHvdroxvl deleted analogues of NAD+
2'a and 3'A-Deoxy analogues of nicotinamide adenine dinucleotide have been used to 
investigate the role of the hydroxyl groups at positions 2 \  and 3'A for coenzyme binding to 
dehydrogenases [176l  2'A and 3'A-deoxy NAD+ were synthesised with modifications to the 
method used by Fawcett and Kaplan [178]. 2'A-deoxy-AMP (17) and 3'A-deoxy-AMP (18) 
were coupled to NMN ( 19) using DCC as coupling agent to yield the corresponding 2 \  and 
3'A-deoxy-NAD+ analogues (21, 22 - Fig 3.9). Pure samples were obtained from ion- 
exchange purification of the crude reaction mixture. ^-N M R analysis of the 2'A-deoxy 
analogue showed the presence of the protons expected (Figure 3.10). The two HA2' protons 
appeared as a multiplet and resonated at a lower frequency of 5 2.8 and 2.5 compared to 5 4.8 
in NAD+ [16!1. This is due to loss of deshielding effect from the 2'A-OH in 2'A-deoxy-NAD+. 
31P-NMR showed an AB system in the region of -10 ppm with Jpp of 20 Hz. This shows that 
the sample contained an unsymmetrical pyrophosphate as expected from the structure of 2'A- 
deoxy-NAD+. Moreover, FAB-MS showed a peak corresponding to the protonated molecule 
[M + HJ+ at m/z 648 and an m/z value of 647 for [M]“ was consistent with the deletion of an 
oxygen atom from NAD of molecular weight 663. m/z of 524 corresponds to the fragment 
[M -  H -  nicotinamide]-. lH and jlP-NMR spectra for 3 'A-deoxy-NAD+ were similar to 
those of 2'A-deoxy-NAD+. The main differences observed were in the proton chemical shifts 
of the 2'a and 3'A protons as would be expected.
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The HA2' resonated at 5 4.7 similar to the chemical shift for HA2' in NAD+ however the HA3' 
protons resonated at a lower frequency as a multiplet at 5 2.3 and 2.1 which is consistent with 
loss of deshielding from the 3'A-OH that is present in NAD+. 31P-NMR showed an AB 
system in the 5 -10 region with a Jpp value of 20 Hz. This supports the formation of an 
unsymmetrical pyrophosphate, as present in the structure of 3 'A-deoxy-NAD+. FAB-MS 
exhibited similar peaks to that observed for 2'A-deoxy NAD+. m/z value 648 for [M + H]+ for 
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Figure 3.10: a) 'H-NMR (400MHz, D20)spectrum and b) 31P-NMR (109MHz, 
D20 ) spectrum of 2 'A-deoxy-NAD+ as its triethylammonium salt.
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B 3f A-Q-Methvl-NAD+
Interest in the synthesis of 3 'A-0-methyl-NAD+ (20) arose with the need to synthesise a 
precursor for the synthesis of cADPR analogues with modification at the 3'A-position. We 
have already discussed that NAD+ analogues are precursors for the synthesis of cADPR 
analogues. The 3'A-OH in NAD is replaced by 3'A-0-Me hence the name 3'A-(9-methyl- 
NAD+. This substituent is larger in size compared to the -OH group and although it can 






Figure 3.11: Structure of 3'A-0-methyl-NAD+ (20)
3'A-0-Methyl-NAD+ (20 Fig. 3.11)) was prepared by coupling of 3'A-0-methyl-AMP (16) 
with NMN (19) using DCC as the coupling agent (see Fig. 3.9). Purification of 3\ -0 -  
methyl-NAD+ proved difficult by ion-exchange chromatography as the sample eluted with 
residual NMN. Most of the residual NMN was removed by treating the mixture of 3'A-0- 
methyl-NAD+ and NMN with alkaline phosphatase. This enzyme is known to cleave 
monophosphates and not pyrophosphates. Cleavage of the monophosphate of NMN by the 
alkaline phosphatase produced the nicotinamide mononucleoside which eluted straight off the 
ion-exchange column. The sample of 3'A-0-methyl-NAD+ obtained, though not pure (83%
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pure by HPLC analysis) was considerably improved in purity. This sample was used in this 
form for the next stage of synthesis.
1 1
P-NMR showed the presence of AB system at 6 -10 region showing that the sample 
contained symmetrical pyrophosphate and ^-N M R  showed the protons expected. The O- 
methyl protons resonated at high frequency of 5 3.5.
3.4.2 8-Modified Analogues o f NAD+
A) Nicotinamide-8-Bromoadenine Dinucleotide (,8-Br-NAD+)
8-Bromo-NAD+ has found use in the synthesis of ligands for affinity chromatography 
employed in selective purification of dehydrogenases. 8-Bromo-NAD+ (24) was synthesised 
by direct bromination of NAD+ (23-see Fig. 3.12) as this reaction is cost effective and gives 
better yield compared chemical coupling of the two mononucleotide subunits (8-Br-AMP and 
NMN) using DCC11451. This reaction involved electrophilic substitution at the 8-position of 
the adenine ring of NAD+. A shift in the UV absorption maximum from 259-264nm was 
observed on conversion of NAD+ to 8-Br-NAD+. ^-N M R  of the pure sample obtained after 
purification, showed the disappearance of HA8 proton upon substitution with a bromo group 
and proton chemical shifts resembled those reported previously. 31P-NMR showed that the 
pyrophosphate was intact as there was an AB system in the region of 5  - 1 1 with a Jpp  value 
of 21.2 Hz. Electrospray mass spectroscopy of 8-Br-NAD+ showed isotopic pattern of m/z 
740/742 (M -  H)-, 618/620 [M -  H -  nicotinamide]- due to isotopic abundance of 79Br and 
81Br (1:1) in the molecule. This is consistent with molecular weight of 741/743 for 8-Br- 
NAD+
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B) Nicotinarmde-8-Piperidvladenine Dinucleotide f8-pio-NAD+)
An attempt was made to synthesise 8-Piperidyl-NAD+ by nucleophilic displacement of 8- 
bromo-NAD+ with the piperidyl group by treating 8-Br-NAD+ with piperidine. This reaction 
was carefully monitored by HPLC as prolonged exposure of NAD+-type compounds to base 
lead to decomposition of the material. This is a result of nucleophilic displacement of the 
nicotinamide ring from the NAD compound to yield the ADP-ribose analogue. It was 
difficult to purify 8-pip-NAD+ synthesised by this pathway by ion-exchange chromatography 
as it co-eluted from the column with 8-Br-NAD+. We therefore prepared 8-pip-NAD+ (28) 
by coupling 8-piperidyl-AMP (10) to NMN using DCC (Fig 3.13). Pure 8-piperidyl-NAD+ 













Figure 3.12: Brommation of NAD+
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^-N M R  chemical shifts revealed the presence of 10 piperidyl protons at 5 3.2 (4 protons 
nearer to the piperidyl nitrogen) and 5 1.6 (6 protons further away from the piperidyl 
nitrogen). All the protons of 8-pip-NAD+ were represented in the ^-NMR. 31P-NMR 
showed the presence of a pyrophosphate in the molecule as there was an AB system at 5 -11 
region with a Jpp value of 20.8 Hz. ES-MS showed -ve ion m/z peaks at 746[M]“, 745[M -  
H]~ in low abundance, 623 [M -  H -  nicotinamide]”. The mass spectroscopic data supports a 
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Figure 3.13: Synthesis of 8-substituted analogues of NAD+
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C) Nicotinamide-8-Metfavladenine Dinucleotide (8-Me-NAD4^
8-Methyl-NAD+ (30) was prepared from 8-methyl-AMP (14) and NMN as described in the 
experimental section. LH-NMR analysis of the pure product obtained from ion-exchange 
purification of the crude mixture showed all the protons expected in the molecule. The three 
8-methyl protons resonated at 5 2.5. 31P-NMR of the product showed an AB system in the 
region of 5 -11 with a Jpp value of 20.5 Hz. This is consistent with the presence of a 
pyrophosphate in the molecule. Electrospray mass spectroscopy showed peak of m/z value of 
676 [M -  H]~ in high relative abundance, consistent with the molecular mass of 677 for 8- 
Me-NAD+.
D) Nicotinamide-8-Methvlaminoadenine Dinucleotide (8-NHMe-NADl
8-Methylamino-NADH, the reduced form of 8-methylamino-NAD+, but not 8-methylamino- 
NAD+ has been synthesised for studying the solution conformation of 8-substituted analogues 
of NADH fl80l  8-Methylamino-NAD+ (25 -Fig. 3.13 & 3.15) was synthesised by chemical 
coupling of 8-methylamino-AMP (6) and NMN (see Fig 3.13). The pure product obtained 
after ion-exchange purification was established as 8-methylamino-NAD+ by and 31P-NMR 
and FAB-MS. 31P-NMR in this case showed a singlet at 5 -11.7. Usually a singlet in this 
region signifies the presence of a symmetrical pyrophosphate, however the sample could not 
have contained a symmetrical pyrophosphate as both the nicotinamide and adenine protons 
were present in the ^-N M R spectrum. The sample could not be mixtures of 
monophosphate from NMN and 8-methylamino AMP (starting materials) as there was no 
peak in the monophosphate region of the 31P-NMR. The 31P-NMR spectrum of this 
compound is therefore unusual in pattern. The three methylamino protons resonated at 5 2.8 
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in the +ve ion mode. This is consistent with a molecular mass of 692 for 8 -NHMe-NAD+. 
No fragements were seen in the -ve ion mode.
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Figure 3.15: Structure of nicotinamide 8 -methylaminoadenine-dinucIeotide.
E) Nicotinamide-8 -Dimethvlaminoadenine Dinucleotide (8 -NMe7-NAD^
8 -Dimethylamino-NADH, but not 8 -dimethylamino-NAD+ has been synthesised for studying 
the conformation of 8 -substituted NAD+ derivatives in solution[181]. 8 -Dimethylamino-NAD+ 
(26) was synthesised from 8 -dimethylamino-AMP (7) and NMN (Fig 3.13). The pure 
product was identified by NMR spectroscopy and FAB-MS. 31P-NMR exhibited an AB 
system in the region of 6 -11 with a Jpp value of 21 Hz. This supports the presence of a 
pyrophosphate in the molecule. ^-N M R showed all the protons with the 6  dimethylamino 
protons resonating as a singlet at 63.1, as they are all chemically equivalent (see Fig 3.16). 
FAB-MS of sample showed peaks with m/z of 707 [M + H]+ in the +ve-ion mode and 706 
[M]‘ 582 [M -  H -  nicotinamide] in the -ve-ion mode in high relative abundance. This 
supports a molecular weight of 706 for 8 -NMe2-NAD+.
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Figure 3.16: a) JH-NMR (400MHz, D:0)spectrum and b) 31P-NMR (162MHz, D20 )  
spectrum of 8-dimethylamino-NAD+ as its triethylammonium salt.
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F) Nicotinamide-8 -Aminoadenine Dinucleotide f8 -NH9-NAD+)
8 -Amino-NAD+ (Fig. 3.17) was synthesised by modification of the method by Walseth et al. 
in which a water soluble carbodiimide was used to couple 8 -amino-AMP (9) to NMN [120]. 
We have used DCC in coupling the mononucleotide subunits of 8-amino-NAD+ to obtain the 
product in question (Fig 3.13). 31P-NMR of product showed an AB system in the region of 5 
-11 with a Jpp value of 19.4 Hz. Electrospray mass spectrometry showed m/z value of 
677[M -  H]- and 555 [M -  H -  nicotinamide]- for the -ve-ion. This supports a molecular 






Figure 3.17: Structure of 8 -amino-NAD+
G) Nicotinamide-8 -Oxvadenine Dinucleotide (8 -Oxv-NAD+)
Coupling of 8 -Oxy-AMP (13 -see chapter 2) to NMN (19) using DCC gave the dinucleotide, 
8 -Oxy-NAD+ (31 -Fig 3.18). This product was identified by the presence of an AB system in 
the 31P-NMR spectrum at 8  — 11 with a Jpp value of 21 Hz. ^-N M R spectrum identified 
the protons on 8 -Oxy-NAD+ and electrospray mass spectrometry showed m/z peaks of 678 





Figure 3.18: Structure of 8-Oxy-NAD+
ID Nicotinamide-8-Methoxvadenine Dinucleotide (8-OCH^-NAD^)
Synthesis of 8-methoxy-NAD+ (29) was achieved by chemical coupling of 8-methoxy-AMP 
(12) with NMN using DCC as the coupling agent. The product obtained was identified by 
spectroscopic analysis. 31P-NMR spectrum showed the presence of an AB system at 5 ~ 
llppm with a Jpp value of 20.9 Hz confirming that a pyrophosphate was present in the 
molecule. ^-N M R  spectrum identified the protons with the methoxy protons at 5 ~ 4.0ppm. 
Electrospray mass spectrometry in the +ve-ion and -ve ion mode showed peaks at m/z value 
of 694 [M + H]+ and 692 [M -  H]- in high abundance. This agrees with a molecular weight 
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I) Nicotinamide-8-Aza-9-deazaadenine Dinucleotide fNFD)
Nicotinamide-8-aza-9-deaza-adenine dinucleotide (33- Fig. 3.20), a formycin analogue of 
NAD+ is a known fluorescent analogue. It has been prepared by a similar method to that used 
by Ward and co-workers [1681, by chemical coupling of formycin 5 '-monophosphate (32) to 
NMN (Fig 3.20). The UV absorption spectra was similar to that previously reported. *H and 
jlP-NMR was not reported by Ward et a f168\  ^-N M R  and jlP-NMR spectroscopy 
identified the product as NFD . 31P-NMR showed an AB system at 5 — 11 with a Jpp value 
of 21.6 Hz. ES-MS showed a -ve ion peak with m/z value of 662 [M -  H]~ consistent with a 
molecular weight of 663 for NFD+.















Figure 3.20: Synthesis of nicotinamide-8-aza-9-deazaadenine dinucleotide [NFD+ (33)].
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3.43 Characterisation o f NAD+ analogues
A) Mass Spectroscopy -FAB-MS and Electrosprav
Due to the high polarity and hence low volatility of NAD+ analogues, FAB-MS and 
electrospray mass spectroscopy have been chosen for mass analysis of this type of 
compounds. Under electron-Impact MS conditions NAD+ thermally decomposed prior to 
ionisation by release of nucleobases nicotinamide and adenine [161l  NAD+ was one of the first 
compounds used to demonstrate the efficiency of the FAB technique for mass spectrometric 
analysis of thermally sensitive, highly polar substances. Electrospray mass spectrometry is 
known to provide inherent gentle ionisation given rise to intact ions from thermally labile 
biological molecules. NAD+ analogues have proven to be good candidates for this technique. 
The choice of method used between FAB-MS and Electrospray depended on availability at 
the time that mass analysis was required.
B) Nuclear Magnetic Resonance
31P-NMR was used to follow the reaction by emergence of an AB system in the 
pyrophosphate region 5 ~ -10. !H and 31P-NMR techniques were used to obtain structural 
information about the analogues prepared. These methods were also used along with HPLC 
techniques to judge purity of the sample as unexpected peaks in the spectra would indicate 
that other impurities were present. The quality of materials obtained after purification can be 
seen from the and 31P-NMR spectra Fig. 3.10 & 3.16.
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C) UV spectroscopy
The presence of chromophores on the nicotinamide and the adenine moiety of NAD+ and 
analogues provide a useful property of this molecule. UV spectroscopic patterns and 
absorption maxima have been used to characterise this compounds. A general red shift was 
observed in the absorption maximum was observed upon subtitution at the 8-position of the 
purine ring. Optical density measurements with molar extinction determination were useful 
in accurate quantification of this compounds. NAD+ compounds were produced as the 
triethylammo-nnium salts and were glasses. Moreover, the small quantity of sample involved 
would have made sample measurement by weight highly inaccurate. Elemental analysis 
could not be carried out as the samples obtained were glasses.
3.4.4 Analysis o f NAD* analogues
A) Qualitative Analysis
i) Chromatographic techniques
NAD+ analogues are highly charged water-soluble molecules. The purification method 
employed for routine use was ion-exchange chromatography on an anion exhange column. 
High perfomance liquid techniques were employed in the analysis of fractions collected from 
the anion exchange column. Samples were judged pure by ion-exchange HPLC analysis in 
combination with 31P and LH-NMR analysis. The quality of the material prepared after 
purification can be seen from a typical HPLC trace for 8-oxy-NAD+ (Fig. 3.21). A UV 
detector was used to detect samples eluting off the column. The chromophores of the 
nicotinamide and the adenine moiety are only detected as one as their absorption maxima are 
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Figure 3.21: HPLC analysis of 8'-ory-NAD
ii) Co-enzyme Activity
All the NAD- synthesised were screened for coenzyme activity [176] and the ability to form a 
complex with cyanide. NAD" is a namral coenzyme for alcohol and other dehydrogenase as 
mentioned previously. NAD" is reduced in the presence of ethanol and alcohol 
dehydrogenase to NADH. This conversion can be monitored by UV spectrophotometry in 
which a new peak at 340nm emerges upon formation of NADH. Conversion of these NAD" 
analogues into the reduced form NADH by incubation with yeast alcohol dehydrogenase m 
the presence of 5% ethanol in 0.1M Tris buffer pH 9 was monitored by UV analysis. A new 
peak at 340nm was recorded for all the analogues indicating that they have intrinsic coenzyme 
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Figure 3.22: Schematic representation of the UV absorption spectrum of 2'A-deoxy- 
NAD+ (— ) and change in the spectrum (— ) after treatment o f 2'A-deoxy-NAD+ with 
alcohol dehydrogenase in 5% ethanol.
iii) Complex formation with Cyanide
ii) Nicotinamide substituted in the ring nitrogen as in NAD’ reacts with cyanide to form a 
cyanide adduct. This new adduct can be monitored by the emergence of a new peak at 
325nm on the UV spectra Complex formation of NAD’ analogues with cyanide was 
performed as described previously [180lThe reaction was monitored by UV and the 
appearance of the new cyanide adduct was recorded at 325nm for all analogues. This test 
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Figure 3.23: Schematic representation of the UV absorption spectrum of 2'A-deoxy- 
NAD+ before treatment with KCN solution (— ) and 2'A-deoxy-NAD+ after treatment 
with KCN solution (—).
B) Quantitative Analysis
In most cases analogues were quantified by quantitative phosphate analysis 11811 as described 
in the experimental section. The amount of phosphate in the sample can be calculated from 
the calibration curve obtained by analysis of a standard sample (KH2PO4) of known 
phosphate content. The extinction coefficient of each sample was calculated from the optical 
density of the known amount of sample in TEAB buffer at pH 8.3. In some cases were 
indicated in the experimental section, the extinction coefficient was obtained from literature 
values.
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CHAPTER 4: SYNTHESIS OF ANALOGUES OF cADPR
4.1 Enzymatic Synthesis of cADPR
Enzymatic conversion of NAD+ into cADPR was first achieved in 1987 [44] by the 
incubation of crude extracts of Lytechnms pictus, with NAD+ for 3-7 hours at 17°C. Lee 
and co-workers used extracts from two species of sea urchin eggs (Lytechinus pictus and 
Strongylocentrotus purpuratus) for the preparation of cADPR, [ then referred to as 
enzyme activated NAD+ (E-NAD+)] from NAD+ 1481. The reaction was terminated at the 
end of the incubation period by the addition of an equal volume of acetone to precipitate 
the protein. The precipitated protein was removed by centrifugation, and the acetone 
was evaporated from the supernatant by a stream of nitrogen gas. This incubation was 
found to contain a multitude of metabolites, as the crude egg extracts contained too 
many other NAD+ utilising enzymes. This caused difficulties in obtaining pure cADPR 
from the incubation mixture. Purification was achieved in two stages, first by a semi­
preparative anion exchange column followed by purification of small volumes on an 
analytical reverse phase high performance liquid chromatography (HPLC) column. 
Partially purified ADP-ribosyl cyclase (the synthesising enzyme) was later prepared from 
dog brain extracts [46]'
ADP-ribosyl cyclase has since been prepared from soluble extracts from the ovotestis of 
Aplysia califom ica1591 as there is an unusual abundance of this enzyme in this organism. 
Hence, enzymatic synthesis of cADPR was carried out by incubating partially purified
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ADP-ribosyl cyclase with 2mM NAD+ for 1-3 hours at 37°C (Fig 1.9). Separation of 
pure cADPR from the incubation mixture was achieved by preparative HPLC.
Another synthetic approache involved enzymatic cyclisation of N 1 -(5 '-phosphoribosyl)- 
ATP catalysed by NAD+ pyrophosphorylase (Fig 4.1). The yield via this method was 
about 4.7%. Nl-(5'-Phosphoribosyl) ATP is predominantly in the protonated form at 
pH 7.5 so its P-N-glycosidic linkage resembles the NAD-like cation and thus , is 
accepted by NAD+ pyrophosphorylase as a substrate to allow cyclisation into cADPR via 
a facile adenylyl transfer[182].
4.2 Chemical Synthesis of cADPR
Chemical synthesis of cADPR from NAD+ has been reported by Yamada and co- 
workers1511. Attempts at chemical synthesis of cADPR produced poor yields and the 
methods are unlikely to be useful for routine synthesis of cADPR analogues. Chemical 
cyclisation of f3-NAD+ by treatment with NaBr and triethylamine in DMSO at 70°C 
produced cADPR in 10% yield (Fig 4.2) Also traces of cADPR (<1%) have been 
noticed by treating Nl-(5'-Phosphoribosyl) AMP with EDC in 1.5M Hepes buffer (pH 
6 .8) [182].
4.3 Analogues of cADPR
At the beginning of this work in May 1993, there was no known analogue of cADPR. 
However, over the years several analogues have been synthesised by other groups as well 
as from our group. The majority of modifications has been on the purine rings with only 
a few analogues possessing modifications in the ribose and pyrophosphate part of the
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molecule in question. Below is a summary of other analogues that have appeared in 
publications, along with brief details on their biological activities. All the analogues have 






O— P— O— P— O— P— <
Nl-fS'-phosphoribosyl) ATP HO OH
NAD pyrophosphorylase 





















Figure 4.2: Chemical Cyclisation of p-NAD+ into cADPR 
4.3.1 Antagonists o f cADPR
In August 1993, while this work was in progress, Walseth and co-workers reported the
synthesis of 8-amino, 8-bromo and 8-azido-cADPR[120] (Fig 4.3). These analogues with
small changes at the 8-position of the purine ring were shown to competitively inhibit
cADPR-induced Ca2+ release in sea urchin eggs. The reason for this behaviour was not
known, although the authors suggested that size of the group could be responsible for
this activity. A change in size of the group from an hydrogen group to an amino-group (a
difference of 15 atomic units) resulted in minimal change in the binding affinity compared
to cADPR, but the analogue could not activate the release mechanism. However, further
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increase in size to azido (42 atomic units) and bromo group (79 atomic units) resulted in 
substantial decrease in antagonist activity which may well be due to reduction in binding 
affinity of the analogues to the cADPR receptor due to steric hinderance. We have 
therefore decided to investigate the structural motif that is responsible for this activity by 
synthesis of analogues with different functional groups at position 8 of the adenine ring. 
Since then, we, in collaboration with a research group in Germany, have shown that 
exocyclic substitution at position 8 of the purine ring also produces analogues that inhibit 
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Figure 4.3: Structures of (a) 8-amino, (b) 8-bromo and (c) 8-azido-cADPR.
4.3.2 Fluorescent analogues o f cADPR
Analogues in which the purine base adenine was replaced with other purine bases such as
guanine, hypoxanthine, xanthine and an etheno-group have been synthesised [184,185].
Structural analysis of these analogues have shown that cyclisation is via N-7 linkage of
the purine ring instead of N -l as in cADPR (Figure 4.4). The UV spectral pattern of
these analogues resembled those of N-7 alkylated purines. In contrast to cADPR, these
analogues were found to be fluorescent. N7-Alkylated purines are known to be
i l l
fluorescent and show a pH-dependent spectral shift similar to those seen in the N7 
substituted analogues synthesised. All the N7-substituted analogues are inactive (Fig
4.4). They do not induce Ca2+ release as they do not bind to the cADPR receptor. It is 
interesting that the same enzyme that catalyses the synthesis of cADPR from NAD+ by 
linkage to the N1 position of adenine can also catalyse formation of the glycosidic link 
with the N7 position if for some reason the N1 position is electron deficient. Supporting 
evidence that ADP-ribosyl cyclase can cyclise the substrate at the N7 position comes 
from cyclisation of a NAD+ analogue in which the N1 position is blocked, etheno-NAD+ 
to yield cyclic 1, A^-etheno-ADP-ribose[184,186]. The fact that the Nl-linkage is preferred 
in the formation of cADPR would indicate that it is either chemically or sterically more 
reactive than N7. The keto group present at position 6 in all the fluorescent analogues 
(apart from etheno-analogue) is likely to render the N1 postion less reactive. The rate of 
formation of cADPR is faster than the rate of formation of these analogues. For 
example, the rate of formation of cADPR is 20 times faster than for cGDPR. The purine 
rings in these analogues are in the ^^/-configuration compared to syn in cADPR. They 
also exist in zwitterionic forms at neutral pH. Moreover the two ribose rings are linked 
via 4-bonds in cADPR, but the link is via two bonds in cGDPR, cIDPR, cXDPR and 
cHDPR (see Fig 4.4). This means that more bulk of the purine ring sticks out of the 
cyclic structure in the fluorescent analogue. The above may contribute to the inability of 
these analogues to bind to the receptor site.
A fluorimetric assay has been demonstrated in which these analogues can be used to 
study cyclisation and hydrolysis reactions. cGDPR is very resistant to hydrolysis[69].
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Fig 4.4: The proposed structures of the fluorescent analogues of cADPR[183]. cyclic 
Guanosine diphosphate ribose (cGDPR), cyclic Inosine diphosphate ribose (cIDPR), 
cyclic Xanthine diphosphate ribose (cXDPR), cyclic Hypoxanthine diphosphate ribose 
(cHDPR) and cyclic l^-etheno-A D PR (e-cADPR)..
4.3.3 Poorly-Hydrolysable Analogues o f cADPR
Synthesis of another poorly hydrolysable, but active, analogue, cyclic aristeromycin 
diphosphate ribose (cArisDPR) has been reported [130]. This analogue has a similar Ca2+ 
release profile to cADPR in sea urchin homogenates, but was shown to have a Xm value 
of 170min compared to 15min for cADPR. The adenosine ribose moiety in cArisDPR is 
replaced by a carbocyclic ring. Carbocyclic rings are known to confer more stability to 
the glycoside bond which is normally labile, however in this case the ribose ring is far 
removed from the site of hydrolysis. The authors suggest that this effect could be due to
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conformational changes in the way cArisDPR binds to the receptor site of the hydrolase, 




Figure 4.5: Cyclic aristeromycin diphosphate ribose (cArisDPR)
Synthesis of cyclic ATP-ribose, an analogue of cADPR in which the diphosphate is 
replace by a triphosphate has been reported [186]. This analogue is about 20 times more 
potent compared to cADPR in releasing Ca2+ in rat brain microsomes and was more 
stable compared to cADPR in buffers at different pH values. The effect of this analogue 
in sea urchin egg homogenate has not yet been reported. Replacement of the diphosphate 
bridge in cADPR with a triphosphate ring is likely to confer more flexibility to the 
molecule. This may account for increase in stability of this analogue. The stability of 
cATPR toward enzymatic cleavage was also investigated [186]. cATPR was more stable 
than cADPR when incubated with pig brain NADase at 37°C for 40 min. After 40 min, 
80% of cADPR was hydrolysed whereas only 30% of cATPR was hydrolysed under the 
same conditions. Poorly hydrolysable and ultimately non-hydrolysable analogues will be
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useful in exploring novel activities of cADPR. It should be easier to isolate and 
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Figure 4.6: Cyclic adenosine triphosphate ribose
4.3.4 2 'a-cADPRP, 3 'a-cAD PRP and 2 a,3 U -cyclic-cAD PRP  
We have synthesised 2'a.cADPRP, 3'a-cADPRP and 2'a,3'a-cADPRP, however while 
this work was in progress, synthesis of 2'a-cADPRP was also reported by various 
research groups I126*127’131] Synthesis is via enzymatic cyclisation of NADP+ (see section
1.5) by ADP-ribosyl cyclase. 2 'A-cADPRP is inactive in sea urchin eggs but is more 
potent compared to cADPR in mobilising Ca2+ in rat brain microsomes [131] and in T- 
cells[187]. This is the first indication that there may be different structural requirements 
for cADPR-induced Ca2+ release in sea urchin compare to rat brain microsomes and T- 
cells. Vu and co-workers showed that NADP+ is a better substrate compared to NAD+ 
for the cyclase indicating that in vivo conversion of NADP+ to 2'a-cADPRP is likely[12?1. 
The mechanism of Ca2+ release by 2'a-cADPRP is similar to that of cADPR. 3'A- 
cADPRP and 2 'A,3'A-cyclic-cADPRP were synthesised from their corresponding NAD+ 
analogues 3'a-NADP+ and 2fA,3'A-cyclic-NADP+ and shown to be inactive in rat brain
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microsomes [131]. However, the effects of 3'a-cADPRP and 2'A,3 Vcyclic-cADPRP in 
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Figure 4.7: Structures of 2 'a-cADPRP, 3 'a-cADPRP and 2 'a,3'a-cADPRP
4.3.5 Caged cADPR
Caged cADPR was synthesised by reacting cADPR with 2-
nitrophenethyldiazoethane[1881. The product obtained was inactive and could induce Ca2+
release from sea urcin egg homogenates only after photolysis. The availability of caged
cADPR should eliminate problems encountered in investigating Ca2+ mobilisation
induced by cADPR. For example, Ca2+ leakage during micro-injection could be mistaken
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as Ca2+ release by cADPR. Ca2+ release by caged cADPR is induced by UV photolysis, 
eliminating the possible injection artefact. Moreover, increase in hydrophobicity due to 






R or R’ =
Figure 4.8: The proposed structure of mono-caged cADPR regioisomers.
4.4 Results and Discussion
4.4.1 2 a and 3 'A-Modified cADPR Analogues
A) 2 'a and 3Vhvdroxvl deleted analogues of cADPR
In order to study the role of the ribose hydroxyl groups, our first step was to synthesise 
2'a and 3 'A-deoxy analogues of cADPR Biological testing of these compounds would 
give a clue toward the importance of the 2 ' a and 3'a ribose hydroxyl groups respectively 
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Figure 4.9: 2 \  and 3fA-Modified Analogues of cADPR
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o f 2'-deoxy (21) and 3'-deoxy-NAD+ (22) to 2'-deoxy (37) and 3'-deoxy-cADPR (38 - 
Fig 4.9) respectively. For comparison, cADPR (40) was also synthesised from NAD+ 
(34). The products from the synthesis were as expected. HPLC analysis of the reaction 
mixture showed two new peaks after conversion to the cyclic product in all cases. The 
first peak corresponded to nicotinamide, followed by residual starting material and finally 
the cyclised product. In some cases, an extra peak corresponding to the hydrolytic 
product of the cADPR analogue (Fig 4.10) e.g. 2 'A-deoxy-ADPR could be recorded on 
the chromatogram. This degradation product, produced by spontaneous breakdown of 
the material in an aqueous medium, can be easily removed by ion exchange purification. 
^ -N M R  spectroscopy showed the disappearance of the nicotinamide protons [compare 
Fig. 3.10 (a) to Fig. 4.11 (a)]. *H and 31P-NMR of cADPR were similar to those 
reported previously. Differences in proton chemical shifts and signal obtained from the 
!H-NMR spectum of 2 'A-deoxy-cADPR and cADPR include the HA1' signal which was 
downfield from H I' and appeared as a triplet as it coupled to two HA2' protons in the 
former, but in 3 'A-deoxy and cADPR, H I' appeared downfield from the HA1' proton. A 
characteristic HA2' proton at 6 5.2ppm was observed in cADPR, however in HA2' 
protons resonated at a lower frequency - 8 3.2 and 2.4 ppm as a multiplet. HA2' 
appeared as a multiplet at 8 5.2ppm in 3A'-deoxy-cADPR and the two HA3' protons 
resonated at a lower frequency - 8 2.8 and 2.1ppm compared to 8 4.7 and 4.8 ppm in 
cADPR and 2A'-deoxy-cADPR respectively. This is consistent with the loss of the 
deshielding effect from the neighbouring hydroxyl group. AB Type signals in the 31P- 
NMR spectra of cADPR, 2A' and 3A'-deoxy-cADPR support the existence of the 




























Figure 4.10: HPLC analysis of the cyclisation of 2'A-deoxy-NAD+ (21). (A) HPLC 
analysis of 2 'A-deoxy;-NAD+ as the starting material, (B) HPLC analysis of the 
products obtained lOmins after incubation of 2 'A-deoxy-NAD+ with crude ADP- 
ribosyl cyclase -  nicotinamide (Nic), 2 'A-deoxy-cADPR (37) and 2 'A-deoxy-ADPR.
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Figure 4.11: (a) ^ -N M R  (400MHz, D20 )  and (b) 31P-NMR (162MHz, D20 )
spectra for 2 'A-deoxy-cADPR as its triethylammonium salt
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analogues from the corresponding NAD* precursor. FAB-MS of of 2A and 3 A-deoxy- 
cADPR showed a m/z peak of 524 for the negative ion [M -H]~. m/z value of 1049 [2M
-  H]“ were characteristic for both deoxy forms showing possible formation of dimeric 
structures. This was, interestingly, not observed in the mass spectrum of cADPR. All 
three compounds showed a UV absorption maximum at 259nm.
Relative rates of turnover and the affinity of the enzyme for the substrates were
compared by kinetic studies. The kinetic parameters of the Aplysia cyclase for NAD*,
2'A-deoxy-NAD+ and 3'A-deoxy-NAD+ were determined using an HPLC method. Km
and Vmax values were obtained from the Lineweaver-Burk plot using the Enzpack3
computer programme. A representative plot is shown in Fig. 4.12 for 3 'A-deoxy-NAD*.
Km values obtained were 75.2jiM, 0.7mM and 0.5mM for NAD+, 2'A-deoxy-NAD+ and
3'A-deoxy-NAD+ respectively. Vmax values obtained were 23.3, 47.9, 22.4jj.mol/mg/min.
Hence the enzyme has a higher affinity for the natural substrate NAD*. The affinity of
the cyclase for NAD* is approximately 10 times better and 7 times higher compared to
2'A-deoxy-NAD* and 3'A-deoxy-NAD* respectively. While the specific activity of the
enzyme for NAD* and 3'A-deoxy-NAD* appears similar, the turnover rate for 2A-deoxy-
NAD* appears to be twice that of NAD*. This shows that, as expected, the relative
turnover rate for NAD* (the natural substrate) is somewhat faster (though not
significantly) compared to 2A-deoxy-NAD* and 3A-deoxy-NAD*. This shows that the
ribose hydroxyl groups are important although not crucial for binding to the active site of
the cyclase. Removal of the ribose hydroxyl groups results in analogues with lesser
affinity for the binding site of ADP-ribosyl cyclase. The Km determination for NAD* as
determined by Graeff and co-workers was 39pM [69]. This is of the same order as the
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value obtained here, 75.2pM. Differences in the assay conditions used, such as buffers 
and buffer concentrations could be accountable for the difference in the Km values
obtained. Also, we have taken time points every minute over 6 mins and calculated 
initial velocity from the slope of a plot of relative area vs time. Graeff and co-workers 
took two time points, after 0 and after 3 min.
LINR/EWER-MXx ie i
3 4
i/iSJ x ieA 2
Figure 4.12: Lineweaver-Burk plot for 3 'A-deoxy-NAD+. The y axis represents 1/V 
(pmol^mg-min) and the x  axis represents 1/S (pm ol1).
B) 3 VO-Methvl-cADPR
To further investigate the role of the 3 'A ribose hydroxyl group, 3'A-0-methyl-cADPR 
(39) was synthesised. In this molecule, a methyl group replaces the hydrogen group. 
The -OM e group, unlike the -OH group which can accept and donate an H-bond, can 
accept, but cannot donate a hydrogen bond, hence biological testing of this molecule 
will, in principle, be a pointer to the type of H-bonding interaction that is likely to occcur 
at the cADPR receptor site taking into account possible newly introduced steric 
constraints. Partially purified 3\-OM e-NAD+ (20) obtained (see section 3.3.IB) was
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cyclised by ADP-ribosyl cyclase to yield 3'A-OA/e-cADPR (39 -Fig 4.9). Pure cyclic 
product was obtained upon ion exchange purification as shown by HPLC analysis, *H 
and 31P-NMR spectroscopy. !H-NMR spectroscopy identified all the purine protons and 
ribose protons. The signal for the ribose O-methyl protons appeared at 5 3.4ppm as 
expected. There were no signals corresponding to nicotinamide protons indicating that 
the nicotinamide ring has been lost. Replacement of the hydrogen of the hydroxyl group 
by a methyl group as in this compound appears to result in a slight hypsochromic effect 
on the wavelength. There was a shift in the absorption maxima from 259 to 256nm. -ve 
ion FAB-MS showed an m/z peak of 554[M-H]_ corresponding to a molecular weight of 
555 for this analogue.
C) 3 VcADPRP
3'a-cADPRP (41) contains a phosphate group at the 3A' position (see Fig 4.9). It was
synthesised to establish the effect of a charged phosphate group at this position relative
to a neutral methyl group and furthermore to investigate the possiblity of an electrostatic
interaction between the phosphate anion and the cADPR receptor site. It was prepared
from the commercially available 3'a-NADP+ (35), by cyclisation with ADP-ribosyl
cyclase. This analogue was a substrate for the cyclase. HPLC analysis of the reaction
mixture showed the production of nicotinamide. The cyclised product and the NAD+
precursor co-eluted from the HPLC column with the same retention time of 15.9 min.
However, it was easy to separate the desired product, 3 VcADPRP, from the crude
mixture on an anion exchange column using buffer at pH 7.6. 31P-NMR spectroscopy
showed that the monophosphate was intact and the signal was observed at 6 l.Oppm.
The pyrophosphate was also intact as an AB system and was seen at 6 — 11 ppm
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(Fig.4.13a). FAB-MS in both +ve and -ve ion modes along with accurate MS confirmed 
the molecular weight of the product as 621 consistent with an increase in mass by 80 
atomic mass units compared to cADPR.
D) 2' a.3 Vcvclic-cADPRP
To investigate the effect of having a phosphate bridge across the 2'A and 3'A position, 
2 'a,3 'a-cADPR was prepared. 2'A,3'A-cyclic-cADPRP (42) were prepared from the 
commercially available 2 'A,3'A-cyclic-NADP+ (36 - Fig 4.9). ADP-ribosyl cyclase 
catalysed the conversion of 2 'A,3 'A-cyclic-NADP+ to the cyclised product with loss of 
nicotinamide. HPLC analysis of the reaction mixture showed the appearance a new peak 
corresponding to nicotinamide. The cyclised product and 2'A,3'A-cyclic-NADP+ eluted 
off the HPLC column with the same retention time under the conditions used for HPLC 
analysis. However, separation of the pure desired product from the crude mixture was 
achieved by purification on an anion exchange column using a buffer gradient at pH 7.6. 
Spectroscopic analysis showed that the product synthesised was authentic. jlP-NMR 
spectroscopy showed the cyclic phosphate at 6 +19 as a singlet and the pyrophosphate at 
8 —1 lppm as an AB system (Fig. 4.13b ). FAB-MS in both the +ve ion and the -ve ion 
mode with accurate mass analysis identified that the product has a molecular mass of 603 
which is true of an increase in molecular weight by 62 compared to cADPR.
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(b) 2 - 2 - C a lH -
PPK
a
Figure 4.13: 31P-NMR (162MHz, D20 )  spectra for (a) 3 'a-cADPRP and (b) 2 'A,3 ', 
cADPRP
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4.4.2 8-Modified Analogues of cADPR
8 -Substituted analogues of cADPR were synthesised in order to study initially the effect 
of replacement of the hydrogen by groups such -NH 2 and -CH 3. While this work was in 
progress a paper appeared11201 that showed that replacement of the HA8 with an amino, 
bromo or azido group converted the activity of the molecule from an agonist to an 
antagonist, o f which 8 -amino-cADPR was the most potent. The reason for this effect 
was however unclear. In order to attempt identifying the feature of the 8 -substituent that 
is required for converting the cADPR molecule to an antagonist, several analogues of 8 - 
substituted-cADPR analogues have been produced (Fig 4.10). The hydrophilic character 
of the amine substituent and molecular volume was varied by synthesising 8 -NHMe (44), 
8 -NMe2 (45) and 8-piperidyl-cADPR(47). Replacement of the amine group was made 
by -CH 3 and an oxy group. The methyl group cannot form a H-bond, hence 8 -CH3- 
cADR would be useful in establishing whether H-bond interaction at position 8  of the 
purine ring is crucial for antagonist activity. Substitution with a -OCH3 group (46) 
provides an analogue that can only accept a H-bond (the -NH 2 group can both accept 
and donate a H-bond). These analogues were all prepared from their 8 -substituted 
NAD+ precursors (Fig 3.11, 3.12). All the 8 -substituted analogues of NAD+ were 
substrates for the cyclase. The relative rates of conversion, though not investigated in 
detail here, appear to be similar in most cases apart from 8 -CH3-CADPR (49) which 
appears to be turned over faster and in greater yield than other analogues (see 
experimental section). In all cases, the formation of the product was followed by HPLC 
analysis. Two new peaks corresponding to nicotinamide and cyclised product were 
obtained in all cases. Purification by anion exchange chromatography afforded pure
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product. Typically, the starting material eluted first, followed by the cyclised product 







X= Br (43) X= NH2 (48)
X=NHCH3 (44) X = C H 3 (49)
X=N(CH3)2 (45)
X =O C H 3 (46)
x=nC ^ 7  (47>
Figure 4.14: 8 -Modified analogues of cADPR . Structures of 8 -bromo-cADPR (43), 
8 -methylamino-cADPR (44), 8 -dimethylamino-cADPR (45), 8 -methoxy-cADPR (46), 8 - 
piperidyl-cADPR(47), 8 -amino-cADPR (48), 8 -methyl-cADPR (49) and 8 -oxy- 
cADPR(50). These were synthesised from 8 -bromo-NAD+ (24), 8 -methylamino-NAD+ 
(25), 8 -dimethylamino-NAD+ (26), 8 -methoxy-NAD+ (27), 8 -piperidyl-NAD+ (28), 8 - 
amino-NAD+ (29) 8 -methyl-NAD+ (30) and 8 -oxy-NAD+ (31) respectively (see Fig 
3.11).
The cADPR analogue in water hydrolyses slowly in solution at room temperature to give 
the linear product. This can easily be removed by purification on the anion exchange 
column.
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Figure 4.15: (a) ’B-VMR (400MHz, D20 )  and (b) Electrospray mass spectra of 8 - 
OCH3-cADPR as its triethylammonium salt.
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31P-NMR spectroscopy showed the existence of a pyrophosphate in the molecule by an 
AB signal in most cases at 5 ~1 lppm. Interestingly, in the case of 8 -OCH3-cADPR the 
31P-NMR showed a signal in the pyrophosphate region as a singlet. However, it is clear 
from the ^ -N M R  data and mass spectroscopic data that 8 -OCH3-CADPR was 
synthesised.
All the above modifications were exocylic. 8-Aza-9-deaza-cADPR was synthesised to 
investigate the effect of modification in the purine ring on the Ca2+ release activity. The 
synthesis was via the NAD+ precusor NFD+ (33 -Fig 3.13) prepared by chemical coupling 
of formycin 5'-monophosphate with NMN. NFD+ was cyclised by ADP-ribosyl cyclase 
to 8-aza-9-deaza-cADPR (50 -Fig 4.11). olP and LH-NMR analysis with mass 
spectroscopy supports the fact that cFDPR was synthesised. Furthermore, the UV 







Figure 4.16: 8-aza-9-deaza-cADPR (cFDPR)
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4.5 Characterisation of cADPR analogues
cADPR analogues, like NAD", are of low volatility and high polarity. Hence 
electrospray and FAB-MS were chosen for mass analysis. Electrospray mass 
spectroscopy appear to be most suitable for this type of compounds as it appeared from 
FAB-MS analysis that the analogues appear to decompose prior to ionisation leading to 
a low abundance of the molecular ion. and jlP-NMR spectroscopy were employed 





Figure 4.17: 'H -‘H COSY of cADPR in D20 .
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to identify the ribose protons (Fig. 4.17). UV absorption spectroscopy was used to 
record the spectroscopic pattern of the analogues.
4.6 Purification, Qualitative and Quantitative Analysis of cADPR analogues
The analytical methods used for cADPR analogues were similar to those used for NAD* 
analogues (Chapter 3). Purification was carried out on an anion exchange 
chromatographic column at pH 7.6 where cADPR analogues in all cases are likely to 
have one extra negative charge compared to NAD+ analogues making separation on a 
basis o f charge possible. A representative chromatogram obtained from the ion-
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Figure 4.18: A schematic representation of the ion-exchange chromatogram
obtained from the purification of cFDPR on a Sepharose Q column.
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exchange purification of the product obtained form cyclisation of NFD+ is illustrated in 
Fig. 4.18. The cyclic product can also be separated from the linear form, ADPR by this 
method even though they are likely to carry the same charge under the condition used for 
purification. The analysis of reaction products was carried out on an anion exchange 
HPLC column. Separation was also on the basis of charge and the size of the molecule 
is likely to play a role as well, as the cyclic product could also be separated from the 
linear form even though they are likely to carry the same amount of charge under the 
experimental conditions for HPLC analysis. The purity of the final products was judged 
by HPLC analysis and NMR spectroscopy .
Quantitative analysis was carried out by total phosphate analysis as described in 
experimental section [181]. This, in combination, with UV spectroscopy was used to 
obtain quantitative data on the analogues.
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CHAPTER 5: BIOLOGICAL EVALUATION OF cADPR ANALOGUES
Several analogues of cADPR were synthesised with modification on the adenine ribose 
moiety as well as in position 8  of the adenine ring as discussed in chapter 4, were used to 
investigate the structure-activity relationships of cADPR. Analogues were tested in two 
systems, sea urchin egg homogenates and in permeabilised Jurkat T-cells as described in 
the experimental section. The biological activities of the analogues were compared to 
those of cADPR and the effect of each analogue on cADPR induced release were also 
investigated.
5.1: Results and Discussion
5. h i  Biological evaluation o f 2 'a and 3 fA-Modified cADPR on Ca*+-release in sea 
urchin eggs
A) 2Vdeoxv-cADPR 3Vdeoxv-cADPR and 3 VO-Methvl-cADPR 
Two hydroxyl deleted analogues, 2 'A and 3 Vdeoxy-cADPR were used to study the 
effect of 2'a and 3'A-hydroxyl group in the adenine moiety of cADPR on the Ca2+- 
releasing potential of cADPR. These two analogues like cADPR were agonists but 
exhibited comparatively different activities as agonists for Ca2+ mobilisation in sea urchin 
egg homogenates. EC50 values were estimated to be 32nM, 58nM and 5pM for cADPR, 
2fA-deoxy-cADPR and 3 Vdeoxy-cADPR respectively. 2 'A-Deoxy-cADPR was similar 
in activity to cADPR, whereas, 3 Vdeoxy-cADPR was at least a hundred fold less 
potent, indicating that the 3'A-hydroxyl group, but not the 2 'A-hydroxyl group is essential 
for calcium releasing activity. A dramatic difference is observed from the dose response 
























Figure 5.1: Concentration response curves for cADPR ( • ) ,  2'A-deoxy-cADPR (A) 
and 3 'A-deoxy-cADPR (■) from Ca2+ release studies in sea urchin homogenates.
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Figure 5.2: Desensitisation effect of 2'A-deoxy and 3'A-deoxy-cADPR on cADPR- 
induced Ca2+ release in sea urchin egg homogenates. (A) Release by cADPR 
(100nM), (B) effect of 2 'A-deoxy-cADPR (200nM) on cADPR-induced release, (C 
and D) effect of 5|iM and 20^iM of 3 'A-deoxy-cADPR respectively on cADPR- 
induced release.
t
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release by 3 'A-deoxy-cADPR (Fig 5.1). This shows that there is a loss of potency on the 
deletion of the 3'A-OH group, hence, a higher concentration of 3'A-deoxy-cADPR is 
required to release the same amount of Ca2+ as cADPR. That Ca2+ release from these 
analogues was from the same Ca2+ pool as cADPR was shown by desensitisation studies 
(see Fig 5.2). Ca2+ release by either analogue desensitised the homogenate to further 
release by cADPR. 200nM of 2'A-deoxy-cADPR was required to desensitise the 
cADPR-sensitive Ca2+ channel to a subsequent addition of lOOnM cADPR, but 20pM of 
3'A-deoxy-cADPR was required to produce the same desensitisation effect. This is 
consistent to a 100 fold lower potency exhibited by 3 'A-deoxy-cADPR. It is currently 
unclear whether the inhibitory effect of these analogues on cADPR-induced release is 
due to desensitisation of cADPR-sensitive receptors or to store depletion. In a control 
experiment to test whether the differing activities between 2 'A-deoxy-cADPR and 3'A- 
deoxy-cADPR was due to different rates of analogue breakdown by endogenous cADPR 
hydrolase, cADPR, 2'A-deoxy-cADPR and 3'A-deoxy-cADPR were each incubated in sea 
urchin homogenates. HPLC analysis of products over 10 h showed that neither 2 'A- 
deoxy-cADPR nor 3 \-deoxy-cADPR were metabolsied faster than cADPR, suggesting 
that the reduced activity of 3 'A-deoxy-cADPR is not due to an unusual hydrolytic 
breakdown under the experimental conditions (J. Sethi & V.Bailey personal 
communication).
The large difference in activity between the 2'A and 3'A hydroxyl deleted analogues 
prompted further study to the role of the 3'A-OH group. 3'A-OMe-cADPR was 
synthesised to investigate the importance of the 3'A position further. The OMe group is 












Figure 5.3: Inhibitory effect of 3’A-0Me-cADPR on cADPR-induced Ca2+ release.
a proton in a potential hydrogen bond interaction with the receptor, although it can still 
act as an acceptor. Interestingly, 3 'A-OMe-cADPR did not mobilise Ca2+ in the sea 
urchin egg homogenate system up to a concentration of 20pM. To investigate whether 
there was a possible interaction of 3 'A-OMe-cADPR at the cADPR receptor, the effect 
of this analogue on cADPR induced release was investigated. It acted, surprisingly as an 
antagonist as it inhibited the cADPR induced release in a concentration dependent 
manner with an approximate IC50 value of 5jxM (see Fig 5.3). The response to lOOnM 
of cADPR was abolished with lOpM of 3'A-OMe-cADPR.
It appears from the above results that the oxygen atom is somehow important for 
interaction at the cADPR receptor site as 3'A-OMe-cADPR must interact with the 
receptor in order to inhibit cADPR-induced Ca2+ release in a dose dependent manner. 
3'A -doexy-cADPR (38), the poor agonist can neither donate nor accept a H-bond at the 
3'A position, hence it appears that the ability of an analogue to potentially accept a 
hydrogen bond as in 3 VOMe-cADPR (39) may be important for receptor binding. 
Furthermore, the possibility of a hydrophobic interaction between 3'A-OMe-cADPR with 
the cADPR receptor may account for the antagonist activity of this analogue. These 
different possibilities need to be explored in order to understand the property which is 
important for antagonist activity. Nevertheless it is interesting that loss of the 3 'A-OH 
group is crucial whereas the 2 \  is not as important for agonist activity and that mere 
substitution of the hydrogen atom of the 3'A-OH group of cADPR by a methyl group is 
sufficient to convert the ligand from an agonist to an antagonist. 3 'A-OMe-cADPR, is 
the first antagonist not modified at the 8-position of the adenine ring and it provides a
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new lead compound for the synthesis of novel potent inhibitors of cADPR-induced 
release.
3 VcADPRP and 2' A.3 VcADPRP.
The calcium release potentials of 3 'a-cADPRP (41) and 2'A,3 Vcyclic-cADPRP (42) 
(Fig.4.9) were investigated to study the effect of a phosphate group at the 2 'A and 3'A 
positions and to investigate the possibility of an electrostatic attraction between the 
phosphate group and the cADPR receptor. These analogues were both inactive in 
releasing calcium in the sea urchin egg homogenate up to concentrations of 20pM and 
did not exhibit any effect on Ca2+ release by lOOnM cADPR. This would infer that they 
are neither agonists nor antagonists. These results are consistent with previous 
preliminary study of the Ca2+ release potential of 3VcADPRP and 2'A,3,A-cyclic- 
cADPRP in rat brain microsomestl31]. This action was found by the authors to contrast 
with the agonistic action of 2 'a-cADPRP (structure shown in Fig 4.7).
3 VcADPRP is similar in structure to cADPR except that it possesses a phosphate group 
at the 3 Vhydroxyl. The 2 'A and 3 Vhydroxyls are both substituted in 2 'A, 3 VcADPR 
by a cyclic phosphate. Moreover, 3 VcADPR has around two extra negative charges 
and 2 'a, 3VcADPR has one extra negative charge at physiological pH compared to 
cADPR. It is likely that a combination of these factors may result in electrostatic 
repulsion and steric hinderance of the molecules at the cADPR receptor site relative to 
cADPR, preventing binding to the receptor. 2 VcADPR, an analogue with a phosphate 
group substituted on the 2 'A-hydroxyl and with two extra negative charge at 
physiological pH compared to cADPR has been found to be active in rat brain
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microsomes[131] and permeabilised T-cells I188], however, we found it to be inactive in 
mobilising Ca2+ in sea urchin egg microsomes, in support of a previous report by Aarhus 
and co-workerst1261. It appears from these studies that there may be subtle differences in 
the cADPR-sensitive Ca2+ release mechanism for the ryanodine receptor of sea urchin 
eggs and mammalian tissue. We have demonstrated that while replacement of the 3'A- 
OH with a hydrogen atom reduced the activity of the analogues, replacement of the H 
atom of 3'a-OH with a phosphate group completely abolished the activity of analogue. 
Moreover, replacement of the 2 'A-OH with a hydrogen atom has little effect on the 
activity of cADPR, but activity is completely abolished by the attachment of a phosphate 
group at this position
5.1,2 Biological evaluation o f 2 'A and 3\^M odified cADPR on C (f+-release in Jurkat 
T-cells
A) 2Vdeoxv-cADPR. 3Vdeoxv-cADPR and 3' a-O-Methvl-cADPR 
The effect of hydroxyl deletion at position 2 \  and 3fA of the adenine ribose as in 2 \  and 
3'A-deoxy-cADPR on Ca2+-release in Jurkat T-cells show remarkably different profile 
compared to the effect seen in the sea urchin egg homogenate system. 2 A-deoxy- 
cADPR showed very poor activity as an agonist. Mamimum release was observed at 
~100pM compared to 7pM in cADPR. There was no release observed with up to 
IOOjiM of 3Vdeoxy-cADPR (see Fig.5.4). It thus appears that unlike the sea urchin egg 
system, where only the 3'A-OH appears to be crucial for activity, both the 2 \  and 3'A 
hydroxyls are necessary for effective Ca2+ release activity in Jurkat T-cells. To further 
investigate the role of the 3'A-hydroxyl group, the Ca2+ release potential of 3'A-OMe-
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cADPR was investigated in Jurkat T-cells. 3fA-0Me- cADPR was an agonist 
comparable to cADPR (Dr Guse-personal communication) in this system in contrast to 
the antagonist activity exhibited in sea urchin egg homogenates. Hence replacement of 
the 3fA-OH group with an -OMe group has little effect on the activity of cADPR, but 
replacement with a hydrogen atom completely abolished its activity in this system. As 
previously explained (section 5.1.1), 3'A-doexy- cADPR can neither donate nor accept a 
hydrogen bond at the 3'A-position the -Ome group in 3'A-OMe- cADPR is larger 
compared to the hydroxyl group in cADPR and does not possess the ability to donate a 
proton ina potential H-bond interaction with the receptor, although it can still act as an 
acceptor. It thus appears that the ability of the functional group at position 3 'A to accept 
a hydrogen bond may be important for binding to the receptor, but activation of the ion 
channel may require donation o f a hydrogen bond. These results further highlights that 
there may be differences in the cADPR-sensitive Ca2+ release mechanism for the 
ryanodine receptor of sea urchin eggs and the mammalian Jurkat T-cell.
B) 3 VcADPRP and 2V3 Vcvclic-cADPRP
The effect of a phosphate group in positions 2 'A and 3'A of cADPR was investigated by 
studying the Ca2+ releasing potential of 3 VcADPR and 2V3 Vcyclic-cADPRP in Jurkat 
T-cells. These analogues were not active in mobilising Ca2+. 2VcADPRP has been 
shown recently to be as potent as cADPR in Ca2+ releasing activity in permeabilised 
Jurkat T-cells. These results are consistent with those reported previously in another 
mammalian system (rat brain microsomes) [131l  It is interesting to note that substitution 
at the 2V O H  with a phosphate group did not appear to affect the activity of cADPR 
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Figure 5.4: Concentration response curves for cADPR, 2'A and 3'A-modified
cADPR analogues and cFDPR (51), showing Ca2+ release activity in permeabilised 
Jurkat T-cells.
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with a hydrogen atom resulted in considerable loss of activity. It is unclear at this stage 
whether loss of activity with 3 VcADPRP and 2'A, 3 Vcyclic-cADPRP is due to the 
removal of the -OH proton by substitution or rather is the result o f increase in steric 
volume by addition of a phosphate.
5.1.3 Biological Evaluation o f 8-Modified analogues o f cADPR on Cc^+-release in 
sea urchin eggs
The first indication that an exocyclic substitution in position 8 of the adenine ring of 
cADPR might be important in designing antagonist of cADPR-induced Ca2+release was 
demonstrated by Walseth & L eell20]. This group found that substitution of HA8 with an 
amino group converted the compound cADPR from an agonist to an antagonist. Two 
other analogues, 8-Br and 8-azido-cADPR were also found to be antagonists, but with 
lesser potency. The potency of 8-azido was in between that of 8-amino-cADPR and 8- 
azido-cADPR although IC50 values were not reported. It was suggested that the size of 
the substituent (expressed in atomic units) may be responsible for the difference in 
potency of the three 8-substituent analogues synthesised as antagonists. The larger size 
the substituent at this position the lower the potency, as an increase in size from 16 (- 
NH2) to 42 (-N 3 )  to 79 (-Br) resulted in decrease in potency as an antagonist in this 
order. We have therefore synthesised various 8-substituted analogues of cADPR in 
order to further investigate this hypothesis.
8-Amino-cADPR was synthesised in our laboratory to enable us to carry out 
comparative studies. 8-Amino-cADPR was also found to act as antagonist in sea urchin 
egg homogenates with an IC50 value of 0.01 pM. Replacement of the amino group with a 
methyl group as in 8-methyl-cADPR (48) gave an antagonist with an IC50 value of
0.53 pM. The -CH 3 group is similar in atomic mass to -NH2 and yet 8 - Me-cADPR was 
53 times less potent as an antagonist compared to 8 -NH2-cADPR. Substitution with an 
oxy group (with an atomic mass of 17) was attempted. The analogue obtained showed 
still weaker activity as an antagonist with an approximate IC50 of 2 pM. Substitution 
with groups of varying sizes such as -NHMe, NMe2 and -piperidyl as in 8 -NHMe, 8 - 
NMe2 and 8 -piperidyl-cADPR produced novel compounds which were investigated for 
antagonist activity (see table 5.1). 8 -NHMe-cADPR was a weaker antagonist compared 
to 8 -NH2-cADPR with an IC50 of ~ 40pM, 8 -NMe2 was weaker than 8 -NHMe-cADPR 
as an antagonist, but 8 -piperidyl was not active at all as antagonist up to 50pM. This 
indicated that the potency of the substituent at the 8 -position could be a function of size 
such as molecular volume. Other analogues such as 8 -OCH3-cADPR and 8 -Br-cADPR 
were also synthesised for comparative study. These analogues were antagonist with IC50 
values of 4.8 and 0.97pM respectively. It appears, therefore, in this preliminary study, 
that the ability of the molecule to hydrogen bond is not important for activity as an 
antagonist as 8 -CH3-cADPR is a better antagonist compared to analogues that can form 
hydrogen bonds such as 8 -OCH3-cADPR and 8 -NHMe-cADPR.
The molecular volume of the substituents were measured using SYBYL molecular 
modelling software package. A qualitative correlation between the molecular volume of 
the substituent and IC50 value was observed. The larger the molecular volume of the 
substituent, the higher the IC50 value of the analogue. Only 8 -Oxo-cADPR did not fit in. 
The volume measured for the substituent in 8 -oxo-cADPR was less than that of 8 -NH2 
and yet the molecule was 200 times less potent as an antagonist. It is well documented 
that 8 -hydroxyl purine can tautomerise to the purinone and it has been shown that the
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keto tautomer is more stable at physiological pH [150,152]. The existence of the keto 
tautomer will alter position 7 of the adenine ring. In the purinone tautomer N7 becomes 
protonated. This small change may be enough to affect the potency of this analogue as 
an antagonist, so that even though -OH has a lower molecular volume compared to - 
NH2, the named molecule is not able to bind well to the receptor site, and hence is a 
weaker antagonist. Hence the following rank of order of activity was obtained in this 
study: 8 -piperidyl-cADPR (inactive) < 8 -NMe2-cADPR < 8 -NHMe-cADPR < 8 -OCH3- 
cADPR< 8 -oxo-cADPR < 8 -CH3-CADPR < 8 -NH2-cADPR. 8 -Amino-cADPR is the 
still the most potent antagonist to date.
8 -substituted analogue of 
cADPR
Molecular Volume of 
substituent (A3)
Action on cADPR-induced 
Ca2+ release (lOOnM), 
antagonist (IC5o)piM
8 -NH2-cADPR (48) 15.6 0 .0 1
8 -Br-cADPR (43) 19.1 0.97
8 -NHMe-cADPR (44) 32.0 <40
8-NMe2-cADPR(45) 47.0 >40
8 -OCH3-cADPR (46) 26.9 4.8
8 -piperidyl-cADPR (47) 8 6 .8 No effect
8 -Me-cADPR (49) 16.5 0.53
8 -Oxy-cADPR (50) 9.1 - 2 .0
Table 5.1: IC50 values of 8-substituted analogues of cADPR (from Ca2+ release 
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Figure 5.5: Graph showing inhibitory effect of some 8 -substituted analogues of cADPR on 
cADPR induced Ca2+ release in sea urchin egg homogenates. x  axis shows response obtained 
with lOOnM cADPR a n d j  axis is the log (dose of antagonist).
Modification in the purine ring as in 8-aza-9-deaza~cADPR (51), resulted in an analogue 
that is 10 times less potent as an agonist compared to cADPR (EC50= 0.3 lpM). In this 
molecule the carbon atom of position 8 in the purine ring is replaced with a nitrogen 
atom and the nitrogen atom of position 9 of the purine ring is replaced with a carbon 
atom. Modification in the purine ring hence did not produce an antagonist compared to 
exocyclic modification as discussed above. Reduction in activity could be due to 
protonation at the N7 which may affect receptor binding. A small modification at this 
position as in 7-deaza-cADPR has been reported to result in partial agonist activity/1911
5.1.4 Biological evaluation o f 8-Modified Analogues o f cADPR on C(f+'release in 
Pemeabilised Jurkat T-cells.
In order to design antagonists for cADPR-induced mechanisms in Jurkat T-cells, we 
decided to investigate whether 8-amino-cADPR and 8-bromo-cADPR (both prepared by 
the author) would have a similar effect to that seen in the sea urchin egg system. We 
found that these two analogues inhibited Ca2+ release mediated by cADPR. 8-Br- 
cADPR was less effective as an antagonist compared to 8-amino-cADPR[951. We 
decided to investigate whether there is a link between the size of the 8-substituent and 
the potency of the antagonist as an aid to designing potent inhibitors of the cADPR- 
induced mechanism. The extension to mammalian cells is essential for the aim of 
defining a wider applicability for the cADPR signalling system.
Substitution of any group other than hydrogen into position 8 of the adenine ring
resulted in analogues with antagonist activity in this system. Hence all the 8-substituted
analogues synthesised (43-50) all inhibited cADPR-induced Ca2+-release. 8 -NH2 (48), 8 -
CH3 (49) and 8 -NMe2-cADPR (45) are potent inhibitors with low IC50 values (see
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R3C-Br (43)
R2C = 0  (50)
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Figure 5.6: Concentration response curves illustration inhibitory effect of 8 -
substituted analogues of cADPR-induced Ca2+ release in permeabilised Jurkat T- 
cells.
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Fig.5.6 and table 5.2) of 0.08pM, 0.2pM and 0.3pM respectively. 20pM of 8 -CH3- 
cADPR completely abolished cADPR induce release, suggesting that hydrogen bond 
interaction between the substituent and the receptor site is unlikely to be responsible for 
antagonist activity as the -CH3 group in (49) cannot form a hydrogen bond. There is, 
however, a possibility of a hydrophobic interaction taking place. This is supported by the 
fact that 8 -NHMe-cADPR, has a higher IC50 value of 8.0pM and shows less potent 
inhibition at 20jjM compared to 8 -NMe2 -cADPR. The -NMe2 substituent being more 
hydrophobic than the -NHMe group. Moreover. 8 -piperidyl-cADPR (47) exhibited a 
low IC50 value o f 0.08jiM comparable to 8 - NH2 -cADPR, though less potent inhibition 
at higher concentrations (see table 5.2). The remaining signal at 20pM (defined in the 
experimental section) of 8 -piperidyl-cADPR was 9.0 compared to 4.7 for 20pM of 8 - 
NH2 -CADPR. The piperidyl group, though large, is hydrophobic and flexible. Hence, it 
can change its conformation to fit the receptor site. 8 -Br-cADPR showed poor 
inhibition, possibly due to the bulk of the bromo substituent and unlike the piperidyl 
group the bromo group is a large rigid structure and hence is potentially hindered from 
fitting tightly into the receptor site. 8 -Oxo-cADPR showed poor inhibitor (IC50 = 8 pM) 
even though the substituent is similar in size to -NH2  and -CH3 substituent. There are 
potential multiple alterations in this analogue compared to cADPR as the ntirogen in 
position 7 can become protonated. This change though small may be sufficient to affect 
the interaction o f this analogue with the receptor. 8 -OCH3-cADPR showed good 
inhibition with an IC50 value of 0.2pM comparable to 8 -CH3 -cADPR. Overall, it appears 
that the presence of a hydrophobic group in position 8  enhances antagonist activity of the 
analogue in permeabilised Jurkat T-cells.
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Modification in the purine ring in analogue (51) did not affect the Ca2+ releasing property 
of the analogue (see Fig. 5.4). This analogue showed similar Ca2+ release profile 
compared to cADPR in Jurkat T-cells even though the 8 -position is altered (although not 
outside the ring), the carbon at position 8 is replaced by nitrogen atom and the nitrogen 
at position 9 is altered to a carbon. These alterations appear to be unimportant for Ca2+ 
releasing activity.
8 -substituted analogue of 
cADPR
Action on cADPR-induced 
Ca2+ release (7pM), 
antagonist (IC5o)mM
Remaining signal at 20jjM 
antagonist [% of total Ca2+ 
pool released]
8 -NH2-CADPR (48) 0.08 4.7
8 -Br-cADPR (43) > 2 0 18
8 -NHMe-cADPR (44) 8 .0 9.7
8 -NMe2-cADPR (45) 0.3 5.5
8 -OCHs-cADPR (46) 0 .2 4.7
8 -piperidyl-cADPR (47) 0.08 9.0
8 -Me-cADPR (49) 0 .2 0
8 -Oxy-cADPR (50) 8 .0 11
Table 5.2: IC50 values of 8 -substituted analogues of cADPR from Ca2+ release 
studies in permeabilised Jurkat T-cells.
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5.2 Conclusion
The chemoenzymatic synthesis of cADPR analogues has proved to be a versatile 
approach [1911. We have demonstrated the broad substrate specificity of ADP-ribosyl 
cyclase for NAD+ analogues with modification to the ribose hydroxyl group and for 
modification to position 8 of the purine ring. All of the NAD+ analogues synthesised in 
this work were substrates for the cyclase.
Biological evaluation of analogues in the sea urchin homogenates (A) and Jurkat T-cells 
(B) have revealed some differences in the structural requirements for cADPR receptor in 
the systems concerned. The 2'A-OH and 3'A-OH both appear to be important for potent 
agonist activity in permeabilised Jurkat T-cells. In the sea urchin egg homogenate, only 
the 3'a-OH is crucial for effective Ca2+ release activity. Addition of a phosphate group at 
the 2'a-OH does not affect agonist activity in the permeabilised Jurkat T-cells, but this 
activity is abolished in the sea urchin egg homogenate. Substitution of the 3'A-OH with a 
phosphate group, however, resulted in loss of activity in both systems. Substitution on 
the 2 \  and 3'A ribose hydroxyl groups with a cyclic phosphate also resulted in loss of 
activity in the biological systems studied. Substitution of the 3'a-OH with a methyl 
group resulted in a change in activity from an agonist to an antagonist in (A), but in (B) 
3'A-OMe-cADPR had potent agonist activity. Hence, it appears that the ability of the - 
OH to donate a hydrogen bond may be important for potent Ca2+-releasing activity in 
(B). Replacement of the hydrogen atom at the 8-position of the purine ring of cADPR 
with other groups produced a change in activity from an agonist to an antagonist. The 
potency of the antagonist appears to be dependent on the molecular volume of the 
substituent in position 8 in (A). The larger the molecular volume of the substituent, the
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higher the IC50 o f the antagonist (i.e. weaker antagonist effect). Substitution with a 
piperidyl group resulted in loss of antagonist activity as the molecule is bulky and 
therefore is likely to be sterically hindered from interacting with the cADPR receptor. 
All the 8-substituted analogues were also antagonists in (B) although there were 
differences in potency and rank order. This activity appear to be enhanced by increasing 
the hydrophobicity o f the substituent, although there is also limitation to the size of the 
group as 8-Br-cADPR was a poor antagonist in this system.
These results represent the first steps towards establishing a wider structure-activity 
profile for cADPR and suggests that there may be structural differences in the cADPR- 
binding protein in the sea-urchin egg homogenate and in permeabilised Jurkat T-cells. 
Identification of the cADPR receptor in biological systems in question will help to verify 
our findings. Combined data from this work and results from a co-worker along with 
results from other groups are summarised below in Fig. 5.7.
5.3 Suggestions for further study.
1. Determine kinetic properties of cADPR hydrolase using various cADPR analogues as 
substrates.
2. Synthesis of fluorescent labelled analogues of cADPR.
3. Synthesis of membrane permeable analogues of cADPR
4. Synthesis of non-hydrolysable analogues of cADPR
5. Study on inhibition of the enzymes involved in the metabolism of cADPR
6. Preparation of analogues with modifications in the top ribose ring (i.e. the ribose ring 
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Figure 5.7: Structure-activity relationships of cyclic adenosine diphosphate ribose
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CHAPTER 6: EXPERIMENTAL \
6.1 General Procedures
Adenosine, Adenosine 5'-monophosphate, Nicotinamide-5'-mononucleotide (NMN), 2 '-
deoxyadeno sine-5 '-monophosphate (2'-deoxy-AMP), 3'-deoxy-adenosine-5'-
monophosphate (3'-deoxy-AMP), 3 '-O-methyl-adenosine (3 '-OMe-adenosine), 3'A-
nicotinamide adenine dinucleotide phosphate (3'A-NADP+), 2'a,3 'A-cyclic-nicotinamide
adenine dinucleotide phosphate (2 '^3 'a-NADP4), 2-[4-(2-hydroxyethyl)piperazin-l-
yl)ethanesulfonic acid (HEPES), N,N-dicyclohexylcarbodiimide (DCC), NAD+, yeast
alcohol dehydrogenase, alkaline phosphatase and tris(hydroxymethyl)aminoethane (Tris)
were purchased from Sigma (London). Organic solvents were obtained from Aldrich.
Pyridine was dried overnight with calcium hydride, re-distilled and stored over potassium
hydroxide pellets. Aplysia ovotestis homogenate containing ADP-ribosyl cyclase was
prepared as previously described t59]. The protein concentration of the Aplysia cyclase
used in all cases was estimated as lOmg/ml using a Bio-rad protein estimation assay.
Fluo-3 was purchased from Molecular Probes Inc. (Camb. BioSci.). All other reagents
were from Aldrich (London). Ion exchange chromatography was performed on an LKB-
Pharmacia medium pressure ion exchange chromatograph using a Sepharose Q fast flow
column with gradients of triethylammonium bicarbonate buffer (TEAB) pH 7.6 as eluent.
1M TEAB was prepared by bubbling carbon dioxide gas into 1M triethylamine solution
for ca. 6 h. HPLC was performed on a Shimadzu LC-6 A chromatograph with the UV
detector operating at 259nm using a combination of a Partisil 1 0 p. SAX guard column
(10x0.46cm) and a Technicol (10x0.46cm) lOp SAX HPLC column, or using a
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Spherisorb lOjx SAX (25x0.46cm) column with an isocratic elution using phosphate 
buffer (KH2PO4), pH 3.0 at a flow rate of lml/min. !H NMR and 31P NMR spectra were 
recorded on either Jeol JNM GX-270 FT NMR or Jeol EX-400 FT NMR spectrometers. 
Chemical shifts were measured in ppm relative to deuteriated water (D2O) for *H NMR 
and to external 85% H3PO4 for 31P NMR. 31P-NMR were measured at 162MHz or 
109MHz in D2O. For the latter, 5 values are positive when downfield from this reference. 
J values are given in Hertz (Hz). Mass spectra were recorded at the EPSRC Mass 
Spectrometry Service Center at the University of Swansea and at the University of Bath. 
Ultraviolet (UV) absorbance was measured with a Perkin-Elmer Lambda 3 UV/VIS 
spectrophotometer. Melting points were determined with a Reichert-Jung Thermo Galen 
Kogler block, using two glass plates and are uncorrected.
6.2 Synthesis of AMP Analogues
6,2.1 3'A-O-Methyl-adenosine 5 -monophosphate (3-OMe-AMP) 16
lOOmg (0.355mmol) of dry 3'-OM?-adenosine was placed in a dry round bottom flask.
2ml of triethyl-phosphate was added to the dry powder. The solution was heated for a
few seconds to ensure formation of a complex with PO(OEt)3. The flask was fitted with
a CaCl2 drying tube and was cooled to 0°C on an ice bath. 50(il (0.54mmol) of
phosphorus oxychloride were added to the solution dropwise at 0°C and the reaction
was left stirring for a total of 2 h at room temperature. HPLC analysis of an aliquot of
the reaction mixture in water after two hours showed the presence of a new product at 2
min, with the starting material eluting at 1.5 min. The reaction was quenched by stirring
in 4ml of pyridine:water (1:3) for 30 min. The solution changed from yellow to
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colourless. The solvent was removed in vacuo and excess PO(OEt)3 was extracted into 
cold petroleum ether 40-60° (3x10ml aliquots). The sample was dried in vacuo, the 
residue dissolved in 200ml of milliQ water and the product was purified by IE 
chromatography using a gradient of 0-400mM TEAB. The sample eluted off between 
110-160mM TEAB, and inorganic phosphate impurity was removed by passing the 
solution through a charcoal column and eluting the product as described under 
phosphorylation of 8 -bromo-adenosine, to afford 48% yield (0.17mmoles).
8h (D20 , 400MHz): 8.3 (H8 ), 7.9 (H2, s), 5.9 (H r, d, J 5.8), 4.75 (H2\ t, J 5.5, 5.8),
4.3 (H3', t), 4.05 (H4\ m ), 3.9 (H5', 5', m ), 3.4 (3H, Me, s). 6p (D 20 ,  162MHz): 2.3, s,
IP (^-decoupled).
m/z (-ve ion ES): 360 [100%, M -  H)"]. Amax256nrn (pH 8.3) e259 15,300.
6.2,2 Synthesis o f 8-Bromo-adenosine 5 -monophosphate (8-Br-AMP) 4 
8 -Br-AMP can be synthesised from adenosine (A) and by direct bromination of AMP (B). 
The synthesis from adenosine is in two stages i) bromination of adenosine, ii) 
phosphorylation of 8 -Br-adenosine.
A) Synthesis from Adenosine
i) Bromination o f adenosine
2g (0.75mmol) of adenosine (1) was dissolved in 50ml of 1.0M acetate buffer pH 3.9 by 
gentle heating. 0.5ml of Br2 was added and the solution was left stirring overnight. The
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nucleoside had precipitated out of the solution after ca. 18 h at room temperature. TLC 
of the precipitated material in solvent system I chloroform:ethanol (3:2) and solvent 
system II dichloromethane:methanol (9:1) showed that the reaction was not complete. 
Therefore the nucleoside suspension was forced back into solution by heating and a 
further 0.5ml of Br2 was added. This solution was left stirring for a further 30min after 
which the reaction was judged complete by TLC. For system I Rf adenosine (0.36), 8 -Br- 
adenosine (0.6) and in system n, Rf adenosine (0.05), 8 -Br-adenosine (0.26). 10 drops of 
1.25M sodium hydrogen sulphite (NaHS03) was added to discharge the colour of the 
solution from dark red to light yellow colour. The sample was dried in vacuo, 
redissolved in 40ml o f water and a further 10  drops of NaHSC>3 was added to discharge 
the colour further. Care was taken not to add too much NaHSC>3 as this can cause 
debromination of the product. The pH of the solution was adjusted to 7 with 5M sodium 
hydroxide and the solution was left in the refrigerator to recrystallize to afford an 
analytically pure material by HPLC. The solvent was decanted off and crystals was 
washed with water: acetone (1:1) solution. The pure product thus obtained was dried in 
a vacuum oven under reduced pressure at 60°C and sample was weighed (91% yield).
Sh (D20 , 270MHz): 8.1 (H2, s), 5.8 (HI', d, J 7.0), 5.2 (H2\ dd, J 5.5, 7.0), 4.2 (H3\ dd),
4.0 (H4'), 3.9 (H5', H5'). m.p. 207-209°C (Ht.[1581 >200°C)
ii) Phosphorylation o f 8-Bromoadenosine.
8 -Bromoadenosine was dried in a vacuum oven at 60°C for 2 h. 0.212g (0.61mmol) of 
dry 8 -bromoadenosine (3) was dissolved in 4.0ml o f dry triethyl-phosphate by heating
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with a heat gun until solution became clear. The flask was fitted with a CaCl2 drying 
tube and the solution cooled to 0°C in an ice bath. 200|il (2.16mmol) of phosphorus 
oxychloride (POCI3) was added dropwise and the flask was left stirring for 3 h at rt. 
with the drying tube in place. HPLC analysis of the reaction mixture dissolved in water 
showed the presence o f a phosphorylated material with the same retention time as an 
authentic sample of 8 -Br-AMP, purchased from Sigma. HPLC analysis was performed 
on a Partisil SAX column (10x0.46cm) using an isocratic gradient of 0.05M KH2PO4 pH 
3.0. Retention times: Rt 8 -Br-adenosine (1.2min) 8 -Br-AMP (1.8min). The reaction was 
quenched with 8ml of pyridine : water (l:3v/v) and left stirring for a further 30min The 
sample was dried in vacuo and 31P NMR spectroscopy in D20  with the pH adjusted to
8.0 with 1.0M TEAB buffer showed the presence of inorganic phosphate at 8  -0.1 and 8 - 
Br-AMP at 8  0.4ppm. The peak due to nucleotide was distinguished by proton coupled 
31P NMR spectroscopy in which the peak due to the inorganic phosphate remained a 
singlet and the peak due to 8 -Br-AMP became a triplet with J value of 5.67Hz, on 
proton coupling.
Ion exchange purification o f 8 -Br-AMP removed contaminating 2 '-phosphorylated
nucleotide, but a large amount of inorganic phosphate was still present. Inorganic
phosphate was removed by passing the nucleotide mixture dissolved in 50ml of water
through a charcoal column. This column (25 x4cm) was prepared by using ca. 1cm of
celite as a bed on top of which 7cm of activated charcoal (NoritB) were added. The
nucleotide solution in water was poured unto the column and the eluent was collected.
Water was used to flush inorganic phosphate off the column and a total of 75ml of eluent
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was collected. The inorganic phosphate-free nucleotide was eluted off the column using 
25:24:1 (v/v) ethanol:water:concentrated ammonia (2x500ml). The first fraction 
collected in water was stirred with 2g of charcoal in 50ml of water and filtered off 
through through a sintered column layered with celite. The filtrate was discarded and 
more nucleotide was eluted off with 100ml o f25:24:1 ethanol:water:conc ammonia. The 
two eluted fractions were combined and dried in vacuo. 31P NMR spectroscopy showed 
the absence of inorganic phosphate impurities. Measurement of OD units before and 
after charcoal treatment showed 80% recovery of pure nucleotide.
Sh (D20 , 400MHz): 8 .0  (H2 , s), 5.8 (HI', d, J 6 .1), 5.1 (H2\ t, J 6 .1), 4.4 (H 3\ t, J 
6 Hz), 4.1 (H4', m), 3.9 (H5\ m), 3.8 (H5\ m). 8 p (D20 , 162MHz):+3.7, s, IP (*H- 
decoupled), IP, t, J 5.67 ^H-coupled). 264nm (pH 7.0) s 15,100
B) Bv direct bromination of AMP
8 -Br-AMP (4) was prepared by bromination of AMP (2) as the disodium sa lt[141]. AMP
(lg, 2.88mmol) was dissolved in 50ml of 1M sodium acetate buffer pH 3.9. 0.5ml
(0.02mol) of Br2 was added dropwise to this solution while stirring and the solution was
left stirring at room temperature for 30min. The progress of the reaction was followed
by UV spectroscopy, where the spectrum showed a shift in from 259 to 264nm
upon conversion of AMP to 8 -Br-AMP. Excess bromine was extracted into 3 x50ml
aliquots of chloroform. The resulting pale yellow aqeous solution was dried at 30°C
under reduced pressure to obtain a dry powder. The powder was dissolved in milliQ
water and purified by ion-exchange chromatography using a gradient of 0-40% TEAB.
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The pure sample eluted off between 170-210mM. The sample was dried in vacuo and 
quantified using an extinction coefficient of 15,100M*1cm'1 at 264nm (Townsend). 8 -Br- 
AMP (1.87mmol) was obtained in 6 8 % yield.
5h (D20 , 400MHz): 8.0 (H2, s), 5.8 (H I', d, J 6.1), 5.1 (H 2\ t, J 6.1), 4.4 (H3\ t, J 
6Hz), 4.1 (H4', m), 3.9 (H5', m), 3.8 (H5f, m). 6 p (D20 , 162MHz):+3.7, s, IP (*H- 
decoupled), IP, t, J 5.67 ^H-coupled). A^ ax 264nm (pH 7.0) e 15,100
6.2.3 8-Methyladenosine 5 -monophosphate (8-Me-AMP) 16
8 -Me-AMP was synthesised in two steps A) synthesis of 8 -methyladenosine (5) 
followed by B) phosphorylation of (5) to 8 -methyladenosine 5'-monophosphate.
A) Synthesis of 8 -Methvladenosine 5 [148]
lg  (2.89mmol) o f dry 8 -bromoadenosine was dissolved in 20ml of hexamethyldisilazane
and 8 ml of dry dioxane in a three-necked flask. A catalytic amount of ammonium
sulphate was added to the suspension and the mixture was left under reflux at 130°C for
2-3 h. TLC in dichloromethane: methanol (9:1) showed that protection was complete. 8 -
Br-adenosine (F / 0.36), Product (Rf 0.57) was observed as a single spot. The sample
was dissolved in 8 ml anhydrous dry THF under an atmosphere of nitrogen. 0.1
equivalent o f triphenylphosphine (76mg, 2.89mmol), 0.05 equivalent of palladium
dichloride (26mg, 0.1445mmol) and 2 equivalents of trimethylaluminium (2.89ml,
5.78mmol) were added to the solution of sample in dry THF under N2. The reaction was
left under reflux and a gentle stream of N2for 2.5 h. The R /of protected 8 -Me-adenosine
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on TLC developed in DCM:MeOH (9:1) was 0.39. The crude mixture was dried in 
vacuo to give a green residue. Deprotection of the crude product was carried out by 
dissolving the residue in 50ml of methanol and refluxing for 4 h with a small amount of 
ammonium chloride. The R/ of the deprotected 8 -methyladenosine was 0.05. The crude 
sample was purified on a short silica gel column eluting first with 200ml of DCM:MeOH 
(9:1) followed by CHC^EtOH (3:2). The sample was dried down on a rotary 
evaporator, the residue dissolved in water and the pH adjusted to 7 with 5M NaOH. The 
sample was allowed to recrystallized at 4°C overnight. The crystals obtained were very 
fine soft jellied, hence the suspension was centrifuged and water was decanted off. The 
crystals were dried overnight in a vacuum oven at 60°C to afford 48% (0.39mg,
1.4mmol) yield dry weight.
8 h (D20 , 270MHz): 8.0 (H2, s), 5.8 (H r, d, J 7.3), 4.8 (H2', dd, J 5.1, 7.3), 4.1 
(H3',dd), 4.0 (H4', m), 3.7 (H5\ m), 3.5 (H5\ m).
m/z (+ve ion FAB) 282 [100%(M + H)+], (-ve ion FAB): 434 (M + NBA).
FAB accurate mass 282.120743. Found 282.120229.
m.p. 208°C, (litC192] 207-208°C)
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B1 Phosphorylation of 8 -methvladenosine
170mg (0.6mmol) of dry 5 was placed in a diy round bottom flask. 4ml of triethyl- 
phosphate was added to the dry powder. 8 -Methyladenosine dissolved readily in 
PO(OEt)3. The solution was heated for a few seconds to ensure formation of a complex 
with PO(OEt)3. The flask was fitted with a CaCl2 drying tube and was cooled to 0°C on 
an ice bath. lOOjil (1.08mmol) of phosphorus oxychloride were added to the solution 
dropwise at 0°C and the reaction was left stirring for a total of 3 h at room temperature. 
HPLC analysis of an aliquot o f the reaction mixture in water after two hours showed the 
presence of a new product at 2 min, with starting material eluting at 1.5 min. The 
reaction was quenched by stirring in 8ml of pyridine:water (1:3) for 30 min. The 
solution changed from yellow to colourless. The solvent was removed in vacuo and 
excess PO(OEt)3 was extracted into cold petroleum ether 40-60° (3x10 ml aliquots). 
The sample was dried in vacuo, the residue dissolved in 350ml of milliQ water and the 
product was purified by IE chromatography using a gradient of 0-400mM TEAB. The 
sample eluted off between 110-160mM TEAB, and inorganic phosphate impurity was 
removed by passing the solution through a charcoal column and eluting the product as 
described under phosphorylation of 8 -bromoadenosine to afford the product 60.3% yield 
(0.38mmole).
6 h  (D20 , 400M H z): 7.9 (H2, s), 5.8(H1\ d, J 6 .8 ), 4.8 (H2\ t, J 6.2), 4.3 (H3\ t, J 6.2),
4.1 (H4', m), 3.9 (H5', 5', m), 2.46 (3H, Me, s). 6 p (D 20 ,  162M Hz): 4.0, s, IP (*H- 
decoupled), IP, t, J 5.6 (^-coupled). Xmax260nm (pH 8.3) e 15,300.
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6.2.4 8-Methylaminoadenosine 5 '-monophosphate (8-NHMe-AMP) 6 
To 270.8pmol of 8 -Br-AMP (4) as the triethylammonium salt were added 10ml of 
anhydrous 2M methylamine in methanol. The solution was left stirring under reflux at 
50°C using an oil bath for 3 h after which little conversion had taken place as monitored 
by HPLC system. The temperature of the reaction mixture was therefore increased to 
60-70°C. Considerable conversion to 8 -NHMe-AMP had occurred after 1 h. The 
reaction was left stirring at this temperature for a further hour, but no further conversion 
was noticed. The progress of the reaction was monitored by HPLC on a combination of 
Partisil 1 0 p SAX 3cm column with Partisil 1 0 |i SAX column (10x0.46cm). Rt 8 -Br- 
AMP 2.5min, 8 -NHMe-AMP 2.3 min. A definite change in A*** from 264-278nm 
followed conversion to the product. The crude sample was dried down in vacuo, the 
residue dissolved in milliQ water and the product purified by IE chromatography using a 
gradient of 0-350mM TEAB. Pure product eluted off between 200-3OOmM TEAB to 
yield 176.02|imoles (65%) of 6  as quantified by phosphate analysis.
5h (D20 , 400MHz): 7.8 (H2, s), 5.8 (HT, d, J 8 ), 4.6 (H2\ t, 5.8Hz), 4.26 (H3', t, J
5.5), 4.1 (H4\ m), 3.9 (H5',m), 3.8 (H5\ m), 2.8 (3H, -NMe, s). 6 p (D20 , 162MHz): 
+3.2, s, IP (^-decoupled). Xmax 278nm, pH 8.3 (e 17,700M'1cm‘1).
in/z (ES~): 376.4 [20% (M)"], 375.4 [100% (M -  H"]).
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6.2.5 8-Dimethylamino-adenosine 5 -monophosphate (8-NMer AMP) 7
10ml of anhydrous 2M dimethylamine solution in methanol were added to 146.93jjmol 
of 4 in a round bottom flask. The solution was left stirring under reflux at 40°C 
overnight, after which the sample was dried down in vacuo. A change in from 264- 
274nm confirmed the change from 8 -Br-AMP to 8 -NMe2-AMP. The crude sample was 
purified on an ion-exchange column using a TEAB gradient of 0-400mM. Pure sample 
eluted off between 140-210mM TEAB to afford 99.9jimoles (6 8 %) of 7. HPLC analysis 
on a Spherisorb column (25x0.46cm) Rt 4.9min.
8h (D20 , 400MHz): 7.9 (HA2, s), 5.6 (HA1', d, J 6.7), 5.1 (HA2', t, J 6.4), 4.3 (HA3 \  t, J 
5), 4 (Ha4', m), 3.9 (HA5 \ 5', m), 2.8 (6H, -NMe2, s). 6 p (D20 , 162MHz): +2.2, s, IP 
(^-decoupled), m/z (+ve ion FAB): 492 [70% (M + TEA)+], 391 [90% (M + H)+], 
283 [20% (ribose + NBA)+].
m/z (-ve ion FAB): 779 [30% (2 M -H )'], 389 [90% 231.9 [100% (P 032' +
NBA)']. Xmax274nm, pH 8.3 (e 10,900MJ cm-1).
6.2.6 8-Amino-adenosine 5 -monophosphate (S-NHrAMP) 9
25mg (59.2|imol) of the comercially available 8 -azido-AMP (8 ) as the bis-ammonium 
salt was dissolved in 7.5ml of 50mM TEAB, pH 8.0 in a round bottom flask covered 
with foil to reduce light. 13.97mg (90.6pmol) of dithiothreitol were added to the
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nucleotide solution, and the mixture was left stirring for 16h at room temperature [150]. 
The reaction was judged to be complete by a change in UV absorption maximum from 
282 to 274nm. The crude sample was dried down in vacuo and the residue purified by 
ion-exchange chromatography using a gradient of 50-1000mM TEAB pH 7.6. Pure 8 - 
NH2-AMP eluted as the triethylammonium salt between 310-390mM TEAB with 65.3% 
(38.69pmols) yield using s 16,000 at Xmax274nm.
8 h (D20 , 400M H z): 7.8 (H2, s), 5.8 (H I', d), 4.6 (H2\ dd), 4.3 (H3'), 4.2 (H4\ m), 4.1 
(H5',H5'). 8p (D 20 ,  162MHz): 0.35, s, IP (^-decoupled).
6,2.7 8-Piperidyl-adenosine 5 '-monophosphate (8-pip-AMP) 10 
To 111.3pmol of dry (4) was added 0.4ml of dry distilled piperidine. The solution was 
left stirring at 50°C for 40 h. The reaction was monitored by HPLC analysis using a 
combination of Partisil lOp SAX guard column (10x0.46cm) and a Technicol 
(10x0.46cm) lOp SAX using an isocratic elution with KH2P(>4, pH 3.0 with a flow rate 
of lml/min. 8 -pip-AMP eluted at 5. lmin followed by 8 -Br-AMP at 6 .8 min. The sample 
was dried in vacuo, the residue dissolved in milliQ water and product purified by ion- 
exchange chromatography using a gradient of 0-300mM TEAB. Pure 8 -pip-AMP eluted 
between 30-65mM TEAB (65% yield). The sample was quantified by phosphate 
analysis11821 and the extinction coefficient was determined therefrom.
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8 h (D 20 ,  400MHz): 7.9 (H2,s), 5.6 (H I', d, J 6.4), 5.1 (HZ', t, J 6 ), 4.34 (H3\ t, J 6 ),
4.0 (H4', m), 3.9 (H5', 5”, m), 3.2 (4H, piperidyl, m), 1 .6  (6 H, piperidyl, m). 8 p  (D20 , 
162MHz): +1.97, s, IP (‘H-decoupled).
m/z (-ve ion FAB): 860 [15% (2M)~], 429 [85% (M -  H)“], 262 (45%), 232 [100% 
(P O 32' + NBA)*].
275nm (pH 8.3) s  1 l^O M T'cm 1.
6.2.8 8-Methoxy-adenosine 5 -monophosphate 8-(OCH;)-AMP (11)
0.229mmol of 8 -Br-AMP (4 ) were treated with a total of 20ml of 0.5M sodium 
methoxide in methanol under reflux overnight. The reaction was monitored by HPLC 
analysis and by measuring a change in from 264 to 260nm. The pH of the solution 
was adjusted to 7 with glacial acetic acid and the solvent was removed in vacuo. The 
residue was redissolved in milli Q water and purified by IE chromatography using a TEA 
gradient from 50-350mM. The pure sample eluted off between 210-250mM TEAB 
followed by 8 -Br-AMP between 280-320mM TEAB. Pure 8-OCH3 was obtained in 
79% yield.
8 h (D20 , 400MHz): 7.8 (H2, s), 5.7(H1', d, J 5.5), 4.8 (H2\ t, J 5.8, 5.5), 4.25 (H 3\ t, 
J 4.2, 5.7), 4.2 (H4\ m), 4.0 (3H,0-CH3, s), 3.8 (H5',m) 3.7(H5', m). 8p (D20 , 
162MHz): 3.7, s, IP (‘H-decoupIed).
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Xmax260nm (pH 8.3) e  13,500.
6.2.9 8-Oxy-adenosine 5 '-monophosphate 8-oxy-AMP 13
128mg (301.9pmol) of 4 was dried by repeated co-evaporation with pyridine. 50mg of 
anhydrous sodium acetate and 4.4ml of acetic anhydride were added to 4. The 
homogenous solution was refluxed at 150-165°C for 2 h and then left stirring for 24 h at 
room temperature after which 2ml of methanol were added to the solution. The sample 
was dried down in vacuo and the residue dissolved in 11ml of NaOH which was stirred 
for 24 h at rt. The resulting solution was neutralised by adding ca. 6 ml of 1M HC1, and 
the pH was adjusted to 8.0 with ammonia. The change in UV absorption from 264- 
271nm confirmed that 8 -oxy-AMP had been synthesised [143]. HPLC retention: 8 -Br- 
AMP (2.5 min), 8 -oxy-AMP (3.7min) using a guard column of Partisil lOp. SAX (3cm) 
in combination with a Partisil column of 1 0 p SAX (10x0.46cm). The sample was 
purified on an IE column using a gradient between 0-400mM TEAB. Pure product 
eluted off between 300-360mM TEAB in 51.4% yield (0.155mmol). h*** 270nm. The 
sample was quantified by using s 10,545M'1cm*1 at 260nm.
5h (D20 , 400M H z): 8.0 (H2, s), 5.6 (H lf, d, J 5.5), 4.9 (H2\ dd, 5.0, 5.5), 4.2 (H3\ dd, 
J 4.6, 5.5), 3.9 (H4', m), 3.7 (H5\ H5'). 6 P (D20 , 162MHz): -0.4, s, IP (1H- 
decoupled).
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6.3 THE SYNTHESIS OF NAD+ ANALOGUES
All NAD+ analogues with the exception of 8 -Br-NAD+ were prepared essentially by 
coupling the two mononucleotide units - AMP analogue and nicotinamide 
mononucleotide, by a method similar to that described by Hughes et al 11671 using 
dicyclohexylcarbodiimide as the coupling agent.
NMN and the appropriate AMP analogue were dissolved in water in a round bottom 
flask, dry pyridine was added to make a 4 :1 pyridine:water mixture and excess DCC was 
subsequently added to the nucleotide mixture. The solution was left stirring at room 
temperature for 7days. The resulting mixture was poured into 100ml o f cold distilled 
water to quench it and left at 4°C for 2 h to precipitate the DCU formed in the reaction. 
DCU was filtered off through a sintered glass funnel and the filtrate was extracted with 
3x50ml aliquots of chloroform to remove other water insoluble organic impurities. The 
aqueous layer contained the desired product and was collected, dried down in vacuo, the 
residue dissolved in milliQ to sufficiently lower the conductivity of the solution before 
ion-exchange purification. The purity of the sample was determined primarily by the 
presence of an AB system in the 31P-NMR spectrum; *H NMR, HPLC analysis, MS, 
quantitative phosphate analysis and UV data were used as analytical techniques to fully 
characterize the sample. In all cases, unreacted starting materials were recovered and 
could be coupled again to obtain more material if required.
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6.3,1 2 'A-Deoxy-nicotinamide adenine dinucleotide (2 fA-deoxy-NAD+) 21
50mg, 149.6|imol of NMN (19) and 80mg, 241.5|unol 2 'A-deoxy AMP (17) were
dissolved in 12.5ml of 75%v/v pyridine/water. 2g (9.7mmol) of N,N-
dicyclohexylcarbodiimide (DCC) was added to the mixture and the solution was left 
stirring at room temperature for 7 days. The reaction was quenched by pouring the 
mixture into 150ml of cold water and the suspension was left at 0°C for 2 h to allow the 
DCU to precipitate. DCU was filtered off through a sintered glass funnel, and the filtrate 
was extracted with 3 x50ml aliquots of chloroform. The aqueous layer was evaporated 
to dryness in vacuo, the residue was re-dissolved in milli Q water and purified on a 
Sepharose Q ion exchange column, using a gradient o f 0-500mM TEAB buffer, pH 7.6. 
2'A-Deoxy-NAD+ eluted as the triethylammonium (TEA) salt between 160-180mM 
TEAB, in 19% yield and was quantified by measuring UV absorbance at 259nm, using 
an extinction coefficient of 17,800M'1cm'1.
8 h (D20 , 270MHz): 9.3 (HN2,s), 9,1 (H n 6, d, J 6.2), 8.78 (H n 4, d, J 8 ), 8.3 (HA8 ,s), 8.1 
(Hn5, t, J 7), 8.0 (Ha2, s), 6.36 (HA1', t, J 7), 6.02 (HN1\ d, J 5.5), 4.7-4.2 (9 ribose 
protons - Ha3', -4', -5', -5' and HN2', -3', -4' -5', -5'), 8  2.8 (HA2', m), 8  2.5 (HA2 \ m). 
8 P (D20 , 109MHz): -11.08, -10.72 (2P, JPP 20).




6,3.2 3 'A-Deoxy-nicotinamide adenine dinucleotide (3fA-deoxy-NAD+)  22 
15.7mg, 47.4jj.mol ofNMN and 25mg, 75.4p.mol of 3'A-deoxy-AMP (18) were dissolved 
in 6 ml of 75% aqueous pyridine. DCC (0.63g, 3.05mmol) was added to the solution, 
which was left stirring at room temperature for 7 days. The reaction was poured into 
50ml of cold distilled water and the mixture was left to stand for 2 h at 0°C, after which 
the precipitate formed was filtered off. Water-insoluble impurities were extracted by 
shaking the filtrate with 3 x50ml aliquots of chloroform. The aqueous layer was dried in 
vacuo, the residue was re-dissolved in milli Q water and purified by ion-exchange 
chromatography, using a buffer gradient of 0-300mM TEAB, pH 7.6. 3'A-Deoxy-NAD+ 
eluted between 165-185mM TEAB, in 25% yield, and was quantified by measuring UV 
absorbance at 259nm using an extinction coefficient of 17,800M~^m'1.
Sh (D20 , 270M H z): 9.2 (HN2, s), 9.0 (Hn6, d, J 6.2), 8.7 (Hn4, d, J 7.7), 8.2 (HA8 , s),
8.1 (Hn5, t ,  J 7.5), 8.0 (H a2, s) 6.0 (HN1', d, J 6.0), 5.9 (HA1', d, J 3), 4.7-4.0 (9H), 2.3 
(Ha3 \ m), 6  2.1 (Ha3', m). 8P (D20 , 109MHz): -10.26, -10.74 (2P, Jpp 20).




6,3.3 3'A-O-Methyl-nicotinamide adenine dinucleotide (3 fA-OMe-NAD+)  20 
149jimol ofN M N  and 170pmol of 3'A-OMe-AMP (16) were dissolved in 8 ml of 75% 
aqueous pyridine. DCC (2.0g, 9.5mmol) was added to the solution, which was left 
stirring at room temperature for 7 days. The reaction was poured into 50ml of cold 
distilled water and the mixture was left to stand for 2 h at 0°C, after which the precipitate 
formed was filtered off. Water-insoluble impurities were extracted by shaking the filtrate 
with 3 x50ml aliquots o f chloroform. The aqueous layer was dried in vacuo, the residue 
was re-dissolved in milli Q water and purified by ion-exchange chromatography, using a 
buffer gradient of 0 - 1 2 0 mM TEAB, pH 7.6. 3'A-OMe-NAD+ co-eluted with NMN 
between 40-55mM. There was no improvement in purity by using a shallower gradient 
o f TEAB from 0-70mM. An attempt was made to remove NMN from the desired 
product by treating the mixture with alkaline phosphatase for 4 h. Care was taken not to 
leave the solution for too long to avoid degradation of 3A'-OMe-NAD+. After 4 h most 
of the NMN obtained was converted to nicotinamide mononucleoside which eluted 
straight off an ion-exchange column upon purification. The sample of 3'-OMe-NAD+ 
thus obtained was 83% pure by HPLC. This material was used directly to obtain the 
cyclised product as further attempts to purify the material would have resulted in more 
loss of material.
8 h (D20 , 270MHz): 9.4 (HN2, s), 9.2 (Hn6 , d, J 6.1), 8.7 (Hn4, d J 7.3), 8.5 (HA8 , s), 
8.35 (Ha2, s ) , 8.2 (HN5, t ) ,  6.15 (HN1\ d, J 6.5), 5.9 (HA1\ d, J 5.2), 6  4.8 (HA2 \ J 5.2,
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5.5), 4.4.6-4.0 (9H), 5 3.5 (3H, s, -OMe). 6 p (D20 , 109MHz): -11.5, -11.8 (2P, JPP
19.8).
Xmax(pH 8.3)/256nm.
6.3.4 Nicotinamide-8-Bromoadenine dinucleotide (8-Br-NAD+)  24
200mg (0.3mmol) of p-NAD+ (23) as free acid were dissolved in 5ml of acetate buffer 
pH 3.9. 0.2ml o f bromine was added dropwise while stirring rapidly. The reaction was 
left for 30min after which a 1.25M solution of NaHS(>3 was added dropwise to discharge 
the bromine colour. The sample was dried in vacuo, the residue dissolved in milliQ 
water and the product purified by IE chromatography using a gradient of 0-350mM 
TEAB. Pure 8 -Br-NAD+ eluted between 45-70mM TEAB 61% (184.12pmol) yield. 
HLPC retention times on technicol column (10x0.46cm) Rt: P-NAD+ (2.0min), 8 -Br- 
NAD+ (2.4min).
6h (D20 , 270M H z): 9.1 (HN2, s), 8.9 (Hn6, d, J 6.2), 8 .6  (Hn4, d, J 8.2Hz), 8.0 (HN5, t, 
J 7), 7.8 (Ha2, s ) ,  5.8 (HN1\ d, J 4.8), 5.7 (HA1', d, J 5.5), 5.0 (HA2 \ t, J 5.8), 4.4-4.0 
(9H - ribose). 6i»(D20 , 109MHz): -11.54, -11.92, 2P, AB, J 21.2 (^-decoupled), 
m/z (ES-): 741.9 [50% (M)-], 637.9 [40% (M + H20  + nicotinamide)-], 619.9 [100% 
(M-nicotinamide)-].
264nm (pH 8.3), s lS^OONTW 1.
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6.3.5 Nicotinamide-8-Methylaminoadenine dinucleotide(8-NHMe-NAD+) 25
174.03 nmol of 8 -methylamino-AMP 6  was coupled to NMN as described above using 
2g of DCC. The reaction was worked up after 7days and the crude product was purified 
by IE chromatography using gradient of 0-350mM TEAB. Residual NMN eluted off 
first, followed by, 8 -NHMe-AMP between 70-100mM TEAB in 16.4% yield. Unreacted 
5 eluted off between 170-220mM TEAB. HPLC retention times Rt (min) on a 
Spherisorb 10p SAX (25x0.46cm) column with a 3cm Partisil guard column: (3-NMN 
3.9min, Product (24) 4.8min, 8 -NHMe-AMP 4.2min.
Sh (D20 , 400MHz): 9.1 (HN2, s), 9.0 (Hn6 , d, J 5.8), 8 .6  (HN4, d, J 7.9), 8.0 (HN5, t. J 
7Hz), 7.9 (Ha2, s ) ,  5.9 (HN1', d, J 4.58), 5.7 (HA1\ d, J 7), 4.5-4.0 (10H - ribose), 2.8 
(3H, NMe, s). 8 ? (D20 , 162MHz): -11.7,2P, s (^-decoupled).
m/z (+ve ion FAB): 693 [60% (M + H)+], 593 [60% M + NBA - (8 -MeNH-adenosine - 
CH20 )+], 1 0 2  (100%).
Amax273nm (pH 8.3), 8  H^OOM ^m '1.
6.3.6Nicotinamide-8-Dimethylamineadenine dinucleotide (8-Me2NH-NAD+) 26
161(imol of 8 -dimethylamino-AMP 7 was coupled to 149.6(imol of 0-NMN with 2g of
DCC in 12.5ml of pyridine: water (4:1). The reaction mixture was worked up after seven
days and the crude product was purified using a gradient of 0-25% TEAB. The desired
product sample eluted off with NMN between 70-90mM TEAB, 8 -Me2NH-AMP eluted
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off pure between 150-205mM TEAB. The first fraction containing product was re- 
purified using a gradient of 0-200mM TEAB and pure product eluted between 75-90mM 
TEAB in 11.5% (17.15p.mol) yield. HPLC Rt on Paritsil lOp SAX (3x0.46cm) in 
combination with a Spherisorb lOp SAX column (25x0.46cm): 8 -(Me2NH-NAD+)
5.5min.
6h (I>20, 400MHz): 9.5 (HN2, s), 9.3 (H>,6 , d, J 6.3), 8.9 (Hn4. d. J 8.0), 8.4 (HN5, t, J 
7), 8.2 (Ha2, s ) ,  6.3 (HN1\ d, 5.4), 5.9 (HA1\ d, J 6.3), 5.4 (HA2 \ t, J 6.3), 5.0-4.4 (9H - 
ribose), 3.1 (3H, NMe2, s). Sp ( D A  162MHz): -11.42, -11.82, 2P, AB. J 21 ('H- 
decoupled). m/z (+ve ion FAB): 707 [70% (M + H)+], 255 (60%), 120 (100%).
m/z (-ve ion FAB): 706 [70% (M)“, 583.2 [100% (M - H - nicotinamide)-], 469.1 
(60%).
A*** 273nm (pH 8.3), e ^lOOM ^cm '1.
6.3.7 Nicotinamide-8-Aminoadenine dinucleotide (8-NHz-NAD+)  27 
14mg, 38.69pmol of 8 -NH2-AMP 9 and 8.08mg, 24.18pmol of NMN were dissolved in
1.25ml o f distilled water, 5ml of pyridine was added and 0.32g of DCC was added. The 
solution was left stirring at RT for 7 days and worked up as described above. The crude 
product was purified using a gradient of 0-150mM TEAB. Pure product eluted between 
70-90mM TEAB and was obtained in 16% yield.
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8 h  (D2 0 ,400MHz): 9.3 (HN2, s), 9.3 (Hn6 , d, J 6 .6 ), 8.75 (Hn4, d, J 6 .6 ), 8.2 (HN5, t, J
6 .6 ), 8 .0  (Ha2,s), 6 .1  (HN1', d, J 4.7), 5.86 (HA1', d, J 7H), 4.9-4.2 (10H - ribose). Sp 
(D2 0 ,162MHz): -11.83, -11.97, AB, 2P, J 19.4. (‘H-decoupled).
m/z (ES~): 677 [1 0% (M-H)~], 555.2 [50% (M-H-nicotinamide)"], 152 [50% (8 -NH2- 
adenine)-], 89.5 (100%).
Ku* (pH 8.3) 274nm
6.3.8 Nicotinamide-8-Piperidyladenine dinucleotide (8-pip-NAD*) 28
An attempt was made to synthesise 8 -pip-NAD+ by nucleophilic deplacement of bromide 
from 8 -Br-NAD+ (24) by piperidine. 62.6pmol of 8 -Br-NAD+ were reacted with 0.4ml 
of piperidine at 50°C for 2.5 h. HPLC analysis showed the presence of a new product. 
Rt 8 -Br-NAD+ (2.4min), |3-NAD+ (2.0min), 8 -pip-NAD+ (4.9min) on a Technicol lOp 
SAX column (10x0.46cm).This was identified as 8 -pip-NAD+ by ^-N M R , however 
attempts to separate product from residual 8 -Br-NAD+ were found to be futile. Hence, 
we decided to couple 8 -pip-AMP to NMN in an attempt to obtain pure 8 -pip-NAD+. 
107.8pmol of 10 were dissolved in 2.5ml of water and 10ml of anhydrous pyridine. 
45.03mg of 3-NMN were added followed by 1.8g of DCC. The sample was left stirring 
for 7 days at room temperature, and worked up. 31P NMR of crude sample showed a 
singlet at 6  0.5 (singlet - 8 -pip-AMP), 0 (singlet (3-NMN), -11.5 (AB, 2P, Product), -
11.75 (singlet, symmetrical pyrophosphate AMP-AMP). The crude sample was purified
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initially using a gradient of 0-500mM TEAB, however, (5-NMN eluted off with 8 -pip- 
NAD+ symmetrical pyrophosphate eluted off between 170-210mM and 8 -pip-AMP 
eluted between 220-280mM TEAB. Fractions containing product were pooled and the 
product was re-purified using a gradient of 0-200mM TEAB. Pure product eluted 
between 80-90mM TEAB in 7% yield.
8h (D 20 ,  400M H z): 9.1 (HN2, s), 8.9 (Hn6, d, J 6.1), 8 .6  (Hn4, d, J 7), 8.1 (HN5, dd, J
6.4, 7.9), 7.9 (Ha2 , s ) ,  5.8 (HN1\ d, J 5.5), 5.5 (HA1\ d , J 6.1), 5.0 (HA2 \ dd, J 6.4, 6.1), 
4.5-4.0 (9H - ribose), 3.2 (4H, piperidyl, m), 1.6 (6 H, piperidyl, m). 8p (D 20 ,  162MHz): 
-11.44, -11.84,2P, AB J 20.8 (^ -d ecou p led ).
m/z (ES“): 747 [20%], 746 [50% (M-)], 624 (M-nicotinamide), 623 [50% ( M -H  - 
nicotinamide)-1, 237 [100% (nicotinamide + ribose)-], 97.2 (100%).
Amax274nm (pH8.3), e l ^ O O M W  \
6.3.9 Nicotinamide-8-Methoxyadenine dinucleotide (8-OCH?-NAD+)  29
166.6(imol of 11 were coupled to 50mg (149.6jimol) of NMN as described in 6.1. The
sample was worked up after 7 days followed by purification of the crude product using a
gradient of 0-130mM TEAB on an ion exchange GP250 column. NMN eluted off
between 4-5mM, 8 -OCH3-NAD+, 5-6mM, 8 -OCH3-AMP ll-11.5mM TEAB. Pure 8 -
OCH3-NAD+ was obtained in 16% (25.3jj.mol) yield. HPLC Rt on a Partisil guard
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column (3x0.46cm) in combination with a (10x0,46cm) Partisil 10|i SAX column 8 - 
(OCH3)NAD+ 2.4min
6 h  ( D A  400MHz): 9.1 (HN2,s), 9.0 (Hn6 , d, J 6.1), 8.6(Hn4, d, J 7.9), 8 .1  (HN5, t, J
6.4, 7.61), 7.9 (Ha2, s), 5.85 (HN1', d, J 4.9), 5.7 (HA1', d, J 5.2), 4.8 (HA2'; t, J 5.2,
5.8), 4.6 - 4 .0  (9H- ribose), 4.0 (3H, O-CHj, s). 8 p (D20 , 162MHz): -11.38, -11.51, -
11.8, -11.97, 2P, AB, J 20.9 (^-decoupled).
m/z (ES*): 694 [1 0 0 %, M+H)*], 795 [40%, M+TEA)+], 239 (50%), 317 (40%). (ES_): 
692 [100%, M-H)-], 677 [40% (M-H-CHs)-].
X«max 259 (pH 8.3), s 13,000M'1cm‘1.
6.3.10 Nicotinamide-8-Methyladenine dinucleotide (8-Me-NAB¥)  30.
139.2pmol of 14 as the triethylammonium salt was coupled to 149.6pmol of (3-NMN 
(19) in 12.5ml of pyridine: water (4:1) and 2g of DCC as described above. The reaction 
mixture was worked up after 7 days followed by ion exchange purification of the crude 
product on GP250 IE chromatograph using a gradient of 0-150mM TEAB. Unreacted 
NMN eluted off between 35-40mM, 8 -Me-NAD+ at 45-50mM, and unreacted 8 -Me- 
AMP at 100-120mM TEAB. Pure product was obtained with 12.4% yield (17.23pmol). 
HPLC Rt: 8 -Me-NAD+ (2.46min).
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8 h  (D20 , 400MHz): 9.3 (HN2, s), 8.9 (Hn6, d, J 6.1), 8.6 (Hn4, d, J 6.3), 8.0 (HN5, t, 7),
7.9 (Ha2, s ) ,  5.8 (Hn1’, d, J 5.2), 5.7 (HA1', d, J 6.4), 4.7 (HA2', t, 6.2), 4.6-4.2 (9H - 
ribose), 2.5 (3H, Me, s). 8 p  (D20 , 162MHz): -10.96, -11.34, 2P, AB, J 20.5 ("H- 
decoupled).
m/z (ES“): 676 [100% (M-H)"], 410 [50% (NMN + H P032J ] ,  338 [45% (M-H + 
TEA- (8-Me-adenosine diphosphate - 0-)~].
Xmk 259nm (pH 8.3), 8 13,755M'1cm‘1.
6.3.11 Nicotinamide-8-Oxyadenine dinucleotide (8-oxy-NAD+)  31 
155.28pmol of 13 were coupled to 50mg (149.6pmol) of NMN in the usual manner. 
The sample was worked up after 7 days followed by purification of the crude product 
using a gradient of 0-150mM TEAB on an ion exchange GP250 column. NMN eluted 
off between 3-4mM, 8-oxy-NAD+, 8-9mM, 8-oxy-AMP 13-20mM TEAB. Pure 8-oxy- 
NAD+ was obtained in 8.8% (13.ljj.mol) yield. HPLC Rt on (3x0.46cm) Partisil guard 
column in combination with a (10x0.46cm) Partisil 10p SAX column 8-oxy-NAD+ 
3.4min.
6h (D20 , 400MHz): 9.1 (HN2,s), 8.9 (Hn6, d, J 6.0), 8.5(Hn4, d, J 6.5), 8.1 (HN5, t, J 
5.1), 7.7 (Ha2, s), 5.85 (HN1', d, J 4.5), 5.5 (HAl f, d, J 5.6), 4.9 (HA2 \ t, J 5.3), 4.4 - 4.0 
(9H- ribose). 8 p  ( D A  162MHz): -11.44, - 1 1.92,2P, AB, J 21 ("H-decoupled).
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m/z (ES~): 678 [100% (M-H)"], 339 (90% ), 277 (60%).
Xmax 266 (pH 8.3), 8 13,100M’1cm'1.
6.3.12 8-Aza-9-deaza-nicotinamide adenine dinucleotied (NFD*) 33 
75mg (205.36pmol) of formycin 5'-monophosphate A (32) as the monoammonium salt 
was coupled to 50mg (149.6pmol) of NMN in 12.5ml Pyridine : water (4:1). 2g of 
DCC was added and the mixture was left stirring at RT for 8 days. The reaction was 
worked up as already described above and products were purified using a TEAB 
gradient between 0-150mM TEAB. The residual NMN eluted first between 50-60mM 
TEAB followed by NFD+ at 80-90mM, and formycin 5'- monophosphate at 120-130mM 
TEAB. Pure product was obtained in 9.3% (13.9jimol) yield. HPLC retention time: 
(column as above) 2.2min (NFD+).
Sh (D20 ,  270MHz): 9.2 (HN2, s), 9.05 (Hn6, d, J 5.3), 8.6 (Hn4, d, J 8), 8.05 (HN5, t), 
8.0 (Ha2, s ) ,  6.0 (HNl f, d, J 5.3), 5.2 HA1', d, J 7.1), 5.0-4.0 (10H). 6P (D20 , 162MHz): 
-11.78, -12.48, 2P, AB J 21.6 (^-decoupled).
m/z (ES"): 662 [30% (M-H)"], 278 (50%), 209 (95%), 164 (100%).
Xmax 275nm (pH 8.3) e275 4,600M*1cm'1.
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6.4 Qualitative Analysis of NAD* analogues.
The authenticity of the NAD* analogues thus synthesized was confirmed by testing for 
coenzyme activity 11761 and the ability to form a complex with cyanide [180]. lpmol of 
NAD* or analogue was diluted to 25ml in 5%v/v ethanol in 0.1M Tris buffer pH 8.8. 
3.75ml o f the nucleotide solution was measured into a curvette. The UV spectrum was 
recorded at this stage as the blank (i.e without alchohol dehydrogenase). 3jil of a 
7.8units/pl solution of alcohol dehydrogenase was added into the solution in the 
curvette. The UV spectrum was scanned after two minutes. A new peak at around 
340nm that was not present in the blank was observed for all analogues. As a further 
control, the UV spectrum of the enzyme in the 5% Ethanol in 0.1M Tris buffer was 
scanned. There was no peak observed at 340nm.
NAD* and analogues were treated with potassium cyanide to see whether they complex 
with cyanide. 2.75ml of 0.1M KCN solution in distilled water was measured in a 
curvette. 0.25ml of 0.2mM of the NAD* or NAD* analogue was added to the cyanide 
solution in the curvette. A new peak at around 325nm was observed which represents 
the complex formed with cycanide. In two control experiment, UV absorption spectra of 
the cyanide solution alone and another with just the dinucleotide, there was no peak at 
325nm.
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6.5 Synthesis of Analogues of Cyclic-Adenosine Diphosphate Ribose.
6.5.1 Cyclic adenosine diphosphate ribose (cADPR) 40.
2.5ml of 1.5mM solution of NAD+ in 25mM HEPES, pH 6 .8  was incubated with lOpl of 
crude ADP-ribosyl cyclase for 10 min at room temperature. The sample was analyzed 
before and after enzymatic incubation by HPLC using a Partisil lOp SAX guard column 
(10x0.46cm) in combination with a Technicol (10x0.46cm) SAX column and isocratic 
elution with 0.05M phosphate buffer pH 3. After 10 min, the incubation mixture was 
diluted with 100ml of milli Q water and the products were purified by ion exchange 
chromatography using a gradient o f 0-300mM TEAB, pH 7.6. The purity of the product 
obtained was verified by HPLC analysis as described above. cADPR was obtained in 
60% yield and was quantified by measuring UV absorbance at 254nm using an extinction 
coefficient of 14,300M'1cm'1 [S5].
Rt - (incubation mixture after lOmin): 4.7min (nicotinamide), 7.8min (cADPR), 10.3min 
(NAD+). 5 h  (D20 , 400MHz): 8.9 (HA2,s), 8.2 (HA8 , s), 6.0 (H I', d, J 3.8), 5.85 (HA1\ 
d, J 7), 5.2 (Ha2 \  t, J 7) 4.7 (HA3'), 4.6 (H2\ H4'), 4.4 (H3', HA5'), 4.3 (H5'), 4.2 (HA4 
'), 4.0 (H5'), 3.8 (Ha5'). 6p (D20 , 162MHz): -11.36, -11.84 (2P, JPP 14.9).
m/z (+ve ion FAB) 541 M*. m/z (-ve ion FAB) 540 (M - H f .
6.5.2 2'A-Deoxy-cyclic adenosine diphosphate ribose (2 fA-deoxy-cADPR) 37
Enzymatic cyclisation of 2 'A-deoxy-NAD+ (21) was carried out as described above for
NAD+. HPLC analysis was on a Spherisorb SAX column using isocratic elution with
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phosphate buffer. Ion exchange purification of the product was carried out using a 
gradient of 0-300mM TEAB.pH 7.6 Nicotinamide eluted straight off the column 
followed by 2 'A-deoxy-cADPR between 190-240mM TEAB, in 61% yield, and lastly 
2 'A-deoxy-ADPR. Pure 2fA-deoxy-cADPR was quantified by measuring UV absorbance 
at 254nm using an extinction coefficient o f 14,300M'1cm'1.
Rt - (incubation mixture): 3.1 min (nicotinamide), 4.9min (2'A-deoxy-NAD+), 7.2min 
(2'A-deoxy-cADPR), 10.2min 2'A-deoxy-ADPR. 5h (D20 , 400MHz): 8.9 (HA2, s), 8.2 
(Ha 8 , s) , 6.4 (HA1', t, J 7), 6.1 (HE, d, 5.5), 4.8 (HA3'), 4.7 (H2\ t), 4.6 (H4'), 4.4 (H3 
', HA5'), 4.3 (HA5'), 4.2 (HA4'), 4.0(H5'), 3.9(HA5'), 3.2 (HA2 \  m), 2.4 (HA2 \  m). 6 p 
(D20 , 162MHz): -11.37, -11.68 (2P, JPP 15.8) (Fig 6 ).
m/z (+ve ion FAB) 1051 (2M + H)+ dimer, 627 (M + TEA)+. m/z (-ve ion FAB) 524 (M 
- H)“ 1049 (2M - H)“
Araax(pH 8.3)/259 nm.
6.5.3 3'A-Deoxy-cyclic adenosine diphosphate ribose (3'A-deoxy-cADPR) 38. 
Enzymatic cyclisation of 3'A-deoxy-NAD+ (22), purification and the analytical 
procedures used were as described for NAD+ above. 3 A-deoxy-cADPR eluted from the 
ion exchange column between 165-185mM in 50% yield, and was quantified by 
measuring UV absorbance at 254nm using an extinction coefficient of 14,300M'1cm'1.
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Rt - (incubation mixture after lOmin) - 4.85min (nicotinamide), 11.3min (3'A-deoxy- 
cADPR), 18.3min (3' A-deoxy-NAD4) . 6 h (D2 0 ,400MHz): 8.7 (HA2, s), 8.4 (HA8 , s), 6.0 
(H I', d, J 6 ), 5.9 (HAr, d, J 3), 5.2 (HA2 \  m) 4 .7  (H2 '), 4.5 (H4\ H5'), 4.4 (H3'), 4.2 
(Ha5', Ha4'), 4.0 (H5'), 3.8 (HA5'), 2.8 (HA3f), 2.1 (HA3'). 6 h (D20 , 400MHz): -11.56, 
-12.44 (2P,JPP=15.13).
m/z (+ve ion FAB) 526 (M + H)+, 627 (M + TEA)+ m/z (-ve ion FAB) 524 (M - H)~, 
1049 (2M - H) ' .
W p H  8.3)/259 nm.
6.5.4 3 fA-0-Methyl-cyclic adenosine diphosphate ribose (3'A-OMe-cADPR) 39 
2x2.5jj.mol of 3'-OMe-NAD+ (20) were each dissolved to 2ml in 25mM HEPES-NaOH 
buffer pH6 .8 . 20pl of Aplysia cyclase (lOmg/ml protein concentration) were added to 
each solution. The mixtures were left to incubate for 20min after which the solutions 
were combined and diluted with 100ml milliQ water and the products purified by ion 
exchange chromatography using a gradient of 0-200mM TEAB. Residual product 3'- 
OMe-NAD+ eluted between 60-70mM, followed by 3'A.OMe-cADPR between 140- 
150mM TEAB. Pure product was obtained in 40% (2.0pmols) yield quantified using by 
measuring UV absorbance at 254nm using an extinction coefficient of 14,300M'1cm'1. 
HPLC retention times were measured on 3x0.46cm guard column in combination with a 
10x0.46cm Partisil 10p SAX column.
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Rt - (incubation mixture after 20min): 1.7 min (nicotinamide), 2.5 min (3'A-OMe- 
N A D V -4  min. 8 h (D20 , 400MHz): 8.9 (HA2, s), 8.3 (HA8 , s), 6.0 (H I', d, J 3.6), 5.9 
(HA1', d, J 5.5), 5.3 (Ha2', dd, J 5.5, 5.2) 4.7-3.8 ( 9H - ribose protons H 2\ 3', 4', 5', 5', 
Ha3', -4', -5', -5'). 6p (D20 , 162MHz): -10.55, -11.55, 2P (^-decoupled).
m/z (+ve ion-FAB): 376.3 (75%), 239.2 (25%), 297.2 (20%). m/z (-ve ion FAB) 
554[20%. M -  H)_], 494 (90%) 478 (70%), 341.
256nm (pH 8.3), 8 * 4  M^OONTW \
6.5.5 3'A-Phospho-cyclic adenosine diphosphate ribose (3'a-cADPRP) 41'
2x3pmol of 3a--NADP+ (35) were each dissolved to 2ml in 25mM HEPES-NaOH buffer 
pH6 .8 . 20|il of Aplysia cyclase (lOmg/ml protein concentration) was added to each 
solution. The mixtures were left to incubate for 20min after which the solutions were 
combined and diluted with 100ml milliQ water and the products purified by ion exchange 
chromatography using a gradient of 0-500mM TEAB. Pure 3A-cADPRP eluted off 
between 120-145mM TEAB. Pure product was obtained in 54% (3.2pmols) yield. 
HPLC retention times were measured on 3x0.46cm guard column in combination with a 
10x0.46cm Partisil 10p SAX column:
Rt -(incubation mixture after 2 0  min) : 2 .1  min (nicotinamide), 15.9 min (3VP-NAD*),
15.9 min (3'a-P-cADPR). § h  (D20 , 400MHz): 8.9 (HA2 , s), 8.3 (HA8 , s), 6 .0  (H I', d, J
185
3.7), 5.98 (Ha1 \ d, J 7.3), 5.3 (HA2', dd, J 5.0, 7.0) 4.6-3.9 (9H - ribose proton* H2', 3', 
4', 5', 5', Ha3', -4', -5', -5'). Sp (D20 , 162MHz): + 1 .0 , (lP,s), -11.0, -11.75, 2 P 
Jpp=22.6Hz (^-decoupled).
m/z (+ve ion FAB): 723.1 [40%, M + TEA)+], 622 [40%, M + H)+], 301.2 (40%). m/z 
(-ve ion FAB): 620.1[30%. M -  H)"], 341 (40%) 188 (100%).
FAB-accurate mass (-ve ion) 621.021317 (18.6%, M)“], 620.019562 (91.3%, M -  H)"].
Xmax 256nm (pH 8.3)
6.5.6 2 'a,3 fA-cyclic-phospho-cyclic adenosine diphosphate ribose (2'A,3'A-cyclic- 
cADPRP) 42
2x3pmol of 2 'A,3'A-cyclic-NADP+ (36) were each dissolved to 2ml in 25mM HEPES- 
NaOH buffer pH6 .8 . 2 0 jil of Aplysia cyclase (lOmg/ml protein concentration) was 
added to each solution. The mixtures were left to incubate for 20min after which the 
solutions were combined and diluted with 100ml milliQ water and the products purified 
by ion exchange chromatography using a gradient of0-400mM TEAB. Residual product 
2 'a,3 'A-cyclic-NADP+ eluted between 180-190mM, followed by 2 'A,3'A-cyclic-cADPRP 
between 260-290mM TEAB. Pure product was obtained in 45% (2.7jimols) yield, 
quantified by measuring UV absorbance at 259nm using an extinction coefficient of
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14,300M'1cm‘1. HPLC retention times were measured on 3x0.46cm guard column in 
combination with a 10x0.46cm Partisil lOjj. SAX column.
Rt - (incubation mixture after 2 0 min) 2 .1  min (nicotinamide), 9.0 min (2'A,3'A-cyclic- 
NADP), 8.3 min (2'A,3'A-cyclic-cADPRP). 8H (D20 , 400MHz): 8.7 (HA2, s), 8.1 (HA8 , 
s), 6.2 (H I', s), 5.9 (HAr, d), 5.3 (HA2 \ dd, J 8.0, 6.4), 5.5 (HA3\ dd, J 4.3, 5.8), 4.6-
3.9 (8H - ribose protons H2', 3', 4f, 5', 5', HA4', - -5f, -5'). 8P (D20 , 162MHz): +19.0, 
(lP,s), -10.8, -11.2, 2P Jpp 13.8Hz (^-decoupled).
m/z (+ve ion FAB): 604 [70%, M + H)+], 490 (20%). (-ve ion FAB): 602.1[100%. M -  
H)-]. FAB-accurate mass (-ve ion) 603.011932 (19.6%, M)~], 620.0008835 (100%, M -  
H)"].
Amax 256nm (pH 8.3)
6.5.7 8-Bromo-cyclic-adenosine diphosphate ribose (8 -Br-cADPR) 43
2x2.24mg of 24 were dissolved in 2.5ml with 25mM HEPES-NaoH buffer pH 6 .8 , lOjil 
of Aplysia cyclase (protein concentration of 10|ig/ml) was added to the solution which 
was shaken. The incubation mixture was left for lOmin at room temperature and the 
course of reaction was followed by HPLC analysis. The mixtures were pooled, dissolved 
in milliQ water and the crude products were purified immediately by ion exchange 
purification using a gradient of 0-30% TEAB, pure 8 -Br-cADPR eluted off between
187
185-220mM TEAB in 60% yield. HPLC retention times was measured on Partisil 10ji 
SAX column (10x0.46cm):
Rt - (incubation mixture after lOmin) 1.5min (nicotinamide), 2.4min (8 -Br NAD-1), 
3.9min (8 -Br-cADPR). 6h (D20 , 400MHz): 8 .8  (HA2', s), 6.3 (HI', d, J 6.1), 6.0 (HA1', 
d, J 2), 5.6 (Ha2 \ t, J 5), 4.2-5.0 (9H - ribose). 8 p (D20 , 162MHz): -10.83, -11.05, 2P, 
AB, J 13.2 (^-decoupled).
m/z (Electrospray): 619.9 (M), 96.9 (H2P 0 4'), 80.9 (H2PO3 ), 78.9 (P032 ).
Xmax 264nm s lS ^ O M 'W 111**
6.5.8 8-Methylamino-cyclic-adenosine diphosphate ribose (8-NHMe-cADPR) 44 
2x2.5mg of 25 were each diluted to 2.5ml in HEPES-NaOH pH 6 .8 . 15pi of crude 
Aplysia cyclase (protein concentration of lOmg/ml) was added to each solution and 
mixed in. The reaction mixture was diluted with milliQ water after lOmin and the 
product subsequently purified using a TEAB gradient of 0-25% TEAB. Pure sample 
eluted off between in 42% (3pmol) yield. HPLC retention times were measured on a 
combination of 3x0.46cm guard column and a Spherisorb 25x0.46cm column.
Rt - (incubation mixture after lOmin): 3.6min (nicotinamide), 4.7min (8 -NHMe-NAD*), 
7.8min (8 -NHMe-cADPR). 5h (D20 , 400MHz): 8 .6  (HA2, s), 5.9 (H lf, d, J 4), 5.7
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(Ha1\ d, J 5.5), 5.4 (Ha2', t, J 5), 4.4-3.8  (9H), 2.8 (3H, -NMe, s). 5P (D20 , 162MHz): 
-10.87, -11.58, 2P, AB, J 14.9 (^-decoupled).
m/z (ES“): 569 [100% (M-H)"], 164 [50% (8 -NMe-adenine)", 79 (100%’).
A*,  ^279nm(pH 8.3) S279 ll,050M '1cm'1.
6,5.9 8-Dimethylamino-cyclic-adenosine diphosphate ribose (8-NMez-cADPR) 45 
2x2.98mg of 26 were each dissolved each in 2.5ml of HEPES-NaOH buffer pH 6 .8 . 15pl 
of Aplysia cyclase (protein concentration o f lOjig/ml) was added to each solution which 
was left to incubated for lOmin at room temperature. The mixtures were combined and the 
crude product was purified by using a TEAB gradient of 50-250mM. Residual 8 -Me2NH- 
NAD+ eluted off between 100-1 lOmM followed by 8 -NMe2-cADPR between 120-140mM 
and lastly 8 -ADPR between 160-170mM TEAB. Pure 8 -NMe2-cADPR was obtained in 
61.6% (5.2|imol) yield. HPLC retention time was measured on a combination of 3x0.46cm 
guard column and 25x0.46cm Spherisorb 1 0 (i SAX column.
Rt - (incubation mixture after lOmin): 3.7min (nicotinamide), 5.8min (8 -NMe2-NAD+), 
9.7min (8 -NMe2-cADPR). 6 r  (D20 , 400MHz): 9.1 (HA2, s), 6.3 (H I', d, J 4), 6.2 
(Ha 1'? d, J 6.4), 5.6 (Ha2 \ dd, J 5.8, 5.5), 5.0-4.2 (9H), 3.2 (6 H, -NMe2, s). 8p (D20 , 
162MHz): -5.66, -6.42, 2P, AB, J 15.4 (^-decoupled).
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m/z (ES“): 583 [100% (M-H)"], 161 (20%).
Xmax282nm e2*2 1 l,800M'1cm‘1.
6.5.10 8-Methoxy-cyclic-adenosine diphosphate ribose (8-OCHs-cADPR) 46 
3x4[imol of 8 -OCH3-NAD+ (29) were each dissolved to 2ml in 25mM HEPES- NaOH 
buffer pH 6 .8  and incubated with 20pl of Aplysia cyclase for 20min after which the crude 
mixtures were pooled, diluted with milliQ water to 100ml and purified using a gradient 
o f 50-250mM TEAB. 8 -OCH3-NAD+ eluted off between 60-65mM TEAB, followed by 
8 -OCH3-CADPR between 70-75mM. Pure product was obtained in 53% yield 
(6.4pmols). HPLC analysis was measured using a 3cm guard column in combination 
with a Partisil IOji SAX (10x0.46cm):
Rt - (incubation mixture after 20min): 1.9min (nicotinamide), 2.4min (8 -OCH3-NAD*), 
4.0min (8 -OCH3-cADPR). 8 H (D20 , 400MHz): 8 .8  (HA2, s), 6.0 (HI', d, J 4.0), 5.9 
(Ha1\ d, J 5.9), 5.2 (Ha2', t, J 5.4, 4.9) 4.65 (H2', HA3'), 4.6 (H4'), 4.35 (H3'), 4.25 
(Ha4', H5'), 4.2 (Ha5'), 4.1 (3H, O-CH3, s) 4.0 (H5', ), 3.9 (HA5 \ ). 8p (D20 , 
162MHz): -10.9,2P, s, (^-decoupled).
m/z (ES‘): 570 [1 0 0%, (M-H)~], 571 [2 0 %, 1VT].
Xmax 259nm (pH 8.3), 8^ 9 10,300M'1cm'1.
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6.5.11 8-Piperidyl-cyclic-adenosine diphosphate ribose (8-pip-cADPR) 47 
3.75mg of 28 were diluted to 3.3ml in 25mM HEPES buffer pH 6 .8 , lOp.1 of crude 
Aplysia cylase (protein concentration of lOpg/ml) was added to the solution which was 
shaken well. Incubation mixture was left for 15min after which it was diluted with milliQ 
water and the product purified using a gradient to 0-350mM TEAB on an ion exchange 
column. Residual 8 -pip-NAD+ eluted off between 60-1 lOmM, followed by 8 -pip- 
cADPR between 135-165mM, and 8 -pip-ADPR at 210-240mM TEAB. Pure product 
was obtained in 49.5% (2.5jimol) yield. HPLC retention times on 3x0.46cm guard colum 
with a partisil IOji SAX column (10x0.46cm):
Rt - (incubation mixture after 15min): 2.1 min (nicotinamide), 6.3min (8 -pip-NAD+), 
16.2min (8 -pip-cADPR). 5h (D20 , 400MHz): 8.9 (HA2, s), 6.1 (HI', d, J 4.0), 5.9 
(Ha1\ d, 5.8), 5.4 (Ha2 \  t, J 4.2), 4.5-4.0 (9H - ribose), 3.2 (4H, piperidyl, m), 1.7 (6 H, 
piperidyl, m). 8P(D20 , 162MHz): -10.92, -11.76, 2P, AB, J 15.9 (^-decoupled).
m/z (ES“): 624 [20% (M)", 623 [1 0 0 % (M-H)"], 291 (ribose diphosphate-O-), 96.8 
80.79 (50%), 78.6 (70%).
Xmax282nrn (pH 8.3) sza 12,000M'1cm'1.
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6.5.12 8-Amino-cyclic-adenosine diphosphate ribose (8-NH2-CADPR) 48
1.5mM solution of 8-NH2-NAD+ (27) in 1ml of 25mM HEPES-NaOH pH 6 .8  was 
incubated with lOpl of Aplysia enzyme at RT for lOmin. The sample was analysed 
before and after incubation by HPLC on a Spherisorb lOp SAX (25 x0.46cm) column. 
The crude products were purified using a TEAB gradient of 50-500mM TEAB, and pure 
8 -NH2-CADPR eluted offbetween 145-170mM TEAB in 48% (0.72pmol) yield.
Rt - (incubation mixture after lOmin): 2.8min (nicotinamide), 4.1 min (8 -NH2-NAD4), 
6.4min (8 -NH2-cADPR).8h (D20 , 400MHz): 9.0 (HA2, s), 6.4 (HI', d, J 5.0), 6 .1  (HAl f, 
d, J 7.6), 5.0-4.2 (9H - ribose). 8p (D20 , 162MHz): -13.35, -14.05, 2P, AB, J 17.5 (*H- 
decoupled).
m/z (ES“): 555.2 [100% (M-H)"], 353 (50%), 176.4 (40%).
Xmax 274, s274 15,730M"1cm"11120].
6.5.13 8-Methyl-cyclic-adenosine diphosphate ribose (8-Me-cADPR) 49
3x3pmol of 30 were each dissolved to 2ml in 2.5mM HEPES-NaOH buffer pH6 .8 . 20pl
of Aplysia cyclase (lOmg/ml protein concentration) was added to each solution. The
mixtures were left to incubate for lOmin after which the solutions were combined and
diluted with 100ml milliQ water and the products purified by ion exchange
chromatography using a gradient of 50-250mM TEAB. Residual product 8 -Me-NAD+
eluted between 60-70mM, followed by 8 -Me-cADPR between 80-90mM TEAB. Pure
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product was obtained in 83.6% (7.5pmols) yield. HPLC retention times were measured 
on 3x0.46cm guard column in combination with a 10x0.46cm Partisil lOp SAX column.
Rt - (incubation mixture after lOmin): 1.96min (nicotinamide), 2.4min (8 -Me-NAD*), 
4.2min (8 -Me-cADPR) 6h (D 20 ,  400MHz): 8 .8  (HA2, s), 6,0 (H I', d, J 4), 5.85 (HA1\ 
d, J 5.5), 5.3 (HA2', t, J 5.5), 4.6-4.0 (9H - ribose), 2.5 (3H, Me, s). 5P(D20 , 162MHz): 
-8.3, -9 .1 ,2P, AB, J 16.1 (^-decoupled).
m/z (ES“): 555 [20% (M)"], 554 [60%(M-H)“], 276 [40% (M+H-(8 -Me-adenosine)'], 
97 (60%), 81, 79 (100%).
X<xnax 260 pH 8.3 8260 lO^OOMrW1.
6.5.14 8-Oxy-cyclic-adenosine diphosphate ribose (8-oxy-cADPR) 50
3x3pmols of 31 were each treated with 2 0 pi of the crude Aplysia cyclase (protein
concentration of lOpg/ml) for 20min as described above. Mixtures were combined and
diluted with 100ml of milliQ water followed by purification using a TEAB gradient of
50-250mM TEAB sample eluted off between 220-250mM with 48.7% (4.4pmol) yield.
HPLC retention times were measured on 3 x0.46cm guard column with a 10x0.46cm
column.
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Rt - (incubation mixture after 20min): 1.96min (nicotinamide), 2.5min (8 -oxy-NAD^, 
5.95min (8 -oxy-cADPR). 8H(D20,400MHz): 8 .8  (HA2, s), 6.0 (H I', d, J 4), 5.8 (HA1\ 
d, J 5.6), 5.2 (Ha2', t, J 5.3), 4.6-3.9 (9H - ribose). 8 p (D20 , 162MHz): -10.85, -11.3, 
2P, AB, J 16.1 (^-decoupled).
m/z (ES~): 556 [20% (M-H)"], 277 [30% (M + 2H - 8 -oxy-adenosine)"], 97 (90%), 81, 
79 (100%).
Amax 279nm pH 8.3 e279 9,800M’1cm'1.
6.5.15 8-Aza-9-deaza-cycIic adenosine diphosphate ribose (cFDPR) 51
3x2pmol of 33 were each dissolved to 2ml in 25mM HEPES- NaOH buffer pH 6 .8  and 
incubated with 2 0 jj1 of Aplysia cyclase for 20min after which the mixture was diluted 
with milliQ water to 100ml and products were purified using a gradient of 0-300mM 
TEAB. The pure product eluted between 170-190mM TEAB with 40% yield. HPLC 
analysis of the incubation mixture was measured on a 3 cm guard column in combination 
with a Partisil lOp SAX (10x0.46cm) column.
Rt - (incubation mixture after 20min): 1.96min (nicotinamide), 2.2min (NFD+), 5.95min 
(cFDPR). 6h (D20 , 400MHz): 8.2 (HA2, s), 6.0 (HI', d, J 5.3), 5.2 (HA1', d, J 7.1), 5.0 
(Ha2 \ t) 4.65 (H2 ', t, Ha3'), 4.6 (H4'), 4.35 (H3'), 4.255 (HA4', H5'), 4.2 (HA5f), 4.0 
<H5"), (HA5'). Sp (D20 , 162MHz): -11.65,-11.95,2P, AB, J 15.7 ( ‘H-decoupled).
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m/z (ES“): [540 (70% M-H)”], 269 (100%).
275nm (pH 8.3), 8275 10,300M'1cm'1.
6.6 Kn, and Vmax Determination for NAD+, 2A' and 3A'-Deoxy-NAD+
The kinetics of enzymatic conversion of the above analogues in their cyclic products 
were investigated using an HPLC method. The conversion was followed by measuring 
the area under the peak for nicotinamide, which is a product formed during conversion. 
Substrate concentrations between 25-500pM in 25mM HEPES buffer pH 6 .8  were used. 
The total volume in the reaction vessel (an Eppendoiff) was kept at 500pl for each 
reaction. The incubation mixture was prepared to have 250pl of sample with 225pi of 
buffer and 25pi of enzyme to make a total of 500pl. A final enzyme concentration of 
5pg/ml was used in the assay for NAD+, and 2.5pg/ml for 2Afdeoxy NAD+ and 3A- 
deoxy-NAD+. Each reaction was analysed every minute over 6  minutes. The relative 
area for nicotinamide was measured and a graph of area of nicotinamide vs time was 
plotted at each concentration of substrate used. The reaction was carried out in 
duplicates. Initial velocity was calculated from the slope of this curve and an average 
initial velocity obtained from the two sets of data. A double reciprocal plot (Lineweaver- 
burke plot) was plotted of 1/V (y axis) vs 1/S (x-axis) using the Enzpak3 computer 
programme (a representative graph plot is shown in Fig. 4.12. Km and Vmax were 
obtained from this plot. Km values obtained were 75.2pM, 0.7mM and 0.5mM and Vmax
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values were 23.3, 47.9, 22.4|ig/mg/min for NAD+, 2 'A-deoxy-NAD+ and 3'A-deoxy- 
NAD+ respectively.
6.7 Protein Estimation of ADP-ribosyl cyclase
The Biorad protein estimation assay was used to estimate the amount of protein in the 
crude Aplysia cyclase. Bovine albumin of known protein concentration was used as a 
standard. Final concentrations of standard were made from 1.56pg.ml to 25pg/ml. 
Serial dilution of test samples of 1 in 25, lin 50, lin 100 and 1 in 200 were made. 200pl 
of test samples (1.56, 3.125, 6.25, 12.5, 15, 20 and 25pg/ml) and test solutions of 
different dilution factor were measured into wells in a microtitre plate in duplicate. 
Solutions were made in 150mM PBS buffer. 50pl o f the Biorad reagent was added to 
each sample and left for 15mins to allow for colour to develop. UV absorption was 
measured and analysed on a Biolink 2.10. A standard curve was obtained of absorbance 
vs. protein concentration for bovine albumin. The protein concentration corresponding 
to the absorbance measured for the test samples were obtained from the standard plot. 
Dilutions lin 25 and lin 50 were over the UV range o f the standard curve. Therefore 
results obtained form the 1 in 100 and 1 in 200 dilution were used for the assay. The 
mean of the two sets of data for each concentration was obtained and estimated value 
obtained was lOmg protein per ml.
6.8 Quantitative Phosphate Analysis
All phosphorus containing compounds were quantified by using a modificatio o f the 
Briggs test for phosphate analysis [1821‘ KH2PO4 was used as a standard. Standard stock
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solution containig lnmol/jil was made from KH2PO4. 50, 100, 150 and 200nmols of 
standard phosphate solution were used. Each solution was made to 400pl in Pyrex test 
tubes. Test stock solutions were prepared to contain an estimated value of 2000nmols of 
phosphate in 5mls. 125, 250 and 375|xl of the test solution were used and each solution 
were made to 400pl. Milli Q water was used throughout test for dilutions and 
experiment was carried out in triplicates. A blank was also prepared with 400jjJ of milli 
Q. The blank, standard and sample solutions were dried in an oven at 175°C for 1 h. 
After 1 h the samples were allowed to cool down and 3 drops of concentrated sulphuric 
acid was added to the sample in each test tube and heated for 1.5 h to free the 
phosphates. Briggs solutions were prepared meanwhile as thus: Solution 1 was 2.5g of 
ammonium molybdate dissolved in 20ml of water. 8ml of concentrated H2SO4 was 
added to ammonium molybdate solution. Solution 2, O.lg of quinol was dissolved in 
20ml o f water and one drop on acid added. Solution 3, 4.0g of sodium sulphite was 
dissolved in 20ml of water. After 1.5 h samples were taken out of the oven and cooled 
down. 200pl of milli Q water was added to each test tube to dissolve the phosphate in 
solution. 400pl of solution 1, 200pl of solution 2 and 200jil of solution 3 were added to 
each solution. Solutions were heated in the test tube for 10 s using a heat gun. Each 
solution was dissolve to 5ml in a 5ml volumetric flask and left for 30mins for the blue 
colour to develop. UV absorbance was measured against blank at 340nm. A standard 
graph of absorbance vs amount of phosphate was plotted. The amount of phosphate in 



































Figure 6.1: A representative standard plot o f absorbance (y axis) nm vs am ount of 
phosphate (x axis) nmols used in Briggs test. The plot is obtained using K H 2P 0 4 as 
the standard sample.
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the original solution was worked out by taking dilution factors into consideration and 
taking a mean value from a total of nine sets of data. The molar extinction coefficient 
was calculated from the absorbance measured from a known concentration of sample.
6.9 Ca2+ Release Assays for cADPR and cADPR Analogues
Ca2+ mobilisation from sea urchin egg microsomes by synthetic analogues was evaluated 
fluorimetrically using 2.5% egg homogenate containing the Ca2+ probe Fluo-3 (3pM). 
The homogenates were prepared from L. Pictus eggs and diluted as previously 
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